Membrane associated proteins

ABSTRACT

The invention provides human membrane associated proteins (MEMAP) and polynucleotides which identify and encode MEMAP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of MEMAP.

[0001] This application claims the benefit of Patent Cooperation Treaty International application Ser. No. PCT/US00/22315, filed Aug. 14, 2000, entitled MEMBRANE ASSOCIATED PROTEINS, which claims the benefit of U.S. Provisional applications U.S. Ser. No.60/149,641, filed Aug. 17, 1999, and U.S. Ser. No. 60/164,203, filed Nov. 9, 1999. All of these applications are hereby expressly incorporated by reference herein.

TECHNICAL FIELD

[0002] This invention relates to nucleic acid and amino acid sequences of membrane associated proteins and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative, autoimmune/inflammatory, neurological and gastrointestinal disorders.

BACKGROUND OF THE INVENTION

[0003] Eukaryotic cells are surrounded by plasma membranes which enclose the cell and maintain an environment inside the cell that is distinct from its surroundings. In addition, eukaryotic organisms are distinct from prokaryotes in possessing many intracellular organelle and vesicle structures. Many of the metabolic reactions which distinguish eukaryotic biochemistry from prokaryotic biochemistry take place within these structures. The plasma membrane and the membranes surrounding organelles and vesicles are composed of phosphoglycerides, fatty acids, cholesterol, phospholipids, glycolipids, proteoglycans, and proteins. These components confer identity and functionality to the membranes with which they associate.

[0004] Integral Membrane Proteins

[0005] The majority of known integral membrane proteins are transmembrane proteins (TM) which are characterized by an extracellular, a transmembrane, and an intracellular domain. TM domains are typically comprised of 15 to 25 hydrophobic amino acids which are predicted to adopt an α-helical conformation. TM proteins are classified as bitopic (Types I and II) and polytopic (Types III and IV) (Singer, S. J. (1990) Annu. Rev. Cell Biol. 6:247-96). Bitopic proteins span the membrane once while polytopic proteins contain multiple membrane-spanning segments. TM proteins that act as cell-surface receptor proteins involved in signal transduction include growth and differentiation factor receptors, and receptor-interacting proteins such as Drosophila pecanex and frizzled proteins, LIV-1 protein, NF2 protein, and GNS1/SUR4 eukaryotic integral membrane proteins. TM proteins also act as transporters of ions or metabolites, such as gap junction channels (connexins) and ion channels, and as cell anchoring proteins, such as lectins, integrins, and fibronectins. TM proteins act as vesicle organelle-forming molecules, such as calveolins, or as cell recognition molecules, such as cluster of differentiation (CD) antigens, glycoproteins, and mucins.

[0006] Many membrane proteins (MPs) contain amino acid sequence motifs that target these proteins to specific subcellular sites. Examples of these motifs include PDZ domains, KDEL, RGD, NGR, and GSL sequence motifs, von Willebrand factor A (vWFA) domains, and EGF-like domains. RGD, NGR, and GSL motif-containing peptides have been used as drug delivery agents in cancer treatments which target tumor vasculature (Arap, W. et al. (1998) Science, 279:377-380). Furthermore, MPs may also contain amino acid sequence motifs, such as the carbohydrate recognition domain (CRD), also known as the C-type lectin domain, that mediate interactions with extracellular or intracellular molecules.

[0007] Membrane proteins may also interact with and regulate the properties of the membrane lipids. Phospholipid scramblase, a type II plasma membrane protein, mediates calcium dependent movement of phospholipids (PL) between membrane leaflets. Calcium induced remodeling of plasma membrane PL plays a key role in expression of platelet anticoagulant activity and in clearance of injured or apoptotic cells (Zhou Q. et al. (1997) J. Biol. Chem. 272:18240-18244). Scott syndrome, a bleeding disorder, is caused by an inherited deficiency in plasma membrane PL scramblase function (Online Mendelian Inheritance in Man (OMIM) *262890 Platelet Receptor for Factor X, Deficiency of).

[0008] Chemical modification of amino acid residue side chains alters the manner in which MPs interact with other molecules, such as phospholipid membranes. Examples of such chemical modifications to amino acid residue side chains are covalent bond formation with glycosaminoglycans, oligosaccharides, phospholipids, acetyl and palmitoyl moieties, ADP-ribose, phosphate, and sulphate groups.

[0009] One function of TM proteins is to facilitate cell-cell communication. The slit proteins are extracellular matrix proteins expressed by cells at the ventral midline of the nervous system. Slit proteins are ligands for the repulsive guidance receptor Robo and thus play a role in repulsive axon guidance (Brose, K. et al. (1999) Cell 96:795-806).

[0010] In some cases TM proteins serve as transporters or channels in the cell membrane. For example, the mouse transporter protein (MTP) has four transmembrane domains and resides in an intracellular membrane compartment. MTP can mediate transport of nucleosides in vitro. The role of MTP in the cell may therefore be to transfer nucleosides between the cytosol and the lumen of intracellular organelles (Hogue, D. L. (1996) J. Biol. Chem. 271:9801-9808). The human stomatin-like protein (hSLP-1), expressed primarily in the brain, contains an N-terminal domain similar to the erythrocyte internal membrane protein stomatin, as well as a non-specific lipid transfer protein domain at the C-terminus. hSLP-1 is the human homologue of the C. elegans behavioral gene unc-24, which is believed to be involved in lipid transfer between closely apposed membranes (Seidel, G. and Prohaska, R (1998) Gene 225:23-29).

[0011] The transmembrane 4 superfamily (TM4SF) or tetraspan family is a multigene family encoding type III integral membrane proteins (Wright, M. D. and Tomlinson, M. G. (1994) Immunol. Today 15:588-594). TM4SF is comprised of membrane proteins which traverse the cell membrane four times. Members of the TM4SF include platelet and endothelial cell membrane proteins, melanoma-associated antigens, leukocyte surface glycoproteins, colonal carcinoma antigens, tumor-associated antigens, and surface proteins of the schistosome parasites (Jankowski, S. A. (1994) Oncogene 9:1205-1211). Members of the TM4SF share about 25-30% amino acid sequence identity with one another.

[0012] A number of TM4SF members have been implicated in signal transduction, control of cell adhesion, regulation of cell growth and proliferation, including development and oncogenesis, and cell motility, including tumor cell metastasis. Expression of TM4SF proteins is associated with a variety of tumors and the level of expression may be altered when cells are growing or activated.

[0013] Tumor antigens are cell surface molecules that are differentially expressed in tumor cells relative to normal cells. Tumor antigens distinguish tumor cells immunologically from normal cells and provide diagnostic and therapeutic targets for human cancers (Takagi, S. et al. (1995) Int. J. Cancer 61: 706-715; Liu, E. et al. (1992) Oncogene 7: 1027-1032). For example, the biliary glycoprotein-encoding gene is a member of the human carcinoembryonic antigen family, which are important tumor markers for colorectal carcinomas (Hammarstrom, S. (1999) Semin. Cancer Bio. 9:67-81). Another example is the neuron and testis specific protein Mal, a marker for paraneoplastic neuronal disorders (Dalmau, J. et al. (1999) Brain 122:27-39).

[0014] Other types of cell surface antigens include those identified on leukocytic cells of the immune system. These antigens have been identified using systematic, monoclonal antibody (mAb)-based “shot gun” techniques. These techniques have resulted in the production of hundreds of mAbs directed against unknown cell surface leukocytic antigens. These antigens have been grouped into “clusters of differentiation” based on common immunocytochemical localization patterns in various differentiated and undifferentiated leukocytic cell types. Antigens in a given cluster are presumed to identify a single cell surface protein and are assigned a “cluster of differentiation” or “CD” designation. Some of the genes encoding proteins identified by CD antigens have been cloned and verified by standard molecular biology techniques. CD antigens have been characterized as both transmembrane proteins and cell surface proteins anchored to the plasma membrane via covalent attachment to fatty acid-containing glycolipids such as glycosylphosphatidylinositol (GPI). (Reviewed in Barclay, A. N. et al. (1995) The Leucocyte Antigen Facts Book, Academic Press, San Diego, Calif., pp. 17-20.)

[0015] The TM cell surface glycoprotein CD69 is an early activation antigen of T lymphocytes. CD69 is homologous to members of a supergene family of type II integral membrane proteins having C-type lectin domains. Although the precise functions of the CD-69 antigen is not known, evidence suggests that these proteins transmit mitogenic signals across the plasma membrane and are up-regulated in response to lymphocyte activation (Hamann, J. et. al. (1993) J. Immunol. 150:4920-4927).

[0016] Macrophages are involved in functions including clearance of senescent or apoptotic cells, cytokine production, hemopoiesis, bone resorption, antigen transport, and neuroendocrine regulation. These diverse roles are influenced by specialized macrophage plasma membrane proteins. The murine macrophage restricted C-type lectin is a type II integral membrane protein expressed exclusively in macrophages. The strong expression of this protein in bone marrow suggests a hemopoeitic function, while the lectin domain suggests it may be involved in cell-cell recognition (Balch, S. G. et al. (1998) J. Biol. Chem. 273:18656-18664).

[0017] The surface of red blood cells is populated with characteristic glycoproteins, such as the major sialoglycoproteins glycophorin A and B. Red blood cells lacking either glycophorin A or B are resistant to infection with the malaria parasite Plasmodium falciparum (OMIM Entry 111300 Blood Group-MN Locus). White blood cells also possess characteristic surface glycoproteins, such as the plasma cell glycoprotein-1 (PC-1). PC-1 is expressed on the surface of plasma cells, which are terminally differentiated, antibody-secreting B-lymphocytes. The extracellular domain of PC-1 has nucleotide phosphodiesterase (pyrophosphatase) activity (Funakoshi, I. et al. (1992) Arch. Biochem. Biophys. 295:180-187). Phosphodiesterase activity is associated with the hydrolytic removal of nucleotide subunits from oligonucleotides. Although the precise physiological role of PC-1 is not clear, increased PC-1 phosphodiesterase activity has been correlated with insulin resistance in patients with noninsulin-dependent diabetes mellitus, with abnormalities of bone mineralization and calcification, and with defects in renal tubule function. In addition, it appears that hPC-1 and mPC-1 are members of a multigene family of transmembrane phosphodiesterases with extracellular active sites. These enzymes may play a role in regulating the concentration of pharmacologically active extracellular compounds such as adenosine or other nucleotide derivatives in a variety of tissues and cell types. (Reviewed in Goding, J. W. et al. (1998) Immunol. Rev. 161:11-26.)

[0018] Peripheral and Anchored Membrane Proteins

[0019] Some membrane proteins are not membrane-spanning but are attached to the plasma membrane via membrane anchors or interactions with integral membrane proteins. Membrane anchors are covalently joined to a protein post-translationally and include such moieties as prenyl, myristyl, and glycosylphosphatidyl inositol (GPI) groups. Membrane localization of peripheral and anchored proteins is important for their function in processes such as receptor-mediated signal transduction. For example, prenylation of Ras is required for its localization to the plasma membrane and for its normal and oncogenic functions in signal transduction.

[0020] The pancortins are a group of four glycoproteins which are predominantly expressed in the cerebral cortex of adult rodents. Immunological localization indicates that the pancortins are endoplasmic reticulum anchored proteins. The pancortins share a common sequence in the middle of their structure, but have alternative sequences at both ends due to differential promoter usage and alternative splicing. Each pancortin appears to be differentially expressed and may perform different functions in the brain (Nagano, T. et al. (1998) Mol. Brain Res. 53:13-23).

[0021] The discovery of new membrane associated proteins and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cell proliferative, autoimmune/inflammatory, neurological and gastrointestinal disorders.

SUMMARY OF THE INVENTION

[0022] The invention features purified polypeptides, membrane associated proteins, referred to collectively as “MEMAP” and individually as “MEMAP-1,” “MEMAP-2,” “MEMAP-3,” “MEMAP-4,” “MEMAP-5,” “MEMAP-6,” “MEMAP-7,” “MEMAP-8,” “MEMAP-9,” “MEMAP-10,” “MEMAP-11,” “MEMAP-12,” “MEMAP-13,” “MEMAP-14,” “MEMAP-15,” “MEMAP-16,” “MEMAP-17,” “MEMAP-18,” “MEMAP-19,” “MEMAP-20,” “MEMAP-21,” “MEMAP-22,” “MEMAP-23,” “MEMAP-24,” “MEMAP-25,” “MEMAP-26,” “MEMAP-27,” “MEMAP-28,” “MEMAP-29,” “MEMAP-30,” “MEMAP-31,” “MEMAP-32,” “MEMAP-33,” “MEMAP-34,” “MEMAP-35,” “MEMAP-36,” and “MEMAP-37.” In one aspect, the invention provides an isolated polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-37.

[0023] The invention further provides an isolated polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-37. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:38-74.

[0024] Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

[0025] The invention also provides a method for producing a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

[0026] Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37.

[0027] The invention further provides an isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:38-74, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:38-74, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

[0028] Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:38-74, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:38-74, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

[0029] The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:38-74, b) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:38-74, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

[0030] The invention further provides a composition comprising an effective amount of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-37. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional MEMAP, comprising administering to a patient in need of such treatment the composition.

[0031] The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional MEMAP, comprising administering to a patient in need of such treatment the composition.

[0032] Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional MEMAP, comprising administering to a patient in need of such treatment the composition.

[0033] The invention further provides a method of screening for a compound that specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

[0034] The invention further provides a method of screening for a compound that modulates the activity of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-37. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

[0035] The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO:38-74, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.

[0036] The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of i) a polynucleotide sequence selected from the group consisting of SEQ ID NO:38-74, ii) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:38-74, iii) a polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:38-74, ii) a naturally occurring polynucleotide sequence having at least 70% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:38-74, iii) a polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of the above polynucleotide sequence; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

BRIEF DESCRIPTION OF THE TABLES

[0037] Table 1 shows polypeptide and nucleotide sequence identification numbers (SEQ ID NOs), clone identification numbers (clone IDs), cDNA libraries, and cDNA fragments used to assemble full-length sequences encoding MEMAP.

[0038] Table 2 shows features of each polypeptide sequence, including potential motifs, homologous sequences, and methods, algorithms, and searchable databases used for analysis of MEMAP.

[0039] Table 3 shows selected fragments of each nucleic acid sequence; the tissue-specific expression patterns of each nucleic acid sequence as determined by northern analysis; diseases, disorders, or conditions associated with these tissues; and the vector into which each cDNA was cloned.

[0040] Table 4 describes the tissues used to construct the cDNA libraries from which cDNA clones encoding MEMAP were isolated.

[0041] Table 5 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

DESCRIPTION OF THE INVENTION

[0042] Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

[0043] It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to “a host cell” includes a plurality of such host cells, and a reference to “an antibody” is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

[0044] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

[0045] Definitions

[0046] “MEMAP” refers to the amino acid sequences of substantially purified MEMAP obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

[0047] The term “agonist” refers to a molecule which intensifies or mimics the biological activity of MEMAP. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of MEMAP either by directly interacting with MEMAP or by acting on components of the biological pathway in which MEMAP participates.

[0048] An “allelic variant” is an alternative form of the gene encoding MEMAP. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

[0049] “Altered” nucleic acid sequences encoding MEMAP include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as MEMAP or a polypeptide with at least one functional characteristic of MEMAP. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding MEMAP, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding MEMAP. The encoded protein may also be “altered,” and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent MEMAP. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of MEMAP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

[0050] The terms “amino acid” and “amino acid sequence” refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where “amino acid sequence” is recited to refer to a sequence of a naturally occurring protein molecule, “amino acid sequence” and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

[0051] “Amplification” relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

[0052] The term “antagonist” refers to a molecule which inhibits or attenuates the biological activity of MEMAP. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of MEMAP either by directly interacting with MEMAP or by acting on components of the biological pathway in which MEMAP participates.

[0053] The term “antibody” refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab′)₂, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind MEMAP polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

[0054] The term “antigenic determinant” refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

[0055] The term “antisense” refers to any composition capable of base-pairing with the “sense” (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2′-methoxyethyl sugars or 2′-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2′-deoxyuracil, or 7-deaza-2′deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation “negative” or “minus” can refer to the antisense strand, and the designation “positive” or “plus” can refer to the sense strand of a reference DNA molecule.

[0056] The term “biologically active” refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, “immunologically active” or “immunogenic” refers to the capability of the natural, recombinant, or synthetic MEMAP, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

[0057] “Complementary” describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5′-AGT-3′ pairs with its complement, 3′-TCA-5′.

[0058] A “composition comprising a given polynucleotide sequence” and a “composition comprising a given amino acid sequence” refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding MEMAP or fragments of MEMAP may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

[0059] “Consensus sequence” refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (PE Biosystems, Foster City Calif.) in the 5′ and/or the 3′ direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison Wis.) or Phrap (University of Washington, Seattle Wash.). Some sequences have been both extended and assembled to produce the consensus sequence.

[0060] “Conservative amino acid substitutions” are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions. Original Residue Conservative Substitution Ala Gly, Ser Arg His, Lys Asn Asp, Gln, His Asp Asn, Glu Cys Ala, Ser Gln Asn, Glu, His Glu Asp, Gln, His Gly Ala His Asn, Arg, Gln, Glu Ile Leu, Val Leu Ile, Val Lys Arg, Gln, Glu Met Leu, Ile Phe His, Met, Leu, Trp, Tyr Ser Cys, Thr Thr Ser, Val Trp Phe, Tyr Tyr His, Phe, Trp Val Ile, Leu, Thr

[0061] Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

[0062] A “deletion” refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

[0063] The term “derivative” refers to a chemically modified polynucleotide or polypeptide. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

[0064] A “detectable label” refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

[0065] A “fragment” is a unique portion of MEMAP or the polynucleotide encoding MEMAP which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50% of a polypeptide) as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

[0066] A fragment of SEQ ID NO:38-74 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:38-74, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:38-74 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:38-74 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:38-74 and the region of SEQ ID NO:38-74 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

[0067] A fragment of SEQ ID NO:1-37 is encoded by a fragment of SEQ ID NO:38-74. A fragment of SEQ ID NO:1-37 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-37. For example, a fragment of SEQ ID NO:1-37 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-37. The precise length of a fragment of SEQ ID NO:1-37 and the region of SEQ ID NO:1-37 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

[0068] A “full-length” polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A “full-length” polynucleotide sequence encodes a “full-length” polypeptide sequence.

[0069] “Homology” refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

[0070] The terms “percent identity” and “% identity,” as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

[0071] Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison Wis.). CLUSTAL V is described in Higgins, D. G. and P. M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D. G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and “diagonals saved”=4. The “weighted” residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the “percent similarity” between aligned polynucleotide sequences.

[0072] Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S. F. et al. (1990) J. Mol. Biol. 215:403410), which is available from several sources, including the NCBI, Bethesda, Md., and on the Internet at http://www.ncbi.nlm.nih.gov/BLAST/. The BLAST software suite includes various sequence analysis programs including “blastn,” that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called “BLAST 2 Sequences” that is used for direct pairwise comparison of two nucleotide sequences. “BLAST 2 Sequences” can be accessed and used interactively at http://www.ncbi.nlm.nih.gov/gorf/bl2.html. The “BLAST 2 Sequences” tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the “BLAST 2 Sequences” tool Version 2.0.12 (Apr. 21, 2000) set at default parameters. Such default parameters may be, for example:

[0073] Matrix: BLOSUM62

[0074] Rewardfor match: 1

[0075] Penalty for mismatch: −2

[0076] Open Gap: 5 and Extension Gap: 2 penalties

[0077] Gap x drop-off: 50

[0078] Expect: 10

[0079] Word Size: 11

[0080] Filter: on

[0081] Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

[0082] Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

[0083] The phrases “percent identity” and “% identity,” as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

[0084] Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and “diagonals saved”=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the “percent similarity” between aligned polypeptide sequence pairs.

[0085] Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the “BLAST 2 Sequences” tool Version 2.0.12 (Apr. 21, 2000) with blastp set at default parameters. Such default parameters may be, for example:

[0086] Matrix: BLOSUM62

[0087] Open Gap: 11 and Extension Gap: 1 penalties

[0088] Gap x drop-off 50

[0089] Expect: 10

[0090] Word Size: 3

[0091] Filter: on

[0092] Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

[0093] “Human artificial chromosomes” (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for chromosome replication, segregation and maintenance.

[0094] The term “humanized antibody” refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

[0095] “Hybridization” refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the “washing” step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68° C. in the presence of about 6× SSC, about 1% (w/v) SDS, and about 100 μg/ml sheared, denatured salmon sperm DNA.

[0096] Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5° C. to 20° C. lower than the thermal melting point (T_(m)) for the specific sequence at a defined ionic strength and pH. The T_(m) is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_(m) and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al., 1989, Molecular Cloning: A Laboratory Manual, 2^(ed., vol.) 1-3, Cold Spring Harbor Press, Plainview N.Y.; specifically see volume 2, chapter 9.

[0097] High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68° C. in the presence of about 0.2× SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65° C., 60° C., 55° C., or 42° C. may be used. SSC concentration may be varied from about 0.1 to 2× SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 μg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

[0098] The term “hybridization complex” refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C₀t or R₀t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

[0099] The words “insertion” and “addition” refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

[0100] “Immune response” can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

[0101] An “immunogenic fragment” is a polypeptide or oligopeptide fragment of MEMAP which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term “immunogenic fragment” also includes any polypeptide or oligopeptide fragment of MEMAP which is useful in any of the antibody production methods disclosed herein or known in the art.

[0102] The term “microarray” refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

[0103] The terms “element” and “array element” refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

[0104] The term “modulate” refers to a change in the activity of MEMAP. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of MEMAP.

[0105] The phrases “nucleic acid” and “nucleic acid sequence” refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

[0106] “Operably linked” refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

[0107] “Peptide nucleic acid” (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript longation, and may be pegylated to extend their lifespan in the cell.

[0108] “Post-translational modification” of an MEMAP may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of MEMAP.

[0109] “Probe” refers to nucleic acid sequences encoding MEMAP, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. “Primers” are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

[0110] Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

[0111] Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2^(nd) ed., vol. 1-3, Cold Spring Harbor Press, Plainview N.Y.; Ausubel, F. M. et al. (1987) Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York N.Y.; Innis, M. et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego Calif. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge Mass.).

[0112] Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas Tex.) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge Mass.) allows the user to input a “mispriming library,” in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

[0113] A “recombinant nucleic acid” is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

[0114] Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

[0115] A “regulatory element” refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5′ and 3′ untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.

[0116] “Reporter molecules” are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

[0117] An “RNA equivalent,” in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

[0118] The term “sample” is used in its broadest sense. A sample suspected of containing nucleic acids encoding MEMAP, or fragments thereof, or MEMAP itself, may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

[0119] The terms “specific binding” and “specifically binding” refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope “A,” the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

[0120] The term “substantially purified” refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

[0121] A “substitution” refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

[0122] “Substrate” refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

[0123] A “transcript image” refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

[0124] “Transformation” describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term “transformed” cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

[0125] A “transgenic organism,” as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants, and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook, J. et al. (1989), supra.

[0126] A “variant” of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the “BLAST 2 Sequences” tool Version 2.0.9 (May 7, 1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% or greater sequence identity over a certain defined length. A variant may be described as, for example, an “allelic” (as defined above), “splice,” “species,” or “polymorphic” variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternative splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass “single nucleotide polymorphisms” (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

[0127] A “variant” of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the “BLAST 2 Sequences” tool Version 2.0.9 (May 7, 1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% or greater sequence identity over a certain defined length of one of the polypeptides.

[0128] The Invention

[0129] The invention is based on the discovery of new human membrane associated proteins (MEMAP), the polynucleotides encoding MEMAP, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative, autoimmune/inflammatory, neurological and gastrointestinal disorders.

[0130] Table 1 lists the Incyte clones used to assemble full length nucleotide sequences encoding MEMAP. Columns 1 and 2 show the sequence identification numbers (SEQ ID NOs) of the polypeptide and nucleotide sequences, respectively. Column 3 shows the clone IDs of the Incyte clones in which nucleic acids encoding each MEMAP were identified, and column 4 shows the cDNA libraries from which these clones were isolated. Column 5 shows Incyte clones and their corresponding cDNA libraries. Clones for which cDNA libraries are not indicated were derived from pooled cDNA libraries. In some cases, GenBank sequence identifiers are also shown in column 5. The Incyte clones and GenBank cDNA sequences, where indicated, in column 5 were used to assemble the consensus nucleotide sequence of each MEMAP and are useful as fragments in hybridization technologies.

[0131] The columns of Table 2 show various properties of each of the polypeptides of the invention: column 1 references the SEQ ID NO; column 2 shows the number of amino acid residues in each polypeptide; column 3 shows potential phosphorylation sites; column 4 shows potential glycosylation sites; column 5 shows the amino acid residues comprising signature sequences and motifs; column 6 shows homologous sequences as identified by BLAST analysis; and column 7 shows analytical methods and in some cases, searchable databases to which the analytical methods were applied. The methods of column 7 were used to characterize each polypeptide through sequence homology and protein motifs.

[0132] The columns of Table 3 show the tissue-specificity and diseases, disorders, or conditions associated with nucleotide sequences encoding MEMAP. The first column of Table 3 lists the nucleotide SEQ ID NOs. Column 2 lists fragments of the nucleotide sequences of column 1. These fragments are useful, for example, in hybridization or amplification technologies to identify SEQ ID NO:38-74 and to distinguish between SEQ ID NO:38-74 and related polynucleotide sequences. The polypeptides encoded by these fragments are useful, for example, as immunogenic peptides. Column 3 lists tissue categories which express MEMAP as a fraction of total tissues expressing MEMAP.

[0133] Column 4 lists diseases, disorders, or conditions associated with those tissues expressing MEMAP as a fraction of total tissues expressing MEMAP. Column 5 lists the vectors used to subclone each cDNA library. Of particular note is the expression of SEQ ID NO:41, SEQ ID NO:48, and SEQ ID NO:56 in nervous tissues, of SEQ ID NO:52, SEQ ID NO:65, and SEQ ID NO:74 in gastrointestinal issues, and of SEQ ID NO:55 in hematopoietic/immune tissues.

[0134] The columns of Table 4 show descriptions of the tissues used to construct the cDNA libraries rom which cDNA clones encoding MEMAP were isolated. Column 1 references the nucleotide SEQ ID NOs, column 2 shows the cDNA libraries from which these clones were isolated, and column 3 shows the tissue origins and other descriptive information relevant to the cDNA libraries in column 2.

[0135] SEQ ID NO:38 maps to chromosome 4 within the interval from 77.9 to 86.0 centiMorgans, to chromosome 6 within the interval from 132.7 to 144.4 centiMorgans, and to chromosome 14 within the interval from 89.4 to 103.7 centiMorgans. The interval on chromosome 4 from 77.9 to 86.0 centiMorgans also contains a gene associated with deoxycytidine kinase deficiency. The interval on chromosome 6 from 132.7 to 144.4 centiMorgans also contains genes associated with peroxisomal disorders and leukemia. The interval on chromosome 14 from 89.4 to 103.7 centiMorgans also contains genes associated with spinocerebellar ataxia and protease inhibitor deficiencies. SEQ ID NO:39 maps to chromosome 2 within the interval from 236.2 to 269.5 centiMorgans, and to the X chromosome within the interval from 94.4 to 97.4 centiMorgans. The interval on chromosome 2 from 236.2 to 269.5 centiMorgans also contains genes associated with Crigler-Najjar syndrome, Oguchi disease, and oxaolis I. The interval on the X chromosome from 94.4 to 97.4 centiMorgans also contains genes associated with Charcot-Marie tooth disease, X-linked severe combined immunodeficiency, alpha thalassemia/mental retardation syndrome, Menkes' syndrome, and choroideremia. SEQ ID NO:42 maps to chromosome 1 within the interval from 218.2 to 232.0 centiMorgans. This interval also contains genes associated with familial hypertrophic cardiomyopathy, malignant hyperthermia, and hypokalemic periodic paralysis. SEQ ID NO:44 maps to chromosome 7 within the interval from 136.4 to 145.8 centiMorgans, to chromosome 14 within the interval from 28.0 to 32.9 centiMorgans, and to chromosome 14 within the interval from 71.5 to 73.7 centiMorgans. The interval on chromosome 7 from 136.4 to 145.8 centiMorgans also contains genes associated with diphosphoglycerate mutase deficiency. SEQ ID NO:60 maps to chromosome 7 within the interval from 167.6 to 184.0 centiMorgans, and to chromosome 14 within the interval from 50.0 to 59.0 centiMorgans. SEQ ID NO:63 maps to chromosome 8 within the interval from 101.0 to 125.8 centiMorgans, and to chromosome 8 within the interval from 132.4 to 135.1 centiMorgans. SEQ ID NO:67 maps to chromosome 4 within the interval from 145.3 to 146.4 centiMorgans.

[0136] The invention also encompasses MEMAP variants. A preferred MEMAP variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the MEMAP amino acid sequence, and which contains at least one functional or structural characteristic of MEMAP.

[0137] The invention also encompasses polynucleotides which encode MEMAP. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:38-74, which encodes MEMAP. The polynucleotide sequences of SEQ ID NO:38-74, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

[0138] The invention also encompasses a variant of a polynucleotide sequence encoding MEMAP. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding MEMAP. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:38-74 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:38-74. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of MEMAP.

[0139] It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding MEMAP, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring MEMAP, and all such variations are to be considered as being specifically disclosed.

[0140] Although nucleotide sequences which encode MEMAP and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring MEMAP under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding MEMAP or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding MEMAP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

[0141] The invention also encompasses production of DNA sequences which encode MEMAP and MEMAP derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding MEMAP or any fragment thereof.

[0142] Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:38-74 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G. M. and S. L. Berger (1987) Methods Enzymol. 152:399407; Kimmel, A. R. (1987) Methods Enzymol. 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in “Definitions.”

[0143] Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland Ohio), Taq polymerase (PE Biosystems, Foster City Calif.), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway N.J.), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg Md.). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno Nev.), PTC200 thermal cycler (MJ Research, Watertown Mass.) and ABI CATALYST 800 thermal cycler (PE Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (PE Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale Calif.), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F. M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York N.Y., unit 7.7; Meyers, R. A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York N.Y., pp. 856-853.)

[0144] The nucleic acid sequences encoding MEMAP may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1: 111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J. D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto C) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences, Plymouth Minn.) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68° C. to 72° C.

[0145] When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5′ regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5′ non-transcribed regulatory regions.

[0146] Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, PE Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

[0147] In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode MEMAP may be cloned in recombinant DNA molecules that direct expression of MEMAP, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express MEMAP.

[0148] The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter MEMAP-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

[0149] The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara Calif.; described in U.S. Pat. No. 5,837,458; Chang, C. -C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F. C. et al. (1999) Nat. Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of MEMAP, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through “artificial” breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

[0150] In another embodiment, sequences encoding MEMAP may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M. H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, MEMAP itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, W H Freeman, New York N.Y., pp. 55-60; and Roberge, J. Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (PE Biosystems). Additionally, the amino acid sequence of MEMAP, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

[0151] The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R. M. and F. Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.) In order to express a biologically active MEMAP, the nucleotide sequences encoding MEMAP or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5′ and 3′ untranslated regions in the vector and in polynucleotide sequences encoding MEMAP. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding MEMAP. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding MEMAP and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.)

[0152] Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding MEMAP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview N.Y., ch. 4, 8, and 16-17; Ausubel, F. M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York N.Y., ch. 9, 13, and 16.)

[0153] A variety of expression vector/host systems may be utilized to contain and express sequences encoding MEMAP. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Heeke, G. and S. M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Bitter, G. A. et al. (1987) Methods Enzymol. 153:516-544; Scorer, C. A. et al. (1994) Bio/Technology 12:181-184; Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; and Harrington, J. J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al. (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R. M. et al. (1985) Nature 317(6040):813-815; McGregor, D. P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I. M. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.

[0154] In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding MEMAP. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding MEMAP can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla Calif.) or PSPORT 1 plasmid (Life Technologies). Ligation of sequences encoding MEMAP into the vector's multiple cloning site disrupts the lacZ gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S. M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of MEMAP are needed, e.g. for the production of antibodies, vectors which direct high level expression of MEMAP may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage promoter may be used.

[0155] Yeast expression systems may be used for production of MEMAP. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Bitter, supra; and Scorer, supra.)

[0156] Plant systems may also be used for expression of MEMAP. Transcription of sequences encoding MEMAP may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, supra; Broglie, supra; and Winter, supra.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York N.Y., pp. 191-196.)

[0157] In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding MEMAP may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses MEMAP in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

[0158] Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J. J. et al. (1997) Nat. Genet. 15:345-355.)

[0159] For long term production of recombinant proteins in mammalian systems, stable expression of MEMAP in cell lines is preferred. For example, sequences encoding MEMAP can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

[0160] Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in tk⁻ and apr⁻ cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, dhfr confers resistance to methotrexate; neo confers resistance to the aminoglycosides neomycin and G418; and als and pat confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., trpB and hisD, which alter cellular requirements for metabolites. (See, e.g., Hartman, S. C. and R. C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β-glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C. A. (1995) Methods Mol. Biol. 55:121-131.)

[0161] Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding MEMAP is inserted within a marker gene sequence, transformed cells containing sequences encoding MEMAP can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding MEMAP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

[0162] In general, host cells that contain the nucleic acid sequence encoding MEMAP and that express MEMAP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

[0163] Immunological methods for detecting and measuring the expression of MEMAP using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on MEMAP is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods a Laboratory Manual, APS Press, St. Paul Minn., Sect. IV; Coligan, J. E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York N.Y.; and Pound, J. D. (1998) Immunochemical Protocols, Humana Press, Totowa N.J.)

[0164] A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding MEMAP include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding MEMAP, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison Wis.), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

[0165] Host cells transformed with nucleotide sequences encoding MEMAP may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode MEMAP may be designed to contain signal sequences which direct secretion of MEMAP through a prokaryotic or eukaryotic cell membrane.

[0166] In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a “prepro” or “pro” form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and W138) are available from the American Type Culture Collection (ATCC, Manassas Va.) and may be chosen to ensure the correct modification and processing of the foreign protein.

[0167] In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding MEMAP may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric MEMAP protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of MEMAP activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, c-myc, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, c-myc, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the MEMAP encoding sequence and the heterologous protein sequence, so that MEMAP may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

[0168] In a further embodiment of the invention, synthesis of radiolabeled MEMAP may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, ³⁵S-methionine.

[0169] MEMAP of the present invention or fragments thereof may be used to screen for compounds that specifically bind to MEMAP. At least one and up to a plurality of test compounds may be screened for specific binding to MEMAP. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

[0170] In one embodiment, the compound thus identified is closely related to the natural ligand of MEMAP, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, Coligan, J. E. et al. (1991) Current Protocols in Immunology 1(2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which MEMAP binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express MEMAP, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing MEMAP or cell membrane fractions which contain MEMAP are then contacted with a test compound and binding, stimulation, or inhibition of activity of either MEMAP or the compound is analyzed.

[0171] An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with MEMAP, either in solution or affixed to a solid support, and detecting the binding of MEMAP to the compound. Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

[0172] MEMAP of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of MEMAP. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for MEMAP activity, wherein MEMAP is combined with at least one test compound, and the activity of MEMAP in the presence of a test compound is compared with the activity of MEMAP in the absence of the test compound. A change in the activity of MEMAP in the presence of the test compound is indicative of a compound that modulates the activity of MEMAP. Alternatively, a test compound is combined with an in vitro or cell-free system comprising MEMAP under conditions suitable for MEMAP activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of MEMAP may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

[0173] In another embodiment, polynucleotides encoding MEMAP or their mammalian homologs may be “knocked out” in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Pat. No. 5,175,383 and U.S. Pat. No. 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M. R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J. D. (1996) Clin. Invest. 97:1999-2002; Wagner, K. U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

[0174] Polynucleotides encoding MEMAP may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J. A. et al. (1998) Science 282:1145-1147).

[0175] Polynucleotides encoding MEMAP can also be used to create “knockin” humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding MEMAP is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress MEMAP, e.g., by secreting MEMAP in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).

[0176] Therapeutics

[0177] Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of MEMAP and membrane associated proteins. In addition, the expression of MEMAP is closely associated with neurological and gastrointestinal tissues, cancer, cell proliferation, and inflammation/trauma. Therefore, MEMAP appears to play a role in cell proliferative, autoimmune/inflammatory, neurological and gastrointestinal disorders. In the treatment of disorders associated with increased MEMAP expression or activity, it is desirable to decrease the expression or activity of MEMAP. In the treatment of disorders associated with decreased MEMAP expression or activity, it is desirable to increase the expression or activity of MEMAP.

[0178] Therefore, in one embodiment, MEMAP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of MEMAP. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjogren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; and a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha₁-antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas.

[0179] In another embodiment, a vector capable of expressing MEMAP or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of MEMAP including, but not limited to, those described above.

[0180] In a further embodiment, a composition comprising a substantially purified MEMAP in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of MEMAP including, but not limited to, those provided above.

[0181] In still another embodiment, an agonist which modulates the activity of MEMAP may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of MEMAP including, but not limited to, those listed above.

[0182] In a further embodiment, an antagonist of MEMAP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of MEMAP. Examples of such disorders include, but are not limited to, those cell proliferative, autoimmune/inflammatory, neurological and gastrointestinal disorders described above. In one aspect, an antibody which specifically binds MEMAP may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express MEMAP.

[0183] In an additional embodiment, a vector expressing the complement of the polynucleotide encoding MEMAP may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of MEMAP including, but not limited to, those described above.

[0184] In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

[0185] An antagonist of MEMAP may be produced using methods which are generally known in the art. In particular, purified MEMAP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind MEMAP. Antibodies to MEMAP may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

[0186] For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with MEMAP or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

[0187] It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to MEMAP have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of MEMAP amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

[0188] Monoclonal antibodies to MEMAP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:3142; Cote, R. J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and Cole, S. P. et al. (1984) Mol. Cell Biol. 62:109-120.)

[0189] In addition, techniques developed for the production of “chimeric antibodies,” such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S. L. et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M. S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce MEMAP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D. R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

[0190] Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

[0191] Antibody fragments which contain specific binding sites for MEMAP may also be generated. For example, such fragments include, but are not limited to, F(ab′)₂ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab′)₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W. D. et al. (1989) Science 246:1275-1281.)

[0192] Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between MEMAP and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering MEMAP epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

[0193] Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for MEMAP. Affinity is expressed as an association constant, Ka, which is defined as the molar concentration of MEMAP-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_(a) determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple MEMAP epitopes, represents the average affinity, or avidity, of the antibodies for MEMAP. The K_(a) determined for a preparation of monoclonal antibodies, which are monospecific for a particular MEMAP epitope, represents a true measure of affinity. High-affinity antibody preparations with K_(a) ranging from about 10⁹ to 10¹² L/mole are preferred for use in immunoassays in which the MEMAP-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with Ka ranging from about 10⁶ to 10⁷ L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of MEMAP, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J. E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York N.Y.).

[0194] The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of MEMAP-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al., supra.)

[0195] In another embodiment of the invention, the polynucleotides encoding MEMAP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding MEMAP. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding MEMAP. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa N.J.)

[0196] In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J. E. et al. (1998) J. Allergy Clin. Immunol. 102(3):469-475; and Scanlon, K. J. et al. (1995) 9(13): 1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A. D. (1990) Blood 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) Pharmacol. Ther. 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J. J. (1995) Br. Med. Bull. 51(1):217-225; Boado, R. J. et al. (1998) J. Pharm. Sci. 87(11):1308-1315; and Morris, M. C. et al. (1997) Nucleic Acids Res. 25(14):2730-2736.)

[0197] In another embodiment of the invention, polynucleotides encoding MEMAP may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R. M. et al. (1995) Science 270:475-480; Bordignon, C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75:207-216; Crystal, R. G. et al. (1995) Hum. Gene Therapy 6:643-666; Crystal, R. G. et al. (1995) Hum. Gene Therapy 6:667-703), thalassamias, familial hypercholesterolemia, and hemophilia resulting from Factor Vm or Factor IX deficiencies (Crystal, R. G. (1995) Science 270:404410; Verma, I. M. and N. Somia (1997) Nature 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci. USA. 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in MEMAP expression or regulation causes disease, the expression of MEMAP from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

[0198] In a further embodiment of the invention, diseases or disorders caused by deficiencies in MEMAP are treated by constructing mammalian expression vectors encoding MEMAP and introducing these vectors by mechanical means into MEMAP-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R. A. and W. F. Anderson (1993) Annu. Rev. Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J -L. and H. Recipon (1998) Curr. Opin. Biotechnol. 9:445450).

[0199] Expression vectors that may be effective for the expression of MEMAP include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad Calif.), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla Calif.), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto Calif.). MEMAP may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β-actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; Rossi, F. M. V. and H. M. Blau (1998) Curr. Opin. Biotechnol. 9:451456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F. M. V. and H. M. Blau, supra)), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding MEMAP from a normal individual.

[0200] Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F. L. and A. J. Eb (1973) Virology 52:456467), or by electroporation (Neumann, E. et al. (1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

[0201] In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to MEMAP expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding MEMAP under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus cis-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M. A. et al. (1987) J. Virol. 61:1639-1646; Adam, M. A. and A. D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Pat. No. 5,910,434 to Rigg (“Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant”) discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4⁺T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M. L. (1997) J. Virol. 71:47074716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

[0202] In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding MEMAP to cells which have one or more genetic abnormalities with respect to the expression of MEMAP. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M. E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Pat. No. 5,707,618 to Armentano (“Adenovirus vectors for gene therapy”), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P. A. et al. (1999) Annu. Rev. Nutr. 19:511-544; and Verma, I. M. and N. Somia (1997) Nature 18:389:239-242, both incorporated by reference herein.

[0203] In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding MEMAP to target cells which have one or more genetic abnormalities with respect to the expression of MEMAP. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing MEMAP to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res.169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent Number 5,804,413 to DeLuca (“Herpes simplex virus strains for gene transfer”), which is hereby incorporated by reference. U.S. Pat. No. 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W. F. et al. (1999) J. Virol. 73:519-532 and Xu, H. et al. (1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

[0204] In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding MEMAP to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K. -J. Li (1998) Curr. Opin. Biotechnol. 9:464469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full-length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for MEMAP into the alphavirus genome in place of the capsid-coding region results in the production of a large number of MEMAP-coding RNAs and the synthesis of high levels of MEMAP in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S. A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of MEMAP into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

[0205] Oligonucleotides derived from the transcription initiation site, e.g., between about positions −10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J. E. et al. (1994) in Huber, B. E. and B. I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco N.Y., pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

[0206] Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding MEMAP.

[0207] Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

[0208] Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding MEMAP. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

[0209] RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5′ and/or 3′ ends of the molecule, or the use of phosphorothioate or 2′O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

[0210] An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding MEMAP. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased MEMAP expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding MEMAP may be therapeutically useful, and in the treament of disorders associated with decreased MEMAP expression or activity, a compound which specifically promotes expression of the polynucleotide encoding MEMAP may be therapeutically useful.

[0211] At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding MEMAP is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an in vitro cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding MEMAP are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding MEMAP. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a Schizosaccharomyces pombe gene expression system (Atkins, D. et al. (1999) U.S. Pat. No. 5,932,435; Arndt, G. M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M. L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T. W. et al. (1997) U.S. Pat. No. 5,686,242; Bruice, T. W. et al. (2000) U.S. Pat. No. 6,022,691).

[0212] Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C. K. et al. (1997) Nat. Biotechnol. 15:462-466.)

[0213] Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

[0214] An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton Pa.). Such compositions may consist of MEMAP, antibodies to MEMAP, and mimetics, agonists, antagonists, or inhibitors of MEMAP.

[0215] The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

[0216] Compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J. S. et al., U.S. Pat. No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

[0217] Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

[0218] Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising MEMAP or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, MEMAP or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S. R. et al. (1999) Science 285:1569-1572).

[0219] For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

[0220] A therapeutically effective dose refers to that amount of active ingredient, for example MEMAP or fragments thereof, antibodies of MEMAP, and agonists, antagonists or inhibitors of MEMAP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED₅₀ (the dose therapeutically effective in 50% of the population) or LD₅₀ (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD₅₀/ED₅₀ ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED₅₀ with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

[0221] The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

[0222] Normal dosage amounts may vary from about 0.1 μg to 100,000 μg, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

[0223] Diagnostics

[0224] In another embodiment, antibodies which specifically bind MEMAP may be used for the diagnosis of disorders characterized by expression of MEMAP, or in assays to monitor patients being treated with MEMAP or agonists, antagonists, or inhibitors of MEMAP. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for MEMAP include methods which utilize the antibody and a label to detect MEMAP in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

[0225] A variety of protocols for measuring MEMAP, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of MEMAP expression. Normal or standard values for MEMAP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibody to MEMAP under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of MEMAP expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

[0226] In another embodiment of the invention, the polynucleotides encoding MEMAP may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of MEMAP may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of MEMAP, and to monitor regulation of MEMAP levels during therapeutic intervention.

[0227] In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding MEMAP or closely related molecules may be used to identify nucleic acid sequences which encode MEMAP. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5′ regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding MEMAP, allelic variants, or related sequences.

[0228] Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the MEMAP encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:38-74 or from genomic sequences including promoters, enhancers, and introns of the MEMAP gene.

[0229] Means for producing specific hybridization probes for DNAs encoding MEMAP include the cloning of polynucleotide sequences encoding MEMAP or MEMAP derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ³²P or ³⁵S, or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

[0230] Polynucleotide sequences encoding MEMAP may be used for the diagnosis of disorders associated with expression of MEMAP. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjogren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; and a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha-antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas. The polynucleotide sequences encoding MEMAP may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered MEMAP expression. Such qualitative or quantitative methods are well known in the art.

[0231] In a particular aspect, the nucleotide sequences encoding MEMAP may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding MEMAP may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding MEMAP in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

[0232] In order to provide a basis for the diagnosis of a disorder associated with expression of MEMAP, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding MEMAP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

[0233] Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

[0234] With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

[0235] Additional diagnostic uses for oligonucleotides designed from the sequences encoding MEMAP may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding MEMAP, or a fragment of a polynucleotide complementary to the polynucleotide encoding MEMAP, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

[0236] In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding MEMAP may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding MEMAP are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSCCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego Calif.).

[0237] Methods which may also be used to quantify the expression of MEMAP include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P. C. et al. (1993) J. Inmunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

[0238] In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described in Seilhamer, J. J. et al., “Comparative Gene Transcript Analysis,” U.S. Pat. No. 5,840,484, incorporated herein by reference. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

[0239] In another embodiment, antibodies specific for MEMAP, or MEMAP or fragments thereof may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

[0240] A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., “Comparative Gene Transcript Analysis,” U.S. Pat. No. 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.

[0241] Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

[0242] Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E. F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N. L. Anderson (2000) Toxicol. Lett. 112-113:467471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released Feb. 29, 2000, available at http:/www.niehs.nih.gov/oc/news/toxchip.htm.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

[0243] In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

[0244] Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

[0245] A proteomic profile may also be generated using antibodies specific for MEMAP to quantify the levels of MEMAP expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem. 270:103-111; Mendoze, L. G. et al. (1999) Biotechniques 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

[0246] Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N. L. and J. Seilhamer (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

[0247] In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

[0248] In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

[0249] Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T. M. et al. (1995) U.S. Pat. No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R. A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M. J. et al. (1997) U.S. Pat. No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

[0250] In another embodiment of the invention, nucleic acid sequences encoding MEMAP may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J. J. et al. (1997) Nat. Genet. 15:345-355; Price, C. M. (1993) Blood Rev. 7:127-134; and Trask, B. J. (1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, e.g., Lander, E. S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.) Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding MEMAP on a 35 physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

[0251] In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R. A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

[0252] In another embodiment of the invention, MEMAP, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between MEMAP and the agent being tested may be measured.

[0253] Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with MEMAP, or fragments thereof, and washed. Bound MEMAP is then detected by methods well known in the art. Purified MEMAP can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

[0254] In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding MEMAP specifically compete with a test compound for binding MEMAP. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with MEMAP.

[0255] In additional embodiments, the nucleotide sequences which encode MEMAP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

[0256] Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

[0257] The disclosures of all patents, applications, and publications mentioned above and below, in particular U.S. Ser. No. 60/149,641 and U.S. Ser. No. 60/164,203 are hereby expressly incorporated by reference.

EXAMPLES

[0258] I. Construction of cDNA Libraries

[0259] RNA was purchased from Clontech or isolated from tissues described in Table 4. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

[0260] Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A+) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth Calif.), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin Tex.).

[0261] In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), pcDNA2.1 plasmid (Invitrogen, Carlsbad Calif.), or pINCY plasmid (Incyte Genomics, Palo Alto Calif.). Recombinant plasmids were transformed into competent E. coli cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5α, DH10B, or ElectroMAX DH10B from Life Technologies.

[0262] II. Isolation of cDNA Clones

[0263] Plasmids obtained as described in Example I were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg Md.); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4° C.

[0264] Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V. B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal 10 cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

[0265] III. Sequencing and Analysis

[0266] Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows. Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (PE Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (PE Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (PE Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VI.

[0267] The polynucleotide sequences derived from cDNA sequencing were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the art. Table 5 summarizes the tools, programs, and algorithms used and provides applicable descriptions, references, and threshold parameters. The first column of Table 5 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score, the greater the homology between two sequences). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco Calif.) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments were generated using the default parameters specified by the clustal algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

[0268] The polynucleotide sequences were validated by removing vector, linker, and polyA sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programing, and dinucleotide nearest neighbor analysis. The sequences were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and PFAM to acquire annotation using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full length polynucleotide sequences using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the GenBank databases (described above), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and Hidden Markov Model (HMM)-based protein family databases such as PFAM. HMM is a probabilistic approach which analyzes consensus primary structures of gene families. (See, e.g., Eddy, S. R. (1996) Curr. Opin. Struct. Biol. 6:361-365.) The programs described above for the assembly and analysis of full length polynucleotide and amino acid sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:38-74. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies were described in The Invention section above.

[0269] IV. Analysis of Polynucleotide Expression

[0270] Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel, 1995, supra, ch. 4 and 16.)

[0271] Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as: $\frac{{BLAST}\quad {Score} \times {Percent}\quad {Identity}}{5 \times {minimum}\quad \left\{ {{{length}\quad \left( {{Seq}.\quad 1} \right)},{{length}\left( {{Seq}.\quad 2} \right)}} \right\}}$

[0272] The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and −4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

[0273] The results of northern analyses are reported as a percentage distribution of libraries in which the transcript encoding MEMAP occurred. Analysis involved the categorization of cDNA libraries by organ/tissue and disease. The organ/tissue categories included cardiovascular, dermatologic, developmental, endocrine, gastrointestinal, hematopoietic/immune, musculoskeletal, nervous, reproductive, and urologic. The disease/condition categories included cancer, inflammation, trauma, cell proliferation, neurological, and pooled. For each category, the number of libraries expressing the sequence of interest was counted and divided by the total number of libraries across all categories. Percentage values of tissue-specific and disease- or condition-specific expression are reported in Table 3.

[0274] V. Chromosomal Mapping of MEMAP Encoding Polynucleotides

[0275] The cDNA sequences which were used to assemble SEQ ID NO:38-74 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:38-74 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 5). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Genethon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO:, to that map location.

[0276] The genetic map locations of SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:60, SEQ ID NO:63, and SEQ ID NO:67 are described in The Invention as ranges, or intervals, of human chromosomes. More than one map location is reported for SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:44, SEQ ID NO:60, and SEQ ID NO:63, indicating that 5 previously mapped sequences having similarity, but not complete identity, to SEQ ID NO:38 ,SEQ ID NO:39, SEQ ID NO:44, SEQ ID NO:60, and SEQ ID NO:63 were assembled into their respective clusters. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase 10 (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Genethon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Diseases associated with the public and Incyte sequences located within the indicated intervals are also reported in the Invention where applicable. Human genome maps and other resources available to the public, such as the NCBI “GeneMap'99” World Wide Web site (http://www.ncbi.nlm.nih.gov/genemap/), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.

[0277] VI. Extension of MEMAP Encoding Polynucleotides

[0278] The full length nucleic acid sequences of SEQ ID NO:38-74 were produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5 extension of the known fragment, and the other primer, to initiate 3′ extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68° C. to about 72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

[0279] Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

[0280] High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg²⁺, (NH₄)₂SO₄, and β-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 60° C., 1 min; Step 4: 68° C., 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68° C., 5 min; Step 7: storage at 4° C. In the alternative, the parameters for primer pair T7 and SK+were as follows: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 57° C., 1 min; Step 4: 68° C., 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68° C., 5 min; Step 7: storage at 4° C.

[0281] The concentration of DNA in each well was determined by dispensing 100 μl PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene Oreg.) dissolved in 1× TE and 0.5 μl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton Mass.), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μl to 10 μl aliquot of the reaction mixture was analyzed by electrophoresis on a 1% agarose mini-gel to determine which reactions were successful in extending the sequence.

[0282] The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison Wis.), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly Mass.) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent E. coli cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37° C. in 384-well plates in LB/2× carb liquid media.

[0283] The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 60° C., 1 min; Step 4: 72° C., 2 min; 25 Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72° C., 5 min; Step 7: storage at 4° C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethysulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (PE Biosystems).

[0284] In like manner, the polynucleotide sequences of SEQ ID NO:38-74 are used to obtain 5′ regulatory sequences using the procedure above, along with oligonucleotides designed for such extension, and an appropriate genomic library.

[0285] VII. Labeling and Use of Individual Hybridization Probes

[0286] Hybridization probes derived from SEQ ID NO:38-74 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250,uCi of [γ-³²P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston Mass.). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10⁷ counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

[0287] The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40° C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1× saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

[0288] VIII. Microarrays

[0289] The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, supra), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Schena (1999), supra). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645; Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.)

[0290] Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorbtion and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

[0291] Tissue or Cell Sample Preparation

[0292] Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)⁺ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)⁺ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/μl oligo-(dT) primer (21mer), 1× first strand buffer, 0.03 units/μl RNase inhibitor, 500 μM dATP, 500 μM dGTP, 500 μM dTTP, 40 μM dCTP, 40 μM dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)⁺ RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)⁺ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37° C. for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85° C. to the stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto Calif.) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14 μl 5× SSC/0.2% SDS.

[0293] Microarray Preparation

[0294] Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 g. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

[0295] Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Coming) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VVVR), West Chester Pa.), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110° C. oven.

[0296] Array elements are applied to the coated glass substrate using a procedure described in U.S. Pat. No. 5,807,522, incorporated herein by reference. 1 μl of the array element DNA, at an average concentration of 100 ng/μl, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

[0297] Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford Mass.) for 30 minutes at 60° C. followed by washes in 0.2% SDS and distilled water as before.

[0298] Hybridization

[0299] Hybridization reactions contain 9 μl of sample mixture consisting of 0.2 μg each of Cy3 and CyS labeled cDNA synthesis products in 5× SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65° C. for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm² coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μl of 5× SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60° C. The arrays are washed for 10 min at 45° C. in a first wash buffer (1× SSC, 0. 1% SDS), three times for 10 minutes each at 45° C. in a second wash buffer (0.1×SSC), and dried.

[0300] Detection

[0301] Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara Calif.) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of CyS. The excitation laser light is focused on the array using a 20× microscope objective (Nikon, Inc., Melville N.Y.). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm×1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

[0302] In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater N.J.) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

[0303] The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

[0304] The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood Mass.) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

[0305] A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

[0306] IX. Complementary Polynucleotides

[0307] Sequences complementary to the MEMAP-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring MEMAP. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of MEMAP. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5′ sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the MEMAP-encoding transcript.

[0308] X. Expression of MEMAP

[0309] Expression and purification of MEMAP is achieved using bacterial or virus-based expression systems. For expression of MEMAP in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the trp-lac (tac) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the lac operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express MEMAP upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of MEMAP in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica califomica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding MEMAP by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

[0310] In most expression systems, MEMAP is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma iaponicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from MEMAP at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified MEMAP obtained by these methods can be used directly in the assays shown in Examples XI and XV.

[0311] XI. Demonstration of MEMAP Activity

[0312] MEMAP activity is demonstrated using a generic immunoblotting strategy or through a MEMAP-specific activity assay as outlined below. As a general approach, cell lines or tissues transformed with a vector containing MEMAP coding sequences can be assayed for MEMAP activity by immunoblotting. Transformed cells are denatured in SDS in the presence of β-mercaptoethanol, nucleic acids are removed by ethanol precipitation, and proteins are purified by acetone precipitation. Pellets are resuspended in 20 mM tris buffer at pH 7.5 and incubated with Protein G-Sepharose pre-coated with an antibody specific for MEMAP. After washing, the Sepharose beads are boiled in electrophoresis sample buffer, and the eluted proteins subjected to SDS-PAGE. Proteins are transferred from the SDS-PAGE gel to a membrane for immunoblotting, and the MEMAP activity is assessed by visualizing and quantifying bands on the blot using antibody specific for MEMAP as the primary antibody and ²⁵I-labeled IgG specific for the primary antibody as the secondary antibody.

[0313] A specific assay for MEMAP activity measures the expression of MEMAP on the cell surface. cDNA encoding MEMAP is transfected into a mammalian (non-human) cell line. Cell surface proteins are labeled with biotin as described in de la Fuente, M. A. et al. ((1997) Blood 90:2398-2405). Immunoprecipitations are performed using MEMAP-specific antibodies, and immunoprecipitated samples are analyzed using SDS-PAGE and immunoblotting techniques. The ratio of labeled immunoprecipitant to unlabeled immunoprecipitant is proportional to the amount of MEMAP expressed on the cell surface.

[0314] In an alternative specific assay, MEMAP transport activity is assayed by measuring uptake of labeled substrates into Xenopus laevis oocytes. Oocytes at stages V and VI are injected with MEMAP mRNA (10 ng per oocyte) and incubated for 3 days at 18° C. in OR2 medium (82.5 mM NaCl, 2.5 mM KCl, 1 mM CaCl₂, 1 mM MgCl₂, 1 mM Na₂HPO₄, 5 mM Hepes, 3.8 mM NaOH, 50 μg/ml gentamycin, pH 7.8) to allow expression of MEMAP protein. Oocytes are then transferred to standard uptake medium (100 mM NaCl, 2 mM KCl, 1 mM CaCl₂, 1 mM MgCl₂, 10 mM Hepes/Tris pH 7.5). Uptake of various substrates (e.g., amino acids, sugars, drugs, and neurotransmitters) is initiated by adding a ³H substrate to the oocytes. After incubating for 30 minutes, uptake is terminated by washing the oocytes three times in Na⁺-free medium, measuring the incorporated ³H, and comparing with controls. MEMAP activity is proportional to the level of internalized ³H substrate.

[0315] XII. Functional Assays

[0316] MEMAP function is assessed by expressing the sequences encoding MEMAP at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT plasmid (Life Technologies) and pCR3.1 plasmid (Invitrogen), both of which contain the cytomegalovirus promoter. 5-10 μg of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μg of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow Cytometry, Oxford, New York N.Y..

[0317] The influence of MEMAP on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding MEMAP and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success N.Y.). MRNA can be purified from the cells using methods well known by those of skill in the art. Expression of MRNA encoding MEMAP and other genes of interest can be analyzed by northern analysis or microarray techniques.

[0318] XIII. Production of MEMAP Specific Antibodies

[0319] MEMAP substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M. G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

[0320] Alternatively, the MEMAP amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

[0321] Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (PE Biosystems) using FMOC chemistry and coupled to KLH (Sigma-Aldrich, St. Louis Mo.) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-MEMAP activity by, for example, binding the peptide or MEMAP to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

[0322] XIV. Purification of Naturally Occurring MEMAP Using Specific Antibodies

[0323] Naturally occurring or recombinant MEMAP is substantially purified by immunoaffinity chromatography using antibodies specific for MEMAP. An immunoaffinity column is constructed by covalently coupling anti-MEMAP antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

[0324] Media containing MEMAP are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of MEMAP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/MEMAP binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and MEMAP is collected.

[0325] XV. Identification of Molecules Which Interact with MEMAP

[0326] MEMAP, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter reagent. (See, e.g., Bolton A. E. and W. M. Hunter (1973) Biochem. J. 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled MEMAP, washed, and any wells with labeled MEMAP complex are assayed. Data obtained using different concentrations of MEMAP are used to calculate values for the number, affinity, and association of MEMAP with the candidate molecules.

[0327] Alternatively, molecules interacting with MEMAP are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989, Nature 340:245-246), or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).

[0328] MEMAP may also be used in the PATHCALLING process (CuraGen Corp., New Haven Conn.) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Pat. No. 6,057,101).

[0329] Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims. TABLE 1 Polypeptide Nucleotide SEQ ID NO: SEQ ID NO: Clone ID Library Fragments 26 63 2795577 NPOLNOT01 867213R6 (BRAITUT03), 2381770H1 (ISLTNOT01), 2795577CT1 (NPOLNOT01), 2795577H1 (NPOLNOT01) 27 64 3255825 OVARTUN01 3255825CT1 (OVARTUN01), 32558925H1 (OVARTUN01) 28 65 3393430 LUNGNOT28 2187169H1 (PROSNOT26), 3393256H1 (LUNGNOT28), 339343OH1 (LUNGNOT28), 3395774H1 (LUNGNOT28), 4689688H1 (LIVRTUT12), 4895996H1 (LIVRTUT12), 4896461F6 (LIVRTUT12), 4984527F6 (LIVRTUT10), 4992946H1 (LIVRTUT11) 29 66 3490990 EPIGNOT01 1235428F1 (LUNGFET03), 1662973T6 (BRSTNOT09), 2362021H1 (LUNGFET05), 2362021R6 (LUNGFET05), 3490990H1 (EPIGNOT01) 30 67 3635154 LIVRNOT03 027592H1 (SPLNFET01), 365154H1 (LIVRNOT03),g1012932 31 68 4374347 CONFNOT03 860875X11 (BRAITUT03), 898143R6 (BRSTNOT05), 4374347H1 (CONFNOT03) 32 69 4596747 COLSTUT01 137213R1 (SYNORAB01), 545568R6 (OVARNOT02), 1235402F1 (LUNGFET03), 1268010F1 (BRAINOT09), 1271078F1 (TESTTUT02), 1301951F6 (BRSTNOT07), 1994442R6 (BRSTTUT03), 2343102H1 (TESTTUT02), 3274538F6 (PROSBPT06), 4596747H1 (COLSTUT01) 33 70 5052680 BRSTNOT33 1973688H1 (UCMCL5T01), 3926410F6 (KIDNNOT19), 4501839F6 (BRAVTXT02), 5052680F6 (BRSTNOT33), 5052680H1 (BRSTNOT33), 5186780F6 (LUNGTMT04) 34 71 5373575 BRAINOT22 262776T6 (HNT2AGT01), 1234057F1 (LUNGFET03), 1741526R6 (HIPONON01), 1871204F6 (SKINBIT01), 2192479F6 (THYRTUT03), 2556849H1 (THYMNOT03), 2722451T6 (LUNGTUT10), 4114985H1 (UTRSTUT07), 5373575H1 (BRAINOT22) 1 38 112301 PITUNOT01 003382R1 (HMC1NOT01), 094523R1 (PITUNOT01), 112301H1 (PITUNOT01), 301778X11 (TESTNOT04), 320551X13 (EOSIHET02), 1368852R1 (SCORNON02), 1800784H1 (COLNNOT27), 2117174X17C1 (BRSTTUT02), 2526345F6 (BRAITUT21), 4333609H1 (KIDCTMT01) 2 39 997947 KIDNTUT01 997947H1 (KIDNTUT01), 997947T6 (KIDNTUT01), 1417936X306D1 (KIDNNOT09), 1672062X307V1 (BLADNOT05), 3738956T6 (MENTNOT01), SCCA01437V1, SCCA05013V1, SCCA016981V1, SCCA02873V1 3 40 1521513 BLADTUT04 1222062H1 (NEUTGMT01), 1521513H1 (BLADTUT04), 1521513T1 (BLADTUT04), 3558522F6 (LUNGNOT31), 3558522T6 (LUNGNOT31) 4 41 1863994 PROSNOT19 265171R6 (HNT2AGT01), 1863994H1 (PROSNOT19), 3750444F6 (UTRSNOT18), 4177677F6 (BRAINOT22), 4697638F6 (BRALNOT01), 4774040F6 (BRAQNOT01), SCEA02960V1 5 42 2071941 ISLTNOT01 286350R1 (EOSIHET02), 491305R1 (HNT2AGT01), 724168R1 (SYNOOAT01), 1466668F1 (PANCTUT02), 2071941H1 (ISLTNOT01), 2071941X11C1 (ISLTNOT01), 3579445H1 (293TF3T01) 6 43 2172512 ENDCNOT03 2172512H1 (ENDCNOT03), 2544419F6 (UTRSNOT11), 2798626H1 (NPOLNOT01), 32033591H1 (PENCNOT02), g1241299 7 44 2483172 SMCANOT01 217987F1 (STOMNOT01), 1289703F6 (BRAINOT11), 1289703T6 (BRAINOT11), 2211377F6 (SINTFET03), 2483172H1 (SMCANOT01), 2493236H1 (ADRETUT05), 3274006F6 (PROSBPT06) 8 45 2656128 THYMNOT04 2654722T6 (THYMNOT04), 2656128H1 (THYMNOT04), 2837168F6 (TLYMNOT03) 9 46 5855841 FIBAUNT02 894553T1 (BRSTNOT05), 1296289F1 (PGANNOT03), 1466541T1 (PANCTUT02), 2046927F6 (THP1T7T01), 2058873R6 (OVARNOT03), 3800875F6 (SPLNNOT12), 5855841H1 (FIBAUNT02) 10 47 603462 BRSTTUT01 603462H1 (BRSTTUT01), 1487733H1 (UCMCL5T01), 1750451F6 (STOMTUT02), 5182853T6 (LUNGTMT03) 11 48 747681 BRAITUT01 747681H1 (BRAITUT01), 752009R1 (BRAITUT01), 1267874F1 (BRAINOT09), 1833308R6 (BRAINON01), 267358X19F1 (KIDNNOT19), SBCA07003F3, SCDA07521V1, SCDA04982V1 SCDA07275V1 12 49 919469 RATRNOT02 153337R6 (THP1PLB02), 1525415F6 (UCMCL5T01), 1527804F1 (UCMCL5T01), 1985565R6 (LUNGAST01), 2397811T6 (THP1AZT01), SARB01416F1, SARA03198F1 13 50 977658 BRSTNOT02 977658H1 (BRSTNOT02), 1873689F6 (LEUKNOT02), 2155095F6 (BRAINOT09), 2186432F6 (PROSNOT26), 2204117F6 (SPLNFET02), 22O6291F6 (SPLNFET02), 3255048R6 (OVARTUN01), 3501520H1 (ADRENOT11), 3743427H1 (THYMNOT08) 14 51 1004703 BRSTNOT03 742178H1 (PANCNOT04), 1444583F6 (THYRNOT03), 2068902X15C1 (ISLTNOT01), 2616367F6 (GBLANOT01), SBVA02190V1 15 52 1334051 COLNNOT13 3222815T6 (COLNNON03), SXBC00794V1, SXBC00639V1 16 53 1336728 COLNNOT13 630458R6 (KIDNNOT05), 1336728H1 (COLNNOT13), SXBC00758V1, SXBC0182SV1, SXBC01531V1, SXBC01624V1, SXBC00128V1 17 54 1452856 PENITUT01 873008R1 (LUNGAST01), 1452856H1 (PENITUT01), 2433573H1 (BRAVUNT02), 2444932F6 (THP1NOT03), 2858295F6 (SININOT03) 18 55 1562471 SPLNNOT04 286237F1 (EOSIHET02), 1562471H1 (SPLNNOT04), 1880730F6 (LEUKNOT03), 3420608F6 (UCMCNOT04), SBWA00968V1, SXBC01387V1, SBWA02301V1 19 56 1618158 BRAITUT12 967563R1 (BRSTNOT05), 1618158H1 (BRAITUT12), 1785271F6 (BRAINOT10), 2074680F6 (ISLTNOT01), 2822196H1 (ADRETUT06) 20 57 1656935 URETTUT01 1656935F6 (URETTUT01), 1656935H1 (URETTUT01), 2827605F6 (TLYMNOT03), 5272146H1 (OVARDIN02), g1482116 21 58 1859305 PROSNOT18 079372F1 (SYNORAB01), 649845R1, (BRSTNOT03), 1859305H1 (PROSNOT18), 3328091F6 (HEADONOT04), 3354812F6 (PROSNOT28), 5510642H1 (BRADDIR01) 22 59 1949083 PITUNOT01 1287161H1 (BRAINOT11), 1949083H1 (PITUNOT010, 1949083R6 (PITUNOT01), 1949083T6 (PITUNOT01), 3814131F6 (TONSNOT03) 23 60 1996357 BRSTTUT03 260527R6 (HNT2RAT01), 260527T6 (HNT2RAT01), 1313441F1 (BLADTUT02), 1442781R1 (THYRNOT03), 1996357H1 (BRSTTUT03), 1996357T6 (BRSTTUT03), 4262451H1 (BSCNDIT02), SAZA00147F1 24 61 2061330 OVARNOT03 2061330H1 (OVARNOT03), 2724233T6 (LUNGTUT10), 5104031T6 (PROSTUS20) 25 62 2346947 TESTTUT02 2346947F6 (TESTTUT02), 2346947H1 (TESTTUT02), 4051345F6 (SINTNOT18) 35 72 5524462 LIVRDIR01 4024068F6 (BRAXNOT02), 5524468H1 (LIVRDIR01), SXBC01952V1 36 73 5944279 COLADIT05 1662182H1 (BRSTNOT09), 1698677F6 (BLADTUT05), 1916639R6 (PROSNOT06), 1916639T6 (PROSNOT06), 2298565R6 (BRSTNOT05), 2298565T6 (BRSTNOT05), 2583019F6 (KIDNTUT13), 2870903F6 (THYRNOT10), 3970715H1 (PROSTUT10), 3971695H1 (PROSTUT10), 5944279H1 (COLADIT05) 37 74 6114480 SINITMT04 1579843F6 (DUODNOT01), 1579843T6 (DUODNOT01), 4181024T6 (SINITUT03), 6114480H1 (SINITMT04), SXBC0007V1, SXBC00504V1, SCSA05104V1

[0330] TABLE 2 Amino Potential Potential Analytical Polypeptide Acid Phosphorylation Glycosyla- Signature Sequences, Homologous Methods and SEQ ID NO: Residues Sites tion Sites Motifs, and Domains Sequences Databases 1 351 S31 T116 S169 N128 Signal peptide: Paraneoplastic BLAST-GenBank T229 T2 S209 M1-A33 neuronal MOTIFS T306 antigen MA1 SPSCAN [Homo sapiens] g4104634 2 458 T198 S27 S37 N75 N159 Signal peptide: Pancortin-3 BLAST-GenBank T87 S251 S257 N279 N445 M1-T24 [Mus musculus] MOTIFS S325 S373 S405 Glycoprotein g3218528 SPSCAN S422 T454 T210 signature: HMMER S228 S401 Y93 C199-L448 BLAST-PRODOM 3 219 T51 S120 S163 N2 N62 Signal peptide: Murine BLAST-GenBank T175 T181 S3 N107 M1-C42 macrophage C- MOTIFS T12 T45 S75 Transmembrane domain: type lectin SPSCAN S104 S128 L32-F49 [Mus musculus] HMMER C-type lectin domain: g5821286 HMMER-PFAM C80-E206 BLIMPS-BLOCKS PROFILESCAN BLAST-DOMO 4 276 S213 S91 S113 Signal peptide: BLAST-GenBank S35 S70 S76 M1-G31 MOTIFS S147 T163 S206 Transmembrane domain: HMMER I184-F201 Cell attachment sequence: R149-D151 5 375 S18 S205 T286 Transmembrane domains: Transmembrane BLAST-GenBank S3 S120 S197 W139-R158; F173-H191 protein MOTIFS T260 Y85 P232-Q254 [S. pombe] HMMER Transmembrane protein g1065898 BLAST-DOMO signature: BLAST-PRODOM I95-C369 6 249 T7 T135 T170 N18 N92 Phospholipid BLAST-GenBank S204 Y154 N147 scramblase MOTIFS [Homo sapiens] g4092081 7 353 T162 T4 S97 N299 Signal peptide: Paraneoplastic BLAST-GenBank T115 S165 S194 M1-A33 neuronal MOTIFS T225 S242 S17 antigen MA1 SPSCAN S47 S205 [Homo sapiens] g4104634 8 194 T12 S115 S29 N95 N147 Signal peptide: Lectin-like NK BLAST-GenBank S99 S187 M1-C50 cell receptor MOTIFS Transmembrane domain: LLT1 SPSCAN L38-L56 [Homo sapiens] HMMER C-type lectin domain: g6651065 HMMER-PFAM C75-E194 BLIMPS-BLOCKS BLAST-DOMO 9 322 S304 S48 S146 N20 N60 Signal peptide: BLAST-GenBank S72 T133 S255 N70 M1-A50 MOTIFS S280 SPSCAN 10 335 S125 S140 S183 Transmembrane domains: GufA protein BLAST-GenBank S222 T252 G71-L94; A255-I283 [Thermotoga MOTIFS GufA transmembrane maritima] HMMER protein domain: g4982315 BLAST-PRODOM L12-H101; G180-G335 BLAST-DOMO Glycosaminoglycan attachment site: S310-G313 11 620 S49 S108 T146 N144 N202 Transmembrane domain: Slit2 BLAST-GenBank S300 T348 T349 N264 N274 M563-W582 [Rattus MOTIFS S607 S4 S128 N293 N341 Immunoglobulin domain: norvegicus] HMMER S183 S234 T420 N492 N505 G439-A499 g4585574 HMMER-PFAM S460 S467 S543 N526 N542 Leucine-rich repeat BLIMPS-PRINTS Y597 signature: BLAST-DOMO L337-L350 Glycoprotein hormone receptor domain: T40-L198 12 491 T231 T232 S253 N56 N220 Transmembrane domains: Selectively BLAST-GenBank T482 S185 S276 N229 I115-I142; I184-V201 expressed in MOTIFS F422-F441 embryonic HMMER Transmembrane protein epithelia BLAST-PRODOM domain: protein-1 L8-Y215; I396-F471 [Mus musculus] g6715148 PB39 [Homo sapiens] g3462515 13 580 S557 S10 T34 N159 N179 Transmembrane domains: MOTIFS S51 T92 T210 N220 N230 F297-F313; I356-I373 HMMER S343 T12 S217 L496-I514 T222 S268 S296 Lipases serine active T417 T523 S550 site: L104-A113 14 455 T53 T182 S239 N67 N180 Transmembrane domains: putative G- BLAST-GenBank S69 S135 S202 N243 V81-V99; I343-I361 protein MOTIFS T280 S355 S372 S375-V392; W425-Y442 coupled HMMER Y38 Glycosaminoglycan receptor attachment site [Homo sapiens] S162-G165 g6649579 15 277 S265 T66 T225 N29 N38 Transmembrane domain: AdRab-A brush BLAST-GenBank S268 S273 S30 N47 N48 K9-F27 border MOTIFS S49 S61 S152 N92 N160 Brush border protein membrane HMMER S193 Y242 N210 domain: protein BLAST-PRODOM Y8-R277 [Oryctolagus RGD cell attachment cuniculus] sequence: g1762 R113-D115 16 647 S490 T50 S67 N261 Signal peptide: LIV-1 protein BLAST-GenBank S105 T110 S121 M1-A22 [Homo sapiens] MOTIFS T220 S249 S264 Transmembrane domains: g1256001 SPSCAN S272 S322 T389 L328-L347; M406-L424 HMMER S469 T501 S639 L559-A578; W618-L638 BLAST-PRODOM S132 T155 S242 GufA transmembrane S324 T381 T400 protein domain: S522 S554 E485-L640 Glycosaminoglycan attachment site: S34-G37 17 406 S29 S215 S236 N23 Transmembrane domains: MOTIFS T69 Q76-V95; W286-S313 HMMER M367-I384 18 290 T221 S44 S69 N88 Signal peptide: NK inhibitory BLAST-GenBank S71 S81 T94 M1-A19 receptor MOTIFS T101 T113 T131 Transmembrane domains: [Homo sapiens] SPSCAN S216 Y284 P160-M181 g6707799 HMMER Immunoglubulin domain: CMRF-35-H9 HMMER-PFAM R33-I110 leukocyte BLAST-PRODOM Transmembrane antigen [Homo BLAST-DOMO glycoprotein domain: sapiens] I22-D116 g4103066 19 390 S7 T68 S153 T23 N5 N88 Immunoglobulins and MOTIFS T166 T281 Y20 N330 N367 MHC proteins BLIMPS-BLOCKS Y37 signature: BLIMPS-PRODOM T90-P112; F242-V259 Glycoprotein antigen signature: L61-V72; V92-I113 20 427 S13 S41 S65 S66 N106 N148 Mucin glycoprotein Gastric mucin BLAST-GenBank S99 T150 S323 N171 N233 precursor domain: [Sus scrofa] MOTIFS S324 S101 S275 N312 V136-P142 g915208 BLIMPS-PRODOM S353 S367 T399 Y71 21 459 T4 S60 S66 S116 N14 N158 Transmembrane domains: six BLAST-GenBank T176 S16 T235 N323 F202-V219; I246-L268 transmembrane MOTIFS W343-L367; P417-P440 epithelial HMMER antigen of prostrate [Homo sapiens] g6572948 22 229 S13 S118 T155 Transmembrane domains: MOTIFS Y24 I93-V111; V132-L150 HMMER F164-V182 BLIMPS-PRODOM Transmembrane protein domain: S156-V182 23 311 S85 S234 S236 N22 Transmembrane domains: MOTIFS S269 S80 S119 W58-I76; P152-K177 HMMER S186 T294 A216-Y232 24 92 S47 T54 T12 S70 N62 HERV-E BLAST-GenBank envelope MOTIFS glycoprotein [Homo sapiens] g2587024 25 258 S34 T33 S148 Transmembrane domains: MOTIFS S243 I39-I57; F86-L106 HMMER V122-I140; L190-S210 26 226 S56 S128 T196 N54 N187 Signal peptide: MTP (mouse BLAST-GenBank T167 Y194 N198 M1-P50 transporter MOTIFS Transmembrane domains: protein) SPSCAN T23-L43; M72-A89 [Mus musculus] HMMER I101-I124; I158-N178 g1276631 PROFILESCAN Transmembrane 4 family BLAST-PRODOM signature: A70-I120 Lysosomal-associated transmembrane protein domain: C15-Y223 27 136 S3 S132 Signal peptide: MOTIFS M1-R53 SPSCAN Transmembrane domains: HMMER I10-L28; T26-I50 BLAST-PRODOM F70-L89 Transmembrane protein domain: D31-V104 28 458 T408 T98 S126 N96 N151 Signal peptide: Potential BLAST-GenBank S170 T334 N293 N332 M1-A20 ligand MOTIFS Transmembrane domain: (odorant) SPSCAN L10-N30 binding HMMER Membrane glycoprotein protein BLAST-PRODOM signature: [Rattus BLAST-DOMO L9-V101; L64-Q457 rattus] g57732 Olfactory ligand binding domain: T67-S452 29 368 S24 T166 T302 N17 Fuzzy (TM BLAST-GenBank S12 S134 Y307 protein MOTIFS involved in tissue polarity) [Drosophila melanogaster] g2564657 30 91 T44 S84 signal peptide: Preglycophorin BLAST-GenBank M1-A19 B [Homo MOTIFS Transmembrane domain: sapiens] SPSCAN P58-S82 g4803699 HMMER Glycophorin A proteins BLIMPS-BLOCKS signature: PROFILESCAN T22-S32; I63-G91 BLAST-PRODOM Glycophorin domain: BLAST-DOMO M1-R86 31 295 S96 T113 S129 N111 N169 Signal peptide: Biliary BLAST-GenBank T155 T125 T157 N223 M1-G48 glycoprotein MOTIFS T187 S222 T231 Transmembrane domain: [Mus musculus] SPSCAN T263 Y212 L241-L259 g312590 HMMER Immunoglobulin domain: HMMER-PFAM K159-V216 BLAST-PRODOM Carcinoembryonic BLAST-DOMO antigen domain: I38-P147 Glycoprotein antigen domain: M1-V140; Y141-Y234 G239-S295 32 724 T39 S47 T171 N279 N348 Transmembrane domain: MOTIFS S205 T224 S225 I611-F630 HMMER T241 S285 S301 Membrane protein BLAST-DOMO T323 S352 T353 domain: S439 S509 S517 T4-L209 S537 T659 T707 S8 S18 S49 S72 T85 T159 S173 S271 S367 S560 S588 Y499 33 331 S117 S147 S149 N222 Signal peptide: Putative Golgi BLAST-GenBank T320 S138 S174 M1-S16 UDP-G1cNAc MOTIFS T274 T319 S328 Transmembrane domains: transporter SPSCAN Y198 A67-N87; I118-C134 [S. pombe] HMMER W240-V269; L294-Y310 g3738167 BLAST-PRODOM Transmembrane protein domain: A6-T311 34 398 T42 T158 S271 Transmembrane domain: Stomatin-like BLAST-GenBank S28 S285 T334 I59-L79 protein UNC24 MOTIFS S375 Band 7 family domain: [Homo sapiens] HMMER F64-A231, A78-V90; g5326747 HMMER-PFAM R116-L154 BLIMPS-BLOCKS Stomatin signature: BLIMPS-PRINTS T84-L106; L131-P152 BLAST-PRODOM T166-L183; I186-G209 BLAST-DOMO L54-Q227 35 220 S199 T120 5192 N107 Signal peptide: Similar to BLAST-GenBank M1-G19 Leucine-rich MOTIFS Leucine rich repeats: transmembrane SPSCAN A62-F85; Q86-S109 proteins HMMER G110-G133; A134-R157 [Homo sapiens] HMMER-PFAM A158-S181; H184-P207 g2781386 BLIMPS-PRINTS 36 706 T564 T74 T113 N101 Transmembrane domains: LAK-4p BLAST-GenBank S291 S452 S632 F158-M178; L344-V368 [Homo sapiens] MOTIFS S14 T42 S66 L425-L442; M478-F498 g7209574 HMMER T115 T142 S286 A581-I604; L641-V665 T551 T575 S701 Glycosaminoglycan attachment site S223-G226 37 466 T326 S10 T46 N368 Signal peptide: Butyrophilin BLAST-GenBank T105 S187 S98 M1-G23 like receptor MOTIFS T164 T310 S321 Transmembrane domain: [Homo sapiens] SPSCAN Y388 A236-I255 g4587209 HMMER SPRY domain: HMMER-PFAM A338-S464; E123-S136 BLIMPS-PFAM E322-W343; V407-F420 BLAST-PRODOM Butyrophilin domain: BLAST-DOMO W19-C114

[0331] TABLE 3 Nucleotide Selected Tissue Expression Disease or Condition SEQ ID NO: Fragments (Fraction of Total) (Fraction of Total) Vector 38 844-888 Nervous (0.377) Cancer (0.410) PBLUESCRIPT Reproductive (0.180) Inflammation/Trauma (0.296) Cardiovascular (0.115) Cell Proliferation (0.131) Gastrointestinal (0.115) 39 579-623 Developmental (0.400) Cancer (0.400) PSPORT1 Musculoskeletal (0.200) Cell Proliferation (0.400) Nervous (0.200) Urologic (0.200) 40 336-380 Cardiovascular (0.267) Cancer (0.400) pINCY Hematopoietic/Immune (0.200) Inflammation/Trauma (0.400) Endocrine (0.133) Cell Proliferation (0.133) Reproductive (0.133) 41 596-640 Nervous (0.588) Inflammation/Trauma (0.470) pINCY Gastrointestinal (0.118) Cancer (0.235) Reproductive (0.118) Cell Proliferation (0.176) 42 1281-1325 Reproductive (0.237) Cancer (0.441) pINCY Hematopoietic/Immune (0.145) Inflammation/Trauma (0.323) Nervous (0.145) Cell Proliferation (0.178) 43 227-271 Reproductive (0.444) Cancer (0.333) pINCY Dermatologic (0.222) Cell Proliferation (0.222) Endocrine (0.111) Inflammation/Trauma (0.222) Gastrointestinal (0.111) Nervous (0.111) 44 1368-1412 Nervous (0.339) Cancer (0.478) pINCY Reproductive (0.278) Inflammation/Trauma (0.278) Gastrointestinal (0.104) Cell Proliferation (0.165) 45 543-587 Hematopoietic/Immune (0.500) Inflammation/Trauma (0.500) pINCY Gastrointestinal (0.188) Cancer (0.250) Cell Proliferation (0.188) 46 280-324 Reproductive (0.267) Cancer (0.483) pINCY Nervous (0.233) Inflammation/Trauma (0.345) Gastrointestinal (0.112) Cell Proliferation (0.155) 47 380-424 Reproductive (0.412) Cancer (0.647) PSPORT1 875-919 Gastrointestinal (0.176) Inflammation/Trauma (0.178) Cardiovascular (0.118) 48 272-316 Nervous (0.645) Cancer (0.355) PSPORT1 1514-1558 Developmental (0.129) Cell Proliferation (0.258) Neurological (0.194) 49 282-326 Hematopoietic/Immune (0.238) Cancer (0.381) PSPORT1 768-812 Gastrointestinal (0.155) Inflammation/Trauma (0.381) Reproductive (0.143) Cell Proliferation (0.202) 50 597-641 Reproductive (0.214) Cancer (0.464) PSPORT1 1074-1118 Nervous (0.196) Inflammation/Trauma (0.304) Hematopoietic/Immune (0.143) Cell Proliferation (0.196) 51  973-1017 Reproductive (0.266) Cancer (0.516) PSPORT1 Nervous (0.234) Inflammation/Trauma (0.359) Hematopoietic/Immune (0.125) Cell Proliferation (0.109) 52 299-343 Gastrointestinal (1.000) Cancer (0.500) pINCY Inflammation/Trauma (0.500) 53 380-424 Gastrointestinal (0.289) Cancer (0.578) pINCY 1199-1243 Reproductive (0.244) Inflammation/Trauma (0.311) Cardiovascular (0.111) Cell Proliferation (0.178) Hematopoietic/Immune (0.111) 54 1135-1179 Nervous (0.195) Cancer (0.449) pINCY Reproductive (0.186) Inflammation/Trauma (0.305) Gastrointestinal (0.144) Cell Proliferation (0.144) 55 325-369 Hematopoietic/Immune (0.750) Inflammation/Trauma (0.625) pINCY 820-864 Cancer (0.125) 56 487-531 Nervous (0.583) Cancer (0.458) pINCY 1090-1134 Inflammation/Trauma (0.250) 57 569-613 Reproductive (0.429) Cancer (0.571) pINCY 1360-1405 Hematopoietic/Immune (0.286) Inflammation/Trauma (0.286) Musculoskeletal (0.143) Cell Proliferation (0.143) Urologic (0.143) 58 272-472 Reproductive (0.350) Cancer (0.500) pINCY 551-595 Nervous (0.150) Inflammation/Trauma (0.500)  812-1012 Cardiovascular (0.100) 1523-1567 Gastrointestinal (0.100) Hematopoietic/Immune (0.100) Urologic (0.100) 59 217-261 Nervous (0.286) Inflammation/Trauma (0.428) PBLUESCRIPT Developmental (0.143) Cancer (0.357) Gastrointestinal (0.143) Cell Proliferation (0.143) Hematopoietic/Immune (0.143) Reproductive (0.143) 60 444-488 Nervous (0.207) Cancer (0.467) PSPORT1 Reproductive (0.207) Inflammation/Trauma (0.359) Gastrointestinal (0.130) Cell Proliferation (0.163) Hematopoietic/Immune (0.130) 61 643-687 Reproductive (0.464) Cancer (0.500) PSPORT1 Endocrine (0.143) Inflammation/Trauma (0.321) Cardiovascular (0.107) Gastrointestinal (0.107) 62 146-344 Gastrointestinal (0.500) Cancer (0.750) pINCY 390-434 Hematopoietic/Immune (0.250) Inflammation/Trauma (0.250) 506-704 Reproductive (0.250) 786-830 63 163-207 Reproductive (0.315) Cancer (0.594) pINCY Gastrointestinal (0.161) Cell Proliferation (0.231) Cardiovascular (0.147) Inflammation/Trauma (0.210) 64 201-506 Gastrointestinal (0.455) Cancer (0.455) PSPORT1 525-569 Cardiovascular (0.273) Inflammation/Trauma (0.367) 606-912 Reproductive (0.189) Cell Proliferation (0.189)  975-1280 1362-1406 65 703-747 Gastrointestinal (0.667) Cancer (1.000) pINCY Cardiovascular (0.167) Reproductive (0.167) 66 271-315 Nervous (0.314) Cancer (0.429) pINCY 319-363 Reproductive (0.314) Cell Proliferation (0.171) Developmental (0.114) Inflammation/Trauma (0.143) Urologic (0.114) 67 319-363 Developmental (0.364) Cell Proliferation (0.727) pINCY Hematopoietic/Immune (0.364) Cancer (0.273) Gastrointestinal (0.182) Inflammation/Trauma (0.182) 68 812-856 Reproductive (0.444) Cancer (0.556) pINCY Nervous (0.222) Inflammation/Trauma (0.333) Endocrine (0.111) Hematopoietic/Immune (0.111) Musculoskeletal (0.111) 69 596-640 Reproductive (0.255) Cancer (0.429) pINCY 1577-1621 Nervous (0.184) Inflammation/Trauma (0.337) Developmental (0.122) Cell Proliferation (0.255) Gastrointestinal (0.122) 70 379-675 Nervous (0.467) Cancer (0.467) pINCY 703-747 Hematopoietic/Immune (0.200) Cell Proliferation (0.267)  766-1062 Reproductive (0.133) Inflammation/Trauma (0.267) 1081-1347 Urologic (0.133) 71 18-62 Nervous (0.265) Cancer (0.500) pINCY Reproductive (0.206) Inflammation/Trauma (0.264) Musculoskeletal (0.147) Cell Proliferation (0.147) 72 290-488 Gastrointestinal (0.333) Inflammation/Trauma (0.667) pINCY 507-704 Hematopoietic/Immune (0.333) Cancer (0.333) 759-803 Nervous (0.333) 73 649-693 Reproductive (0.392) Cancer (0.686) pINCY 1711-1755 Gastrointestinal (0.294) Inflammation/Trauma (0.294) Cardiovascular (0.118) 74 704-748 Gastrointestinal (0.923) Cancer (0.462) pINCY Inflammation/Trauma (0.385)

[0332] TABLE 4 Nucleotide SEQ ID NO: Library Library Description 38 PITUNOT01 This library was constructed using RNA obtained from Clontech (CLON 6584-2, lot 35278). The RNA was isolated from pituitary glands removed from a pool of 18 male and female Caucasian donors, 16 to 70 years old, who died from trauma. 39 KIDNTUT01 This library was constructed using RNA isolated from kidney tumor tissue removed from an 8-month-old female during nephroureterectomy. Pathology indicated Wilms' tumor (nephroblastoma), which involved 90 percent of the renal parenchyma. Prior to surgery, the patient was receiving heparin anticoagulant therapy. 40 BLADTUT04 This library was constructed using RNA isolated from bladder tumor tissue removed from a 60-year-old Caucasian male during a radical cystectomy, prostatectomy, and vasectomy. Pathology indicated grade 3 transitional cell carcinoma in the left bladder wall. Carcinoma in-situ was identified in the dome and trigone, Patient history included tobacco use. Family history included type I diabetes, malignant neoplasm of the stomach, atherosclerotic coronary artery disease, and acute myocardial infarction. 41 PROSNOT19 This library was constructed using RNA isolated from diseased prostate tissue removed from a 59-year-old Caucasian male during a radical prostatectomy with regional lymph node excision. Pathology indicated adenofibromatous hyperplasia. Pathology for the associated tumor tissue indicated an adenocarcinoma (Gleason grade 3 + 3) . The patient presented with elevated prostate-specific antigen (PSA) . Patient history included colon diverticuli, asbestosis, and thrombophlebitis. Family history included benign hypertension, multiple myeloma, hyperlipidemia and rheumatoid arthritis. 42 ISLTNOT01 This library was constructed using RNA isolated from a pooled collection of pancreatic islet cells. 43 ENDCNOT03 This library was constructed using RNA isolated from dermal microvascular endothelial cells removed from a neonatal Caucasian male. 44 SMCANOT01 This library was constructed using RNA isolated from an aortic smooth muscle cell line derived from the explanted heart of a male obtained during a heart transplant. 45 THYMNOT04 This library was constructed using RNA isolated from thymus tissue removed from a 3-year-old Caucasian male, who died from anoxia. 46 FIBAUNT02 This library was constructed using RNA isolated from untreated aortic adventitial fibroblasts removed from a 65-year-old Caucasian female. 47 BRSTTUT01 This library was constructed using RNA isolated from breast tumor tissue removed from a 55-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated invasive grade 4 mammary adenocarcinoma. Patient history included atrial tachycardia and a benign breast neoplasm. Family history included cardiovascular and cerebrovascular disease and depressive disorder. 48 BRAITUT01 This library was constructed using RNA isolated from brain tumor tissue removed from a 50-year-old Caucasian female during a frontal lobectomy. Pathology indicated recurrent grade 3 oligoastrocytoma with focal necrosis and extensive calcification. Patient history included a speech disturbance and epilepsy. The patient's brain had also been irradiated with a total dose of 5,082 cyg (Fraction 8). Family history included a brain tumor. 49 RATRNOT02 This library was constructed using RNA isolated from the right atrium tissue of a 39-year-old Caucasian male, who died from a gunshot wound. 50 BRSTNOT02 This library was constructed using RNA isolated from diseased breast tissue removed from a 55-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated proliferative fibrocysytic changes characterized by apocrine metaplasia, sclerosing adenosis, cyst formation, and ductal hyperplasia without atypia. Pathology for the associated tumor tissue indicated an invasive grade 4 mammary adenocarcinoma. Patient history included atrial tachycardia and a benign neoplasm. Family history included cardiovascular and cerebrovascular disease. 51 BRSTNOT03 This library was constructed using RNA isolated from diseased breast tissue removed from a 54-year-old Caucasian female during a bilateral radical mastectomy. Pathology for the associated tumor tissue indicated residual invasive grade 3 mammary ductal adenocarcinoma. Patient history included kidney infection and condyloma acuminatum. Family history included benign hypertension, hyperlipidemia and a malignant neoplasm of the colon. 52 COLNNOT13 This library was constructed using RNA isolated from ascending colon tissue of a 28-year-old Caucasian male with moderate chronic ulcerative colitis. 53 COLNNOT13 This library was constructed using RNA isolated from ascending colon tissue of a 28-year-old Caucasian male with moderate chronic ulcerative colitis. 54 PENITUT01 This library was constructed using RNA isolated from tumor tissue removed from the penis of a 64-year-old Caucasian male during penile amputation. Pathology indicated a fungating invasive grade 4 squamous cell carcinoma involving the inner wall of the foreskin and extending onto the glans penis. Patient history included benign neoplasm of the large bowel, atherosclerotic coronary artery disease, angina pectoris, gout, and obesity. Family history included malignant pharyngeal neoplasm, chronic lymphocytic leukemia, and chronic liver disease.

[0333] TABLE 5 Program Description Reference Parameter Threshold ABI FACTURA A program that removes vector sequences and PE Biosystems, Foster City, CA. masks ambiguous bases in nucleic acid sequences. ABI/PARACEL FDF A Fast Data Finder useful in comparing and PE Biosystems, Foster City, CA; Mismatch <50% annotating amino acid or nucleic acid sequences. Paracel Inc., Pasadena, CA. ABI AutoAssembler A program that assembles nucleic acid sequences. PE Biosystems, Foster City, CA. BLAST A Basic Local Alignment Search Tool useful in Altschul, S. F. et al. (1990) J. Mol. Biol. ESTs: Probability value = sequence similarity search for amino acid and 215:403-410; Altschul, S. F. et al. (1997) 1.0E−8 or less nucleic acid sequences. BLAST includes five Nucleic Acids Res. 25:3389-3402. Full Length sequences: functions: blastp, blastn, blastx, tblastn, and Probability value = tblastx. 1.0E−10 or less FASTA A Pearson and Lipman algorithm that searches for Pearson, W. R. and D. J. Lipman (1988) ESTs: fasta E value = similarity between a query sequence and a group Proc. Natl. Acad Sci. USA 85:2444-2448; 1.06E−6 Assembled ESTs: of sequences of the same type. FASTA comprises Pearson, W. R. (1990) Methods Enzymol. fasta Identity = 95% as least five functions: fasta, tfasta, fastx, 183:63-98; and Smith, T. F. and or greater and Match length = tfastx, and ssearch. M. S. Waterman (1981) Adv. Appl. 200 bases or greater; Math. 2:482-489. fastx E value = 1.0E−8 or less Full Length sequences: fastx score = 100 or greater BLIMPS A BLocks IMProved Searcher that matches a Henikoff, S. and J. G. Henikoff (1991) Score = 1000 or greater; sequence against those in BLOCKS, PRINTS, Nucleic Acids Res. 19:6565-6572; Henikoff, Ratio of Score/Strength = DOMO, PRODOM, and PFAM databases to J. G. and S. Henikoff (1996) Methods 0.75 or larger; and, if search for gene families, sequence Enzymol. 266:88-105; and Attwood, T. K. applicable, Probability value = homology, and structural fingerprint regions. et al. (1997) J. Chem. Inf. Comput. 1.0E−3 or less Sci. 37:417-424. HMMER An algorithm for searching a query sequence Krogh, A. et al. (1994) J. Mol. Biol. Score = 10-50 bits for against hidden Markov model (HMM)-based 235:1501-1531; Sonnhammer, E. L. L. et al. PFAM hits, depending on databases of protein family consensus sequences, (1988) Nucleic Acids Res. 26:320-322. individual protein families such as PFAM. ProfileScan An algorithm that searches for structural and Gribskov, M. et al, (1988) CABIOS Normalized quality sequence motifs in protein sequences that match 4:61-66; Gribskov, M. et al. score ≧ GCG-specified sequence patterns defined in Prosite. (1989) Methods Enzymol. 183:146-159; “HIGH” value for that Bairoch, A. et al. (1997) particular Prosite motif. Nucleic Acids Res. 25:217-221. Generally, score = 1.4-2.1. Phred A base-calling algorithm that examines automated Ewing, B. et al. (1998) Genome Res. sequencer traces with high sensitivity and 8:175-185; Ewing, B. and P. Green probability. (1998) Genome Res. 8:186-194. Phrap A Phils Revised Assembly Program including Smith, T. F. and M. S. Waterman (1981) Score = 120 or greater; SWAT and CrossMatch, programs based on Adv. Appl. Math. 2:482-489; Smith, T. F. Match length = 56 or greater efficient implementation of the and M. S. Waterman (1981) J. Mol. Biol. Smith-Waterman algorithm, useful in searching 147:195-197; and Green, P., University sequence homology and assembling DNA of Washington, Seattle, WA. sequences. Consed A graphical tool for viewing and editing Phrap Gordon, D. et al. (1998) Genome assemblies. Res. 8:195-202. SPScan A weight matrix analysis program that scans Nielson, H. et al. (1997) Protein Engineering Score = 3.5 or greater protein sequences for the presence of 10:1-6; Claverie, J. M. and S. Audic (1997) secretory signal peptides. CABIOS 12:431-439. Motifs A program that searches amino acid sequences for Bairoch, A. et al. (1997) Nucleic Acids Res. patterns that matched those defined in Prosite. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.

[0334]

1 74 1 351 PRT Homo sapiens misc_feature Incyte ID No 112301CD1 1 Met Thr Leu Arg Leu Leu Glu Asp Trp Cys Arg Gly Met Asp Met 1 5 10 15 Asn Pro Arg Lys Ala Leu Leu Ile Ala Gly Ile Ser Gln Ser Cys 20 25 30 Ser Val Ala Glu Ile Glu Glu Ala Leu Gln Ala Gly Leu Ala Pro 35 40 45 Leu Gly Glu Tyr Arg Leu Leu Gly Arg Met Phe Arg Arg Asp Glu 50 55 60 Asn Arg Lys Val Ala Leu Val Gly Leu Thr Ala Glu Thr Ser His 65 70 75 Ala Leu Val Pro Lys Glu Ile Pro Gly Lys Gly Gly Ile Trp Arg 80 85 90 Val Ile Phe Lys Pro Pro Asp Pro Asp Asn Thr Phe Leu Ser Arg 95 100 105 Leu Asn Glu Phe Leu Ala Gly Glu Gly Met Thr Val Gly Glu Leu 110 115 120 Ser Arg Ala Leu Gly His Glu Asn Gly Ser Leu Asp Pro Glu Gln 125 130 135 Gly Met Ile Pro Glu Met Trp Ala Pro Met Leu Ala Gln Ala Leu 140 145 150 Glu Ala Leu Gln Pro Ala Leu Gln Cys Leu Lys Tyr Lys Lys Leu 155 160 165 Arg Val Phe Ser Gly Arg Glu Ser Pro Glu Pro Gly Glu Glu Glu 170 175 180 Phe Gly Arg Trp Met Phe His Thr Thr Gln Met Ile Lys Ala Trp 185 190 195 Gln Val Pro Asp Val Glu Lys Arg Arg Arg Leu Leu Glu Ser Leu 200 205 210 Arg Gly Pro Ala Leu Asp Val Ile Arg Val Leu Lys Ile Asn Asn 215 220 225 Pro Leu Ile Thr Val Asp Glu Cys Leu Gln Ala Leu Glu Glu Val 230 235 240 Phe Gly Val Thr Asp Asn Pro Arg Glu Leu Gln Val Lys Tyr Leu 245 250 255 Thr Thr Tyr Gln Lys Asp Glu Glu Lys Leu Ser Ala Tyr Val Leu 260 265 270 Arg Leu Glu Pro Leu Leu Gln Lys Leu Val Gln Arg Gly Ala Ile 275 280 285 Glu Arg Asp Ala Val Asn Gln Ala Arg Leu Asp Gln Val Ile Ala 290 295 300 Gly Ala Val His Lys Thr Ile Arg Arg Glu Leu Asn Leu Pro Glu 305 310 315 Asp Gly Pro Ala Pro Gly Phe Leu Gln Leu Leu Val Leu Ile Lys 320 325 330 Asp Tyr Glu Ala Ala Glu Glu Glu Glu Ala Leu Leu Gln Ala Ile 335 340 345 Leu Glu Gly Asn Phe Thr 350 2 458 PRT Homo sapiens misc_feature Incyte ID No 997947CD1 2 Met Gln Ala Thr Ser Asn Leu Leu Asn Leu Leu Leu Leu Ser Leu 1 5 10 15 Phe Ala Gly Leu Asp Pro Ser Lys Thr Gln Ile Ser Pro Lys Glu 20 25 30 Gly Trp Gln Val Tyr Ser Ser Ala Gln Asp Pro Asp Gly Arg Cys 35 40 45 Ile Cys Thr Val Val Ala Pro Glu Gln Asn Leu Cys Ser Arg Asp 50 55 60 Ala Lys Ser Arg Gln Leu Arg Gln Leu Leu Glu Lys Val Gln Asn 65 70 75 Met Ser Gln Ser Ile Glu Val Leu Asn Leu Arg Thr Gln Arg Asp 80 85 90 Phe Gln Tyr Val Leu Lys Met Glu Thr Gln Met Lys Gly Leu Lys 95 100 105 Ala Lys Phe Arg Gln Ile Glu Asp Asp Arg Lys Thr Leu Met Thr 110 115 120 Lys His Phe Gln Glu Leu Lys Glu Lys Met Asp Glu Leu Leu Pro 125 130 135 Leu Ile Pro Val Leu Glu Gln Tyr Lys Thr Asp Ala Lys Leu Ile 140 145 150 Thr Gln Phe Lys Glu Glu Ile Arg Asn Leu Ser Ala Val Leu Thr 155 160 165 Gly Ile Gln Glu Glu Ile Gly Ala Tyr Asp Tyr Glu Glu Leu His 170 175 180 Gln Arg Val Leu Ser Leu Glu Thr Arg Leu Arg Asp Cys Met Lys 185 190 195 Lys Leu Thr Cys Gly Lys Leu Met Lys Ile Thr Gly Pro Val Thr 200 205 210 Val Lys Thr Ser Gly Thr Arg Phe Gly Ala Trp Met Thr Asp Pro 215 220 225 Leu Ala Ser Glu Lys Asn Asn Arg Val Trp Tyr Met Asp Ser Tyr 230 235 240 Thr Asn Asn Lys Ile Val Arg Glu Tyr Lys Ser Ile Ala Asp Phe 245 250 255 Val Ser Gly Ala Glu Ser Arg Thr Tyr Asn Leu Pro Phe Lys Trp 260 265 270 Ala Gly Thr Asn His Val Val Tyr Asn Gly Ser Leu Tyr Phe Asn 275 280 285 Lys Tyr Gln Ser Asn Ile Ile Ile Lys Tyr Ser Phe Asp Met Gly 290 295 300 Arg Val Leu Ala Gln Arg Ser Leu Glu Tyr Ala Gly Phe His Asn 305 310 315 Val Tyr Pro Tyr Thr Trp Gly Gly Phe Ser Asp Ile Asp Leu Met 320 325 330 Ala Asp Glu Ile Gly Leu Trp Ala Val Tyr Ala Thr Asn Gln Asn 335 340 345 Ala Gly Asn Ile Val Ile Ser Gln Leu Asn Gln Asp Thr Leu Glu 350 355 360 Val Met Lys Ser Trp Ser Thr Gly Tyr Pro Lys Arg Ser Ala Gly 365 370 375 Glu Ser Phe Met Ile Cys Gly Thr Leu Tyr Val Thr Asn Ser His 380 385 390 Leu Thr Gly Ala Lys Val Tyr Tyr Ser Tyr Ser Thr Lys Thr Ser 395 400 405 Thr Tyr Glu Tyr Thr Asp Ile Pro Phe His Asn Gln Tyr Phe His 410 415 420 Ile Ser Met Leu Asp Tyr Asn Ala Arg Asp Arg Ala Leu Tyr Ala 425 430 435 Trp Asn Asn Gly His Gln Val Leu Phe Asn Val Thr Leu Phe His 440 445 450 Ile Ile Lys Thr Glu Asp Asp Thr 455 3 219 PRT Homo sapiens misc_feature Incyte ID No 1521513CD1 3 Met Asn Ser Ser Lys Ser Ser Glu Thr Gln Cys Thr Glu Arg Gly 1 5 10 15 Cys Phe Ser Ser Gln Met Phe Leu Trp Thr Val Ala Gly Ile Pro 20 25 30 Ile Leu Phe Leu Ser Ala Cys Phe Ile Thr Arg Cys Val Val Thr 35 40 45 Phe Arg Ile Phe Gln Thr Cys Asp Glu Lys Lys Phe Gln Leu Pro 50 55 60 Glu Asn Phe Thr Glu Leu Ser Cys Tyr Asn Tyr Gly Ser Gly Ser 65 70 75 Val Lys Asn Cys Cys Pro Leu Asn Trp Glu Tyr Phe Gln Ser Ser 80 85 90 Cys Tyr Phe Phe Ser Thr Asp Thr Ile Ser Trp Ala Leu Ser Leu 95 100 105 Lys Asn Cys Ser Ala Met Gly Ala His Leu Val Val Ile Asn Ser 110 115 120 Gln Glu Glu Gln Glu Phe Leu Ser Tyr Lys Lys Pro Lys Met Arg 125 130 135 Glu Phe Phe Ile Gly Leu Ser Asp Gln Val Val Glu Gly Gln Trp 140 145 150 Gln Trp Val Asp Gly Thr Pro Leu Thr Lys Ser Leu Ser Phe Trp 155 160 165 Asp Val Gly Glu Pro Asn Asn Ile Ala Thr Leu Glu Asp Cys Ala 170 175 180 Thr Met Arg Asp Ser Ser Asn Pro Arg Gln Asn Trp Asn Asp Val 185 190 195 Thr Cys Phe Leu Asn Tyr Phe Arg Ile Cys Glu Met Val Gly Ile 200 205 210 Asn Pro Leu Asn Lys Gly Lys Ser Leu 215 4 276 PRT Homo sapiens misc_feature Incyte ID No 1863994CD1 4 Met Glu Ser Arg Met Trp Pro Ala Leu Leu Leu Ser His Leu Leu 1 5 10 15 Pro Leu Trp Pro Leu Leu Leu Leu Pro Leu Pro Pro Pro Ala Gln 20 25 30 Gly Ser Ser Ser Ser Pro Arg Thr Pro Pro Ala Pro Ala Arg Pro 35 40 45 Pro Cys Ala Arg Gly Gly Pro Ser Ala Pro Arg His Val Cys Val 50 55 60 Trp Glu Arg Ala Pro Pro Pro Ser Arg Ser Pro Arg Val Pro Arg 65 70 75 Ser Arg Arg Gln Val Leu Pro Gly Thr Ala Pro Pro Ala Thr Pro 80 85 90 Ser Gly Phe Glu Glu Gly Pro Pro Ser Ser Gln Tyr Pro Trp Ala 95 100 105 Ile Val Trp Gly Pro Thr Val Ser Arg Glu Asp Gly Gly Asp Pro 110 115 120 Asn Ser Ala Asn Pro Gly Phe Leu Asp Tyr Gly Phe Ala Ala Pro 125 130 135 His Gly Leu Ala Thr Pro His Pro Asn Ser Asp Ser Met Arg Gly 140 145 150 Asp Gly Asp Gly Leu Ile Leu Gly Glu Ala Pro Ala Thr Leu Arg 155 160 165 Pro Phe Leu Phe Gly Gly Arg Gly Glu Gly Val Asp Pro Gln Leu 170 175 180 Tyr Val Thr Ile Thr Ile Ser Ile Ile Ile Val Leu Val Ala Thr 185 190 195 Gly Ile Ile Phe Lys Phe Cys Trp Asp Arg Ser Gln Lys Arg Arg 200 205 210 Arg Pro Ser Gly Gln Gln Gly Ala Leu Arg Gln Glu Glu Ser Gln 215 220 225 Gln Pro Leu Thr Asp Leu Ser Pro Ala Gly Val Thr Val Leu Gly 230 235 240 Ala Phe Gly Asp Ser Pro Thr Pro Thr Pro Asp His Glu Glu Pro 245 250 255 Arg Gly Gly Pro Arg Pro Gly Met Pro His Pro Lys Gly Ala Pro 260 265 270 Ala Phe Gln Leu Asn Arg 275 5 375 PRT Homo sapiens misc_feature Incyte ID No 2071941CD1 5 Met Ser Ser His Lys Gly Ser Val Val Ala Gln Gly Asn Gly Ala 1 5 10 15 Pro Ala Ser Asn Arg Glu Ala Asp Thr Val Glu Leu Ala Glu Leu 20 25 30 Gly Pro Leu Leu Glu Glu Lys Gly Lys Arg Val Ile Ala Asn Pro 35 40 45 Pro Lys Ala Glu Glu Glu Gln Thr Cys Pro Val Pro Gln Glu Glu 50 55 60 Glu Glu Glu Val Arg Val Leu Thr Leu Pro Leu Gln Ala His His 65 70 75 Ala Met Glu Lys Met Glu Glu Phe Val Tyr Lys Val Trp Glu Gly 80 85 90 Arg Trp Arg Val Ile Pro Tyr Asp Val Leu Pro Asp Trp Leu Lys 95 100 105 Asp Asn Asp Tyr Leu Leu His Gly His Arg Pro Pro Met Pro Ser 110 115 120 Phe Arg Ala Cys Phe Lys Ser Ile Phe Arg Ile His Thr Glu Thr 125 130 135 Gly Asn Ile Trp Thr His Leu Leu Gly Phe Val Leu Phe Leu Phe 140 145 150 Leu Gly Ile Leu Thr Met Leu Arg Pro Asn Met Tyr Phe Met Ala 155 160 165 Pro Leu Gln Glu Lys Val Val Phe Gly Met Phe Phe Leu Gly Ala 170 175 180 Val Leu Cys Leu Ser Phe Ser Trp Leu Phe His Thr Val Tyr Cys 185 190 195 His Ser Glu Lys Val Ser Arg Thr Phe Ser Lys Leu Asp Tyr Ser 200 205 210 Gly Ile Ala Leu Leu Ile Met Gly Ser Phe Val Pro Trp Leu Tyr 215 220 225 Tyr Ser Phe Tyr Cys Ser Pro Gln Pro Arg Leu Ile Tyr Leu Ser 230 235 240 Ile Val Cys Val Leu Gly Ile Ser Ala Ile Ile Val Ala Gln Trp 245 250 255 Asp Arg Phe Ala Thr Pro Lys His Arg Gln Thr Arg Ala Gly Val 260 265 270 Phe Leu Gly Leu Gly Leu Ser Gly Val Val Pro Thr Met His Phe 275 280 285 Thr Ile Ala Glu Gly Phe Val Lys Ala Thr Thr Val Gly Gln Met 290 295 300 Gly Trp Phe Phe Leu Met Ala Val Met Tyr Ile Thr Gly Ala Gly 305 310 315 Leu Tyr Ala Ala Arg Ile Pro Glu Arg Phe Phe Pro Gly Lys Phe 320 325 330 Asp Ile Trp Phe Gln Ser His Gln Ile Phe His Val Leu Val Val 335 340 345 Ala Ala Ala Phe Val His Phe Tyr Gly Val Ser Asn Leu Gln Glu 350 355 360 Phe Arg Tyr Gly Leu Glu Gly Gly Cys Thr Asp Asp Thr Leu Leu 365 370 375 6 249 PRT Homo sapiens misc_feature Incyte ID No 2172512CD1 6 Met Ser Gly Val Val Pro Thr Ala Pro Glu Gln Pro Ala Gly Glu 1 5 10 15 Met Glu Asn Gln Thr Lys Pro Pro Asp Pro Arg Pro Asp Ala Pro 20 25 30 Pro Glu Tyr Ser Ser His Phe Leu Pro Gly Pro Pro Gly Thr Ala 35 40 45 Val Pro Pro Pro Thr Gly Tyr Pro Gly Gly Leu Pro Met Gly Tyr 50 55 60 Tyr Ser Pro Gln Gln Pro Ser Thr Phe Pro Leu Tyr Gln Pro Val 65 70 75 Gly Gly Ile His Pro Val Arg Tyr Gln Pro Gly Lys Tyr Pro Met 80 85 90 Pro Asn Gln Ser Val Pro Ile Thr Trp Met Pro Gly Pro Thr Pro 95 100 105 Met Ala Asn Cys Pro Pro Gly Leu Glu Tyr Leu Val Gln Leu Asp 110 115 120 Asn Ile His Val Leu Gln His Phe Glu Pro Leu Glu Met Met Thr 125 130 135 Cys Phe Glu Thr Asn Asn Arg Tyr Asp Ile Lys Asn Asn Ser Asp 140 145 150 Gln Met Val Tyr Ile Val Thr Glu Asp Thr Asp Asp Phe Thr Arg 155 160 165 Asn Ala Tyr Arg Thr Leu Arg Pro Phe Val Leu Arg Val Thr Asp 170 175 180 Cys Met Gly Arg Glu Ile Met Thr Met Gln Arg Pro Phe Arg Cys 185 190 195 Thr Cys Cys Cys Phe Cys Cys Pro Ser Ala Arg Gln Glu Leu Glu 200 205 210 Val Gln Cys Pro Pro Gly Val Thr Ile Gly Phe Val Ala Glu His 215 220 225 Trp Asn Leu Cys Arg Ala Val Tyr Ser Ile Gln Lys Lys Lys Lys 230 235 240 Lys Ile Ala Ala Gln Ala Tyr Ser Leu 245 7 353 PRT Homo sapiens misc_feature Incyte ID No 2483172CD1 7 Met Ala Met Thr Leu Leu Glu Asp Trp Cys Arg Gly Met Asp Val 1 5 10 15 Asn Ser Gln Arg Ala Leu Leu Val Trp Gly Ile Pro Val Asn Cys 20 25 30 Asp Glu Ala Glu Ile Glu Glu Thr Leu Gln Ala Ala Met Pro Gln 35 40 45 Val Ser Tyr Arg Met Leu Gly Arg Met Phe Trp Arg Glu Glu Asn 50 55 60 Ala Lys Ala Ala Leu Leu Glu Leu Thr Gly Ala Val Asp Tyr Ala 65 70 75 Ala Ile Pro Arg Glu Met Pro Gly Lys Gly Gly Val Trp Lys Val 80 85 90 Leu Phe Lys Pro Pro Thr Ser Asp Ala Glu Phe Leu Glu Arg Leu 95 100 105 His Leu Phe Leu Ala Arg Glu Gly Trp Thr Val Gln Asp Val Ala 110 115 120 Arg Val Leu Gly Phe Gln Asn Pro Thr Pro Thr Pro Gly Pro Glu 125 130 135 Met Pro Ala Glu Met Leu Asn Tyr Ile Leu Asp Asn Val Ile Gln 140 145 150 Pro Leu Val Glu Ser Ile Trp Tyr Lys Arg Leu Thr Leu Phe Ser 155 160 165 Gly Arg Asp Ile Pro Gly Pro Gly Glu Glu Thr Phe Asp Pro Trp 170 175 180 Leu Glu His Thr Asn Glu Val Leu Glu Glu Trp Gln Val Ser Asp 185 190 195 Val Glu Lys Arg Arg Arg Leu Met Glu Ser Leu Arg Gly Pro Ala 200 205 210 Ala Asp Val Ile Arg Ile Leu Lys Ser Asn Asn Pro Ala Ile Thr 215 220 225 Thr Ala Glu Cys Leu Lys Ala Leu Glu Gln Val Phe Gly Ser Val 230 235 240 Glu Ser Ser Arg Asp Ala Gln Ile Lys Phe Leu Asn Thr Tyr Gln 245 250 255 Asn Pro Gly Glu Lys Leu Ser Ala Tyr Val Ile Arg Leu Glu Pro 260 265 270 Leu Leu Gln Lys Val Val Glu Lys Gly Ala Ile Asp Lys Asp Asn 275 280 285 Val Asn Gln Ala Arg Leu Glu Gln Val Ile Ala Gly Ala Asn His 290 295 300 Ser Gly Ala Ile Arg Arg Gln Leu Trp Leu Thr Gly Ala Gly Glu 305 310 315 Gly Pro Ala Pro Asn Leu Phe Gln Leu Leu Val Gln Ile Arg Glu 320 325 330 Glu Glu Ala Lys Glu Glu Glu Glu Glu Ala Glu Ala Thr Leu Leu 335 340 345 Gln Leu Gly Leu Glu Gly His Phe 350 8 194 PRT Homo sapiens misc_feature Incyte ID No 2656128CD1 8 Met His Asp Ser Asn Asn Val Glu Lys Asp Ile Thr Pro Ser Glu 1 5 10 15 Leu Pro Ala Asn Pro Gly Cys Leu His Ser Lys Glu His Ser Ile 20 25 30 Lys Ala Thr Leu Ile Trp Arg Leu Phe Phe Leu Ile Met Phe Leu 35 40 45 Thr Ile Ile Val Cys Gly Met Val Ala Ala Leu Ser Ala Ile Arg 50 55 60 Ala Asn Cys His Gln Glu Pro Ser Val Cys Leu Gln Ala Ala Cys 65 70 75 Pro Glu Ser Trp Ile Gly Phe Gln Arg Lys Cys Phe Tyr Phe Ser 80 85 90 Asp Asp Thr Lys Asn Trp Thr Ser Ser Gln Arg Phe Cys Asp Ser 95 100 105 Gln Asp Ala Asp Leu Ala Gln Val Glu Ser Phe Gln Glu Leu Asn 110 115 120 Phe Leu Leu Arg Tyr Lys Gly Pro Ser Asp His Trp Ile Gly Leu 125 130 135 Ser Arg Glu Gln Gly Gln Pro Trp Lys Trp Ile Asn Gly Thr Glu 140 145 150 Trp Thr Arg Gln Leu Val Met Lys Glu Asp Gly Ala Asn Leu Tyr 155 160 165 Val Ala Lys Val Ser Gln Val Pro Arg Met Asn Pro Arg Pro Val 170 175 180 Met Val Ser Tyr Pro Gly Ser Arg Arg Val Cys Leu Phe Glu 185 190 9 322 PRT Homo sapiens misc_feature Incyte ID No 5855841CD1 9 Met Ser Ser Leu Gly Gly Gly Ser Gln Asp Ala Gly Gly Ser Ser 1 5 10 15 Ser Ser Ser Thr Asn Gly Ser Gly Gly Ser Gly Ser Ser Gly Pro 20 25 30 Lys Ala Gly Ala Ala Asp Lys Ser Ala Val Val Ala Ala Ala Ala 35 40 45 Pro Ala Ser Val Ala Asp Asp Thr Pro Pro Pro Glu Arg Arg Asn 50 55 60 Lys Ser Gly Ile Ile Ser Glu Pro Leu Asn Lys Ser Leu Arg Arg 65 70 75 Ser Arg Pro Leu Ser His Tyr Ser Ser Phe Gly Ser Ser Gly Gly 80 85 90 Ser Gly Gly Gly Ser Met Met Gly Gly Glu Ser Ala Asp Lys Ala 95 100 105 Thr Ala Ala Ala Ala Ala Ala Ser Leu Leu Ala Asn Gly His Asp 110 115 120 Leu Ala Ala Ala Met Ala Val Asp Lys Ser Asn Pro Thr Ser Lys 125 130 135 His Lys Ser Gly Ala Val Ala Ser Leu Leu Ser Lys Ala Glu Arg 140 145 150 Ala Thr Glu Leu Ala Ala Glu Gly Gln Leu Thr Leu Gln Gln Phe 155 160 165 Ala Gln Ser Thr Glu Met Leu Lys Arg Val Val Gln Glu His Leu 170 175 180 Pro Leu Met Ser Glu Ala Gly Ala Gly Leu Pro Asp Met Glu Ala 185 190 195 Val Ala Gly Ala Glu Ala Leu Asn Gly Gln Ser Asp Phe Pro Tyr 200 205 210 Leu Gly Ala Phe Pro Ile Asn Pro Gly Leu Phe Ile Met Thr Pro 215 220 225 Ala Gly Val Phe Leu Ala Glu Ser Ala Leu His Met Ala Gly Leu 230 235 240 Ala Glu Tyr Pro Met Gln Gly Glu Leu Ala Ser Ala Ile Ser Ser 245 250 255 Gly Lys Lys Lys Arg Lys Arg Cys Gly Met Cys Ala Pro Cys Arg 260 265 270 Arg Arg Ile Asn Cys Glu Gln Cys Ser Ser Cys Arg Asn Arg Lys 275 280 285 Thr Gly His Gln Ile Cys Lys Phe Arg Lys Cys Glu Glu Leu Lys 290 295 300 Lys Lys Pro Ser Ala Ala Leu Glu Lys Val Met Leu Pro Thr Gly 305 310 315 Ala Ala Phe Arg Trp Phe Gln 320 10 335 PRT Homo sapiens misc_feature Incyte ID No 603462CD1 10 Met Leu Gln Gly His Ser Ser Val Phe Gln Ala Leu Leu Gly Thr 1 5 10 15 Phe Phe Thr Trp Gly Met Thr Ala Ala Gly Ala Ala Leu Val Phe 20 25 30 Val Phe Ser Ser Gly Gln Arg Arg Ile Leu Asp Gly Ser Leu Gly 35 40 45 Phe Ala Ala Gly Val Met Leu Ala Ala Ser Tyr Trp Ser Leu Leu 50 55 60 Ala Pro Ala Val Glu Met Ala Thr Ser Ser Gly Gly Phe Gly Ala 65 70 75 Phe Ala Phe Phe Pro Val Ala Val Gly Phe Thr Leu Gly Ala Ala 80 85 90 Phe Val Tyr Leu Ala Asp Leu Leu Met Pro His Leu Gly Ala Ala 95 100 105 Glu Asp Pro Gln Thr Ala Leu Ala Leu Asn Phe Gly Ser Thr Leu 110 115 120 Met Lys Lys Lys Ser Asp Pro Glu Gly Pro Ala Leu Leu Phe Pro 125 130 135 Glu Ser Glu Leu Ser Ile Arg Ile Asp Lys Ser Glu Asn Gly Glu 140 145 150 Ala Tyr Gln Arg Lys Lys Ala Ala Ala Thr Gly Leu Pro Glu Gly 155 160 165 Pro Ala Val Pro Val Pro Ser Arg Gly Asn Leu Ala Gln Pro Gly 170 175 180 Gly Ser Ser Trp Arg Arg Ile Ala Leu Leu Ile Leu Ala Ile Thr 185 190 195 Ile His Asn Val Pro Glu Gly Leu Ala Val Gly Val Gly Phe Gly 200 205 210 Ala Ile Glu Lys Thr Ala Ser Ala Thr Phe Glu Ser Ala Arg Asn 215 220 225 Leu Ala Ile Gly Ile Gly Ile Gln Asn Phe Pro Glu Gly Leu Ala 230 235 240 Val Ser Leu Pro Leu Arg Gly Ala Gly Phe Ser Thr Trp Arg Ala 245 250 255 Phe Trp Tyr Gly Gln Leu Ser Gly Met Val Glu Pro Leu Ala Gly 260 265 270 Val Phe Gly Ala Phe Ala Val Val Leu Ala Glu Pro Ile Leu Pro 275 280 285 Tyr Ala Leu Ala Phe Ala Ala Gly Ala Met Val Tyr Val Val Met 290 295 300 Asp Asp Ile Ile Pro Glu Ala Gln Ile Ser Gly Asn Gly Lys Leu 305 310 315 Ala Ser Trp Ala Ser Ile Leu Gly Phe Val Val Met Met Ser Leu 320 325 330 Asp Val Gly Leu Gly 335 11 620 PRT Homo sapiens misc_feature Incyte ID No 747681CD1 11 Met Gln Val Ser Lys Arg Met Leu Ala Gly Gly Val Arg Ser Met 1 5 10 15 Pro Ser Pro Leu Leu Ala Cys Trp Gln Pro Ile Leu Leu Leu Val 20 25 30 Leu Gly Ser Val Leu Ser Gly Ser Ala Thr Gly Cys Pro Pro Arg 35 40 45 Cys Glu Cys Ser Ala Gln Asp Arg Ala Val Leu Cys His Arg Lys 50 55 60 Arg Phe Val Ala Val Pro Glu Gly Ile Pro Thr Glu Thr Arg Leu 65 70 75 Leu Asp Leu Gly Lys Asn Arg Ile Lys Thr Leu Asn Gln Asp Glu 80 85 90 Phe Ala Ser Phe Pro His Leu Glu Glu Leu Glu Leu Asn Glu Asn 95 100 105 Ile Val Ser Ala Val Glu Pro Gly Ala Phe Asn Asn Leu Phe Asn 110 115 120 Leu Arg Thr Leu Gly Leu Arg Ser Asn Arg Leu Lys Leu Ile Pro 125 130 135 Leu Gly Val Phe Thr Gly Leu Ser Asn Leu Thr Lys Leu Asp Ile 140 145 150 Ser Glu Asn Lys Ile Val Ile Leu Leu Asp Tyr Met Phe Gln Asp 155 160 165 Leu Tyr Asn Leu Lys Ser Leu Glu Val Gly Asp Asn Asp Leu Val 170 175 180 Tyr Ile Ser His Arg Ala Phe Ser Gly Leu Asn Ser Leu Glu Gln 185 190 195 Leu Thr Leu Glu Lys Cys Asn Leu Thr Ser Ile Pro Thr Glu Ala 200 205 210 Leu Ser His Leu His Gly Leu Ile Val Leu Arg Leu Arg His Leu 215 220 225 Asn Ile Asn Ala Ile Arg Asp Tyr Ser Phe Lys Arg Leu Tyr Arg 230 235 240 Leu Lys Val Leu Glu Ile Ser His Trp Pro Tyr Leu Asp Thr Met 245 250 255 Thr Pro Asn Cys Leu Tyr Gly Leu Asn Leu Thr Ser Leu Ser Ile 260 265 270 Thr His Cys Asn Leu Thr Ala Val Pro Tyr Leu Ala Val Arg His 275 280 285 Leu Val Tyr Leu Arg Phe Leu Asn Leu Ser Tyr Asn Pro Ile Ser 290 295 300 Thr Ile Glu Gly Ser Met Leu His Glu Leu Leu Arg Leu Gln Glu 305 310 315 Ile Gln Leu Val Gly Gly Gln Leu Ala Val Val Glu Pro Tyr Ala 320 325 330 Phe Arg Gly Leu Asn Tyr Leu Arg Val Leu Asn Val Ser Gly Asn 335 340 345 Gln Leu Thr Thr Leu Glu Glu Ser Val Phe His Ser Val Gly Asn 350 355 360 Leu Glu Thr Leu Ile Leu Asp Ser Asn Pro Leu Ala Cys Asp Cys 365 370 375 Arg Leu Leu Trp Val Phe Arg Arg Arg Trp Arg Leu Asn Phe Asn 380 385 390 Arg Gln Gln Pro Thr Cys Ala Thr Pro Glu Phe Val Gln Gly Lys 395 400 405 Glu Phe Lys Asp Phe Pro Asp Val Leu Leu Pro Asn Tyr Phe Thr 410 415 420 Cys Arg Arg Ala Arg Ile Arg Asp Arg Lys Ala Gln Gln Val Phe 425 430 435 Val Asp Glu Gly His Thr Val Gln Phe Val Cys Arg Ala Asp Gly 440 445 450 Asp Pro Pro Pro Ala Ile Leu Trp Leu Ser Pro Arg Lys His Leu 455 460 465 Val Ser Ala Lys Ser Asn Gly Arg Leu Thr Val Phe Pro Asp Gly 470 475 480 Thr Leu Glu Val Arg Tyr Ala Gln Val Gln Asp Asn Gly Thr Tyr 485 490 495 Leu Cys Ile Ala Ala Asn Ala Gly Gly Asn Asp Ser Met Pro Ala 500 505 510 His Leu His Val Arg Ser Tyr Ser Pro Asp Trp Pro His Gln Pro 515 520 525 Asn Lys Thr Phe Ala Phe Ile Ser Asn Gln Pro Gly Glu Gly Glu 530 535 540 Ala Asn Ser Thr Arg Ala Thr Val Pro Phe Pro Phe Asp Ile Lys 545 550 555 Thr Leu Ile Ile Ala Thr Thr Met Gly Phe Ile Ser Phe Leu Gly 560 565 570 Val Val Leu Phe Cys Leu Val Leu Leu Phe Leu Trp Ser Arg Gly 575 580 585 Lys Gly Asn Thr Lys His Asn Ile Glu Ile Glu Tyr Val Pro Arg 590 595 600 Lys Ser Asp Ala Gly Ile Ser Ser Ala Asp Ala Pro Arg Lys Phe 605 610 615 Asn Met Lys Met Ile 620 12 491 PRT Homo sapiens misc_feature Incyte ID No 919469CD1 12 Met Ala Gly Gln Gly Leu Pro Leu His Val Ala Thr Leu Leu Thr 1 5 10 15 Gly Leu Leu Glu Cys Leu Gly Phe Ala Gly Val Leu Phe Gly Trp 20 25 30 Pro Ser Leu Val Phe Val Phe Lys Asn Glu Asp Tyr Phe Lys Asp 35 40 45 Leu Cys Gly Pro Asp Ala Gly Pro Ile Gly Asn Ala Thr Gly Gln 50 55 60 Ala Asp Cys Lys Ala Gln Asp Glu Arg Phe Ser Leu Ile Phe Thr 65 70 75 Leu Gly Ser Phe Met Asn Asn Phe Met Thr Phe Pro Thr Gly Tyr 80 85 90 Ile Phe Asp Arg Phe Lys Thr Thr Val Ala Arg Leu Ile Ala Ile 95 100 105 Phe Phe Tyr Thr Thr Ala Thr Leu Ile Ile Ala Phe Thr Ser Ala 110 115 120 Gly Ser Ala Val Leu Leu Phe Leu Ala Met Pro Met Leu Thr Ile 125 130 135 Gly Gly Ile Leu Phe Leu Ile Thr Asn Leu Gln Ile Gly Asn Leu 140 145 150 Phe Gly Gln His Arg Ser Thr Ile Ile Thr Leu Tyr Asn Gly Ala 155 160 165 Phe Asp Ser Ser Ser Ala Val Phe Leu Ile Ile Lys Leu Leu Tyr 170 175 180 Glu Lys Gly Ile Ser Leu Arg Ala Ser Phe Ile Phe Ile Ser Val 185 190 195 Cys Ser Thr Trp His Val Ala Arg Thr Phe Leu Leu Met Pro Arg 200 205 210 Gly His Ile Pro Tyr Pro Leu Pro Pro Asn Tyr Ser Tyr Gly Leu 215 220 225 Cys Pro Gly Asn Gly Thr Thr Lys Glu Glu Lys Glu Thr Ala Glu 230 235 240 His Glu Asn Arg Glu Leu Gln Ser Lys Glu Phe Leu Ser Ala Lys 245 250 255 Glu Glu Thr Pro Gly Ala Gly Gln Lys Gln Glu Leu Arg Ser Phe 260 265 270 Trp Ser Tyr Ala Phe Ser Arg Arg Phe Ala Trp His Leu Val Trp 275 280 285 Leu Ser Val Ile Gln Leu Trp His Tyr Leu Phe Ile Gly Thr Leu 290 295 300 Asn Ser Leu Leu Thr Asn Met Ala Gly Gly Asp Met Ala Arg Val 305 310 315 Ser Thr Tyr Thr Asn Ala Phe Ala Phe Thr Gln Phe Gly Val Leu 320 325 330 Cys Ala Pro Trp Asn Gly Leu Leu Met Asp Arg Leu Lys Gln Lys 335 340 345 Tyr Gln Lys Glu Ala Arg Lys Thr Gly Ser Ser Thr Leu Ala Val 350 355 360 Ala Leu Cys Ser Thr Val Pro Ser Leu Ala Leu Thr Ser Leu Leu 365 370 375 Cys Leu Gly Phe Ala Leu Cys Ala Ser Val Pro Ile Leu Pro Leu 380 385 390 Gln Tyr Leu Thr Phe Ile Leu Gln Val Ile Ser Arg Ser Phe Leu 395 400 405 Tyr Gly Ser Asn Ala Ala Phe Leu Thr Leu Ala Phe Pro Ser Glu 410 415 420 His Phe Gly Lys Leu Phe Gly Leu Val Met Ala Leu Ser Ala Val 425 430 435 Val Ser Leu Leu Gln Phe Pro Ile Phe Thr Leu Ile Lys Gly Ser 440 445 450 Leu Gln Asn Asp Pro Phe Tyr Val Asn Val Met Phe Met Leu Ala 455 460 465 Ile Leu Leu Thr Phe Phe His Pro Phe Leu Val Tyr Arg Glu Cys 470 475 480 Arg Thr Trp Lys Glu Ser Pro Ser Ala Ile Ala 485 490 13 580 PRT Homo sapiens misc_feature Incyte ID No 977658CD1 13 Met Thr Ala Pro Ala Gly Pro Arg Gly Ser Glu Thr Glu Arg Leu 1 5 10 15 Leu Thr Pro Asn Pro Gly Tyr Gly Thr Gln Ala Gly Pro Ser Pro 20 25 30 Ala Pro Pro Thr Pro Pro Glu Glu Glu Asp Leu Arg Arg Arg Leu 35 40 45 Lys Tyr Phe Phe Met Ser Pro Cys Asp Lys Phe Arg Ala Lys Gly 50 55 60 Arg Lys Pro Cys Lys Leu Met Leu Gln Val Val Lys Ile Leu Val 65 70 75 Val Thr Val Gln Leu Ile Leu Phe Gly Leu Ser Asn Gln Leu Ala 80 85 90 Val Thr Phe Arg Glu Glu Asn Thr Ile Ala Phe Arg His Leu Phe 95 100 105 Leu Leu Gly Tyr Ser Asp Gly Ala Asp Asp Thr Phe Ala Ala Tyr 110 115 120 Thr Arg Glu Gln Leu Tyr Gln Ala Ile Phe His Ala Val Asp Gln 125 130 135 Tyr Leu Ala Leu Pro Asp Val Ser Leu Gly Arg Tyr Ala Tyr Val 140 145 150 Arg Gly Gly Gly Asp Pro Trp Thr Asn Gly Ser Gly Leu Ala Leu 155 160 165 Cys Gln Arg Tyr Tyr His Arg Gly His Val Asp Pro Ala Asn Asp 170 175 180 Thr Phe Asp Ile Asp Pro Met Val Val Thr Asp Cys Ile Gln Val 185 190 195 Asp Pro Pro Glu Arg Pro Pro Pro Pro Pro Ser Asp Asp Leu Thr 200 205 210 Leu Leu Glu Ser Ser Ser Ser Tyr Lys Asn Leu Thr Leu Lys Phe 215 220 225 His Lys Leu Val Asn Val Thr Ile His Phe Arg Leu Lys Thr Ile 230 235 240 Asn Leu Gln Ser Leu Ile Asn Asn Glu Ile Pro Asp Cys Tyr Thr 245 250 255 Phe Ser Val Leu Ile Thr Phe Asp Asn Lys Ala His Ser Gly Arg 260 265 270 Ile Pro Ile Ser Leu Glu Thr Gln Ala His Ile Gln Glu Cys Lys 275 280 285 His Pro Ser Val Phe Gln His Gly Asp Asn Ser Phe Arg Leu Leu 290 295 300 Phe Asp Val Val Val Ile Leu Thr Cys Ser Leu Ser Phe Leu Leu 305 310 315 Cys Ala Arg Ser Leu Leu Arg Gly Phe Leu Leu Gln Asn Glu Phe 320 325 330 Val Gly Phe Met Trp Arg Gln Arg Gly Arg Val Ile Ser Leu Trp 335 340 345 Glu Arg Leu Glu Phe Val Asn Gly Trp Tyr Ile Leu Leu Val Thr 350 355 360 Ser Asp Val Leu Thr Ile Ser Gly Thr Ile Met Lys Ile Gly Ile 365 370 375 Glu Ala Lys Asn Leu Ala Ser Tyr Asp Val Cys Ser Ile Leu Leu 380 385 390 Gly Thr Ser Thr Leu Leu Val Trp Val Gly Val Ile Arg Tyr Leu 395 400 405 Thr Phe Phe His Asn Tyr Asn Ile Leu Ile Ala Thr Leu Arg Val 410 415 420 Ala Leu Pro Ser Val Met Arg Phe Cys Cys Cys Val Ala Val Ile 425 430 435 Tyr Leu Gly Tyr Cys Phe Cys Gly Trp Ile Val Leu Gly Pro Tyr 440 445 450 His Val Lys Phe Arg Ser Leu Ser Met Val Ser Glu Cys Leu Phe 455 460 465 Ser Leu Ile Asn Gly Asp Asp Met Phe Val Thr Phe Ala Ala Met 470 475 480 Gln Ala Gln Gln Gly Arg Ser Ser Leu Val Trp Leu Phe Ser Gln 485 490 495 Leu Tyr Leu Tyr Ser Phe Ile Ser Leu Phe Ile Tyr Met Val Leu 500 505 510 Ser Leu Phe Ile Ala Leu Ile Thr Gly Ala Tyr Asp Thr Ile Lys 515 520 525 His Pro Gly Gly Ala Gly Ala Glu Glu Ser Glu Leu Gln Ala Tyr 530 535 540 Ile Ala Gln Cys Gln Asp Ser Pro Thr Ser Gly Lys Phe Arg Arg 545 550 555 Gly Ser Gly Ser Ala Cys Ser Leu Leu Cys Cys Cys Gly Arg Asp 560 565 570 Pro Ser Glu Glu His Ser Leu Leu Val Asn 575 580 14 455 PRT Homo sapiens misc_feature Incyte ID No 1004703CD1 14 Met Ser Phe Leu Ile Asp Ser Ser Ile Met Ile Thr Ser Gln Ile 1 5 10 15 Leu Phe Phe Gly Phe Gly Trp Leu Phe Phe Met Arg Gln Leu Phe 20 25 30 Lys Asp Tyr Glu Ile Arg Gln Tyr Val Val Gln Val Ile Phe Ser 35 40 45 Val Thr Phe Ala Phe Ser Cys Thr Met Phe Glu Leu Ile Ile Phe 50 55 60 Glu Ile Leu Gly Val Leu Asn Ser Ser Ser Arg Tyr Phe His Trp 65 70 75 Lys Met Asn Leu Cys Val Ile Leu Leu Ile Leu Val Phe Met Val 80 85 90 Pro Phe Tyr Ile Gly Tyr Phe Ile Val Ser Asn Ile Arg Leu Leu 95 100 105 His Lys Gln Arg Leu Leu Phe Ser Cys Leu Leu Trp Leu Thr Phe 110 115 120 Met Tyr Phe Phe Trp Lys Leu Gly Asp Leu Phe Pro Ile Leu Ser 125 130 135 Pro Lys His Gly Ile Leu Ser Ile Glu Gln Leu Ile Ser Arg Val 140 145 150 Gly Val Ile Gly Val Thr Leu Met Ala Leu Leu Ser Gly Phe Gly 155 160 165 Ala Val Asn Cys Pro Tyr Thr Tyr Met Ser Tyr Phe Leu Arg Asn 170 175 180 Val Thr Asp Thr Asp Ile Leu Ala Leu Glu Arg Arg Leu Leu Gln 185 190 195 Thr Met Asp Met Ile Ile Ser Lys Lys Lys Arg Met Ala Met Ala 200 205 210 Arg Arg Thr Met Phe Gln Lys Gly Glu Val His Asn Lys Pro Ser 215 220 225 Gly Phe Trp Gly Met Ile Lys Ser Val Thr Thr Ser Ala Ser Gly 230 235 240 Ser Glu Asn Leu Thr Leu Ile Gln Gln Glu Val Asp Ala Leu Glu 245 250 255 Glu Leu Ser Arg Gln Leu Phe Leu Glu Thr Ala Asp Leu Tyr Ala 260 265 270 Thr Lys Glu Arg Ile Glu Tyr Ser Lys Thr Phe Lys Gly Lys Tyr 275 280 285 Phe Asn Phe Leu Gly Tyr Phe Phe Ser Ile Tyr Cys Val Trp Lys 290 295 300 Ile Phe Met Ala Thr Ile Asn Ile Val Phe Asp Arg Val Gly Lys 305 310 315 Thr Asp Pro Val Thr Arg Gly Ile Glu Ile Thr Val Asn Tyr Leu 320 325 330 Gly Ile Gln Phe Asp Val Lys Phe Trp Ser Gln His Ile Ser Phe 335 340 345 Ile Leu Val Gly Ile Ile Ile Val Thr Ser Ile Arg Gly Leu Leu 350 355 360 Ile Thr Leu Thr Lys Phe Phe Tyr Ala Ile Ser Ser Ser Lys Ser 365 370 375 Ser Asn Val Ile Val Leu Leu Leu Ala Gln Ile Met Gly Met Tyr 380 385 390 Phe Val Ser Ser Val Leu Leu Ile Arg Met Ser Met Pro Leu Glu 395 400 405 Tyr Arg Thr Ile Ile Thr Glu Val Leu Gly Glu Leu Gln Phe Asn 410 415 420 Phe Tyr His Arg Trp Phe Asp Val Ile Phe Leu Val Ser Ala Leu 425 430 435 Ser Ser Ile Leu Phe Leu Tyr Leu Ala His Lys Gln Ala Pro Glu 440 445 450 Lys Gln Met Ala Pro 455 15 277 PRT Homo sapiens misc_feature Incyte ID No 1334051CD1 15 Met Lys Ile Ser Met Ile Asn Tyr Lys Ser Leu Leu Ala Leu Leu 1 5 10 15 Phe Ile Leu Ala Ser Trp Ile Ile Phe Thr Val Phe Gln Asn Ser 20 25 30 Thr Lys Val Trp Ser Ala Leu Asn Leu Ser Ile Ser Leu His Tyr 35 40 45 Trp Asn Asn Ser Thr Lys Ser Leu Phe Pro Lys Thr Pro Leu Ile 50 55 60 Ser Leu Lys Pro Leu Thr Glu Thr Glu Leu Arg Ile Lys Glu Ile 65 70 75 Ile Glu Lys Leu Asp Gln Gln Ile Pro Pro Arg Pro Phe Thr His 80 85 90 Val Asn Thr Thr Thr Ser Ala Thr His Ser Thr Ala Thr Ile Leu 95 100 105 Asn Pro Arg Asp Thr Tyr Cys Arg Gly Asp Gln Leu His Ile Leu 110 115 120 Leu Glu Val Arg Asp His Leu Gly Arg Arg Lys Gln Tyr Gly Gly 125 130 135 Asp Phe Leu Arg Ala Arg Met Ser Ser Pro Ala Leu Met Ala Gly 140 145 150 Ala Ser Gly Lys Val Thr Asp Phe Asn Asn Gly Thr Tyr Leu Val 155 160 165 Ser Phe Thr Leu Phe Trp Glu Gly Gln Val Ser Leu Ser Leu Leu 170 175 180 Leu Ile His Pro Ser Glu Gly Val Ser Ala Leu Trp Ser Ala Arg 185 190 195 Asn Gln Gly Tyr Asp Arg Val Ile Phe Thr Gly Gln Phe Val Asn 200 205 210 Gly Thr Ser Gln Val His Ser Glu Cys Gly Leu Ile Leu Asn Thr 215 220 225 Asn Ala Glu Leu Cys Gln Tyr Leu Asp Asn Arg Asp Gln Glu Gly 230 235 240 Phe Tyr Cys Val Arg Pro Gln His Met Pro Cys Ala Ala Leu Thr 245 250 255 His Met Tyr Ser Lys Asn Lys Lys Val Ser Tyr Leu Ser Lys Gln 260 265 270 Glu Lys Ser Leu Phe Glu Arg 275 16 647 PRT Homo sapiens misc_feature Incyte ID No 1336728CD1 16 Met Ala Ser Leu Val Ser Leu Glu Leu Gly Leu Leu Leu Ala Val 1 5 10 15 Leu Val Val Thr Ala Thr Ala Ser Pro Pro Ala Gly Leu Leu Ser 20 25 30 Leu Leu Thr Ser Gly Gln Gly Ala Leu Asp Gln Glu Ala Leu Gly 35 40 45 Gly Leu Leu Asn Thr Leu Ala Asp Arg Val His Cys Thr Asn Gly 50 55 60 Pro Cys Gly Lys Cys Leu Ser Val Glu Asp Ala Leu Gly Leu Gly 65 70 75 Glu Pro Glu Gly Ser Gly Leu Pro Pro Gly Pro Val Leu Glu Ala 80 85 90 Arg Tyr Val Ala Arg Leu Ser Ala Ala Ala Val Leu Tyr Leu Ser 95 100 105 Asn Pro Glu Gly Thr Cys Glu Asp Thr Arg Ala Gly Leu Trp Ala 110 115 120 Ser His Ala Asp His Leu Leu Ala Leu Leu Glu Ser Pro Lys Ala 125 130 135 Leu Thr Pro Gly Leu Ser Trp Leu Leu Gln Arg Met Gln Ala Arg 140 145 150 Ala Ala Gly Gln Thr Pro Lys Thr Ala Cys Val Asp Ile Pro Gln 155 160 165 Leu Leu Glu Glu Ala Val Gly Ala Gly Ala Pro Gly Ser Ala Gly 170 175 180 Gly Val Leu Ala Ala Leu Leu Asp His Val Arg Ser Gly Ser Cys 185 190 195 Phe His Ala Leu Pro Ser Pro Gln Tyr Phe Val Asp Phe Val Phe 200 205 210 Gln Gln His Ser Ser Glu Val Pro Met Thr Leu Ala Glu Leu Ser 215 220 225 Ala Leu Met Gln Arg Leu Gly Val Gly Arg Glu Ala His Ser Asp 230 235 240 His Ser His Arg His Arg Gly Ala Ser Ser Arg Asp Pro Val Pro 245 250 255 Leu Ile Ser Ser Ser Asn Ser Ser Ser Val Trp Asp Thr Val Cys 260 265 270 Leu Ser Ala Arg Asp Val Met Ala Ala Tyr Gly Leu Ser Glu Gln 275 280 285 Ala Gly Val Thr Pro Glu Ala Trp Ala Gln Leu Ser Pro Ala Leu 290 295 300 Leu Gln Gln Gln Leu Ser Gly Ala Cys Thr Ser Gln Ser Arg Pro 305 310 315 Pro Val Gln Asp Gln Leu Ser Gln Ser Glu Arg Tyr Leu Tyr Gly 320 325 330 Ser Leu Ala Thr Leu Leu Ile Cys Leu Cys Ala Val Phe Gly Leu 335 340 345 Leu Leu Leu Thr Cys Thr Gly Cys Arg Gly Val Thr His Tyr Ile 350 355 360 Leu Gln Thr Phe Leu Ser Leu Ala Val Gly Ala Leu Thr Gly Asp 365 370 375 Ala Val Leu His Leu Thr Pro Lys Val Leu Gly Leu His Thr His 380 385 390 Ser Glu Glu Gly Leu Ser Pro Gln Pro Thr Trp Arg Leu Leu Ala 395 400 405 Met Leu Ala Gly Leu Tyr Ala Phe Phe Leu Phe Glu Asn Leu Phe 410 415 420 Asn Leu Leu Leu Pro Arg Asp Pro Glu Asp Leu Glu Asp Gly Pro 425 430 435 Cys Gly His Ser Ser His Ser His Gly Gly His Ser His Gly Val 440 445 450 Ser Leu Gln Leu Ala Pro Ser Glu Leu Arg Gln Pro Lys Pro Pro 455 460 465 His Glu Gly Ser Arg Ala Asp Leu Val Ala Glu Glu Ser Pro Glu 470 475 480 Leu Leu Asn Pro Glu Pro Arg Arg Leu Ser Pro Glu Leu Arg Leu 485 490 495 Leu Pro Tyr Met Ile Thr Leu Gly Asp Ala Val His Asn Phe Ala 500 505 510 Asp Gly Leu Ala Val Gly Ala Ala Phe Ala Ser Ser Trp Lys Thr 515 520 525 Gly Leu Ala Thr Ser Leu Ala Val Phe Cys His Glu Leu Pro His 530 535 540 Glu Leu Gly Asp Phe Ala Ala Leu Leu His Ala Gly Leu Ser Val 545 550 555 Arg Gln Ala Leu Leu Leu Asn Leu Ala Ser Ala Leu Thr Ala Phe 560 565 570 Ala Gly Leu Tyr Val Ala Leu Ala Val Gly Val Ser Glu Glu Ser 575 580 585 Glu Ala Trp Ile Leu Ala Val Ala Thr Gly Leu Phe Leu Tyr Val 590 595 600 Ala Leu Cys Asp Met Leu Pro Ala Met Leu Lys Val Arg Asp Pro 605 610 615 Arg Pro Trp Leu Leu Phe Leu Leu His Asn Val Gly Leu Leu Gly 620 625 630 Gly Trp Thr Val Leu Leu Leu Leu Ser Leu Tyr Glu Asp Asp Ile 635 640 645 Thr Phe 17 406 PRT Homo sapiens misc_feature Incyte ID No 1452856CD1 17 Met Ala Glu Asn Gly Lys Asn Cys Asp Gln Arg Arg Val Ala Met 1 5 10 15 Asn Lys Glu His His Asn Gly Asn Phe Thr Asp Pro Ser Ser Val 20 25 30 Asn Glu Lys Lys Arg Arg Glu Arg Glu Glu Arg Gln Asn Ile Val 35 40 45 Leu Trp Arg Gln Pro Leu Ile Thr Leu Gln Tyr Phe Ser Leu Glu 50 55 60 Ile Leu Val Ile Leu Lys Glu Trp Thr Ser Lys Leu Trp His Arg 65 70 75 Gln Ser Ile Val Val Ser Phe Leu Leu Leu Leu Ala Val Leu Ile 80 85 90 Ala Thr Tyr Tyr Val Glu Gly Val His Gln Gln Tyr Val Gln Arg 95 100 105 Ile Glu Lys Gln Phe Leu Leu Tyr Ala Tyr Trp Ile Gly Leu Gly 110 115 120 Ile Leu Ser Ser Val Gly Leu Gly Thr Gly Leu His Thr Phe Leu 125 130 135 Leu Tyr Leu Gly Pro His Ile Ala Ser Val Thr Leu Ala Ala Tyr 140 145 150 Glu Cys Asn Ser Val Asn Phe Pro Glu Pro Pro Tyr Pro Asp Gln 155 160 165 Ile Ile Cys Pro Asp Glu Glu Gly Thr Glu Gly Thr Ile Ser Leu 170 175 180 Trp Ser Ile Ile Ser Lys Val Arg Ile Glu Ala Cys Met Trp Gly 185 190 195 Ile Gly Thr Ala Ile Gly Glu Leu Pro Pro Tyr Phe Met Ala Arg 200 205 210 Ala Ala Arg Leu Ser Gly Ala Glu Pro Asp Asp Glu Glu Tyr Gln 215 220 225 Glu Phe Glu Glu Met Leu Glu His Ala Glu Ser Ala Gln Asp Phe 230 235 240 Ala Ser Arg Ala Lys Leu Ala Val Gln Lys Leu Val Gln Lys Val 245 250 255 Gly Phe Phe Gly Ile Leu Ala Cys Ala Ser Ile Pro Asn Pro Leu 260 265 270 Phe Asp Leu Ala Gly Ile Thr Cys Gly His Phe Leu Val Pro Phe 275 280 285 Trp Thr Phe Phe Gly Ala Thr Leu Ile Gly Lys Ala Ile Ile Lys 290 295 300 Met His Ile Gln Lys Ile Phe Val Ile Ile Thr Phe Ser Lys His 305 310 315 Ile Val Glu Gln Met Val Ala Phe Ile Gly Ala Val Pro Gly Ile 320 325 330 Gly Pro Ser Leu Gln Lys Pro Phe Gln Glu Tyr Leu Glu Ala Gln 335 340 345 Arg Gln Lys Leu His His Lys Ser Glu Met Gly Thr Pro Gln Gly 350 355 360 Glu Asn Trp Leu Ser Trp Met Phe Glu Lys Leu Val Val Val Met 365 370 375 Val Cys Tyr Phe Ile Leu Ser Ile Ile Asn Ser Met Ala Gln Ser 380 385 390 Tyr Ala Lys Arg Ile Gln Gln Arg Leu Asn Ser Glu Glu Lys Thr 395 400 405 Lys 18 290 PRT Homo sapiens misc_feature Incyte ID No 1562471CD1 18 Met Pro Leu Leu Thr Leu Tyr Leu Leu Leu Phe Trp Leu Ser Gly 1 5 10 15 Tyr Ser Ile Ala Thr Gln Ile Thr Gly Pro Thr Thr Val Asn Gly 20 25 30 Leu Glu Arg Gly Ser Leu Thr Val Gln Cys Val Tyr Arg Ser Gly 35 40 45 Trp Glu Thr Tyr Leu Lys Trp Trp Cys Arg Gly Ala Ile Trp Arg 50 55 60 Asp Cys Lys Ile Leu Val Lys Thr Ser Gly Ser Glu Gln Glu Val 65 70 75 Lys Arg Asp Arg Val Ser Ile Lys Asp Asn Gln Lys Asn Arg Thr 80 85 90 Phe Thr Val Thr Met Glu Asp Leu Met Lys Thr Asp Ala Asp Thr 95 100 105 Tyr Trp Cys Gly Ile Glu Lys Thr Gly Asn Asp Leu Gly Val Thr 110 115 120 Val Gln Val Thr Ile Asp Pro Ala Pro Val Thr Gln Glu Glu Thr 125 130 135 Ser Ser Ser Pro Thr Leu Thr Gly His His Leu Asp Asn Arg His 140 145 150 Lys Leu Leu Lys Leu Ser Val Leu Leu Pro Leu Ile Phe Thr Ile 155 160 165 Leu Leu Leu Leu Leu Val Ala Ala Ser Leu Leu Ala Trp Arg Met 170 175 180 Met Lys Tyr Gln Gln Lys Ala Ala Gly Met Ser Pro Glu Gln Val 185 190 195 Leu Gln Pro Leu Glu Gly Asp Leu Cys Tyr Ala Asp Leu Thr Leu 200 205 210 Gln Leu Ala Gly Thr Ser Pro Arg Lys Ala Thr Thr Lys Leu Ser 215 220 225 Ser Ala Gln Val Asp Gln Val Glu Val Glu Tyr Val Thr Met Ala 230 235 240 Ser Leu Pro Lys Glu Asp Ile Ser Tyr Ala Ser Leu Thr Leu Gly 245 250 255 Ala Glu Asp Gln Glu Pro Thr Tyr Cys Asn Met Gly His Leu Ser 260 265 270 Ser His Leu Pro Gly Arg Gly Pro Glu Glu Pro Thr Glu Tyr Ser 275 280 285 Thr Ile Ser Arg Pro 290 19 390 PRT Homo sapiens misc_feature Incyte ID No 1618158CD1 19 Met Phe Ser Thr Asn Tyr Ser His Met Glu Asn Tyr Arg Lys Arg 1 5 10 15 Glu Asp Leu Val Tyr Gln Ser Thr Val Arg Leu Pro Glu Val Arg 20 25 30 Ile Ser Asp Asn Gly Pro Tyr Glu Cys His Val Gly Ile Tyr Asp 35 40 45 Arg Ala Thr Arg Glu Lys Val Val Leu Ala Ser Gly Asn Ile Phe 50 55 60 Leu Asn Val Met Ala Pro Pro Thr Ser Ile Glu Val Val Ala Ala 65 70 75 Asp Thr Pro Ala Pro Phe Ser Arg Tyr Gln Ala Gln Asn Phe Thr 80 85 90 Leu Val Cys Ile Val Ser Gly Gly Lys Pro Ala Pro Met Val Tyr 95 100 105 Phe Lys Arg Asp Gly Glu Pro Ile Asp Ala Val Pro Leu Ser Glu 110 115 120 Pro Pro Ala Ala Ser Ser Gly Pro Leu Gln Asp Ser Arg Pro Phe 125 130 135 Arg Ser Leu Leu His Arg Asp Leu Asp Asp Thr Lys Met Gln Lys 140 145 150 Ser Leu Ser Leu Leu Asp Ala Glu Asn Arg Gly Gly Arg Pro Tyr 155 160 165 Thr Glu Arg Pro Ser Arg Gly Leu Thr Pro Asp Pro Asn Ile Leu 170 175 180 Leu Gln Pro Thr Thr Glu Asn Ile Pro Glu Thr Val Val Ser Arg 185 190 195 Glu Phe Pro Arg Trp Val His Ser Ala Glu Pro Thr Tyr Phe Leu 200 205 210 Arg His Ser Arg Thr Pro Ser Ser Asp Gly Thr Val Glu Val Arg 215 220 225 Ala Leu Leu Thr Trp Thr Leu Asn Pro Gln Ile Asp Asn Glu Ala 230 235 240 Leu Phe Ser Cys Glu Val Lys His Pro Ala Leu Ser Met Pro Met 245 250 255 Gln Ala Glu Val Thr Leu Val Ala Pro Lys Gly Pro Lys Ile Val 260 265 270 Met Thr Pro Ser Arg Ala Arg Val Gly Asp Thr Val Arg Ile Leu 275 280 285 Val His Gly Phe Gln Asn Glu Val Phe Pro Glu Pro Met Phe Thr 290 295 300 Trp Thr Arg Val Gly Ser Arg Leu Leu Asp Gly Ser Ala Glu Phe 305 310 315 Asp Gly Lys Glu Leu Val Leu Glu Arg Val Pro Ala Glu Leu Asn 320 325 330 Gly Ser Met Tyr Arg Cys Thr Ala Gln Asn Pro Leu Gly Ser Thr 335 340 345 Asp Thr His Thr Arg Leu Ile Val Phe Glu Asn Pro Asn Ile Pro 350 355 360 Arg Gly Thr Glu Asp Ser Asn Gly Ser Ile Gly Pro Thr Gly Ala 365 370 375 Arg Leu Thr Leu Val Leu Ala Leu Thr Val Ile Leu Glu Leu Thr 380 385 390 20 427 PRT Homo sapiens misc_feature Incyte ID No 1656935CD1 20 Met Asn Val Asn Ser Met Asp Met Thr Gly Gly Leu Ser Val Lys 1 5 10 15 Asp Pro Ser Gln Ser Gln Ser Arg Leu Pro Gln Trp Thr His Pro 20 25 30 Asn Ser Met Asp Asn Leu Pro Ser Ala Ala Ser Pro Leu Glu Gln 35 40 45 Asn Pro Ser Lys His Gly Ala Ile Pro Gly Gly Leu Ser Ile Gly 50 55 60 Pro Pro Gly Lys Ser Ser Ile Asp Asp Ser Tyr Gly Arg Tyr Asp 65 70 75 Leu Ile Gln Asn Ser Glu Ser Pro Ala Ser Pro Pro Val Ala Val 80 85 90 Pro His Ser Trp Ser Arg Ala Lys Ser Asp Ser Asp Lys Ile Ser 95 100 105 Asn Gly Ser Ser Ile Asn Trp Pro Pro Glu Phe His Pro Gly Val 110 115 120 Pro Trp Lys Gly Leu Gln Asn Ile Asp Pro Glu Asn Asp Pro Asp 125 130 135 Val Thr Pro Gly Ser Val Pro Thr Gly Pro Thr Ile Asn Thr Thr 140 145 150 Ile Gln Asp Val Asn Arg Tyr Leu Leu Lys Ser Gly Gly Ser Ser 155 160 165 Pro Pro Ser Ser Gln Asn Ala Thr Leu Pro Ser Ser Ser Ala Trp 170 175 180 Pro Leu Ser Ala Ser Gly Tyr Ser Ser Ser Phe Ser Ser Ile Ala 185 190 195 Ser Ala Pro Ser Val Ala Gly Lys Leu Ser Asp Ile Lys Ser Thr 200 205 210 Trp Ser Ser Gly Pro Thr Ser His Thr Gln Ala Ser Leu Ser His 215 220 225 Glu Leu Trp Lys Val Pro Arg Asn Ser Thr Ala Pro Thr Arg Pro 230 235 240 Pro Pro Gly Leu Thr Asn Pro Lys Pro Ser Ser Thr Trp Gly Ala 245 250 255 Ser Pro Leu Gly Trp Thr Ser Ser Tyr Ser Ser Gly Ser Ala Trp 260 265 270 Ser Thr Asp Thr Ser Gly Arg Thr Ser Ser Trp Leu Val Leu Arg 275 280 285 Asn Leu Thr Pro Gln Ile Asp Gly Ser Lys Leu Arg Thr Leu Cys 290 295 300 Leu Gln His Gly Pro Leu Ile Thr Phe His Leu Asn Leu Thr Gln 305 310 315 Gly Asn Ala Val Val Arg Tyr Ser Ser Lys Glu Glu Gly Leu Pro 320 325 330 Lys Ala Gln Glu Val Leu Cys Thr Ile Val Arg Pro Trp Glu Thr 335 340 345 Leu Ser His Ser Leu Gly Pro Ser Phe Arg Leu Val Gly Thr Lys 350 355 360 Glu Val Gly Ile Arg Val Ser Phe Lys Pro Pro Glu Gly Pro Gly 365 370 375 Arg Ile Gly Gln Ser Thr Ile Phe Gln Gly Leu Ala Gln Phe His 380 385 390 Asp Gln Arg Gly Val Ser Lys Leu Thr Gly Arg Gly Gly Ile His 395 400 405 Arg Pro Arg Gly Arg Gly Lys Ala Ser His Gln Leu Ala His Met 410 415 420 Arg His Cys Glu Leu Thr Phe 425 21 459 PRT Homo sapiens misc_feature Incyte ID No 1859305CD1 21 Met Glu Lys Thr Cys Ile Asp Ala Leu Pro Leu Thr Met Asn Ser 1 5 10 15 Ser Glu Lys Gln Glu Thr Val Cys Ile Phe Gly Thr Gly Asp Phe 20 25 30 Gly Arg Ser Leu Gly Leu Lys Met Leu Gln Cys Gly Tyr Ser Val 35 40 45 Val Phe Gly Ser Arg Asn Pro Gln Lys Thr Thr Leu Leu Pro Ser 50 55 60 Gly Ala Glu Val Leu Ser Tyr Ser Glu Ala Ala Lys Lys Ser Asp 65 70 75 Ile Ile Ile Ile Ala Ile His Arg Glu His Tyr Asp Phe Leu Thr 80 85 90 Glu Leu Thr Glu Val Leu Asn Gly Lys Ile Leu Val Asp Ile Ser 95 100 105 Asn Asn Leu Lys Ile Asn Gln Tyr Pro Glu Ser Asn Ala Glu Tyr 110 115 120 Leu Ala His Leu Val Pro Gly Ala His Val Val Lys Ala Phe Asn 125 130 135 Thr Ile Ser Ala Trp Ala Leu Gln Ser Gly Ala Leu Asp Ala Ser 140 145 150 Arg Gln Val Phe Val Cys Gly Asn Asp Ser Lys Ala Lys Gln Arg 155 160 165 Val Met Asp Ile Val Arg Asn Leu Gly Leu Thr Pro Met Asp Gln 170 175 180 Gly Ser Leu Met Ala Ala Lys Glu Ile Glu Lys Tyr Pro Leu Gln 185 190 195 Leu Phe Pro Met Trp Arg Phe Pro Phe Tyr Leu Ser Ala Val Leu 200 205 210 Cys Val Phe Leu Phe Phe Tyr Cys Val Ile Arg Asp Val Ile Tyr 215 220 225 Pro Tyr Val Tyr Glu Lys Lys Asp Asn Thr Phe Arg Met Ala Ile 230 235 240 Ser Ile Pro Asn Arg Ile Phe Pro Ile Thr Ala Leu Thr Leu Leu 245 250 255 Ala Leu Val Tyr Leu Pro Gly Val Ile Ala Ala Ile Leu Gln Leu 260 265 270 Tyr Arg Gly Thr Lys Tyr Arg Arg Phe Pro Asp Trp Leu Asp His 275 280 285 Trp Met Leu Cys Arg Lys Gln Leu Gly Leu Val Ala Leu Gly Phe 290 295 300 Ala Phe Leu His Val Leu Tyr Thr Leu Val Ile Pro Ile Arg Tyr 305 310 315 Tyr Val Arg Trp Arg Leu Gly Asn Leu Thr Val Thr Gln Ala Ile 320 325 330 Leu Lys Lys Glu Asn Pro Phe Ser Thr Ser Ser Ala Trp Leu Ser 335 340 345 Asp Ser Tyr Val Ala Leu Gly Ile Leu Gly Phe Phe Leu Phe Val 350 355 360 Leu Leu Gly Ile Thr Ser Leu Pro Ser Val Ser Asn Ala Val Asn 365 370 375 Trp Arg Glu Phe Arg Phe Val Gln Ser Lys Leu Gly Tyr Leu Thr 380 385 390 Leu Ile Leu Cys Thr Ala His Thr Leu Val Tyr Gly Gly Lys Arg 395 400 405 Phe Leu Ser Pro Ser Asn Leu Arg Trp Tyr Leu Pro Ala Ala Tyr 410 415 420 Val Leu Gly Leu Ile Ile Pro Cys Thr Val Leu Val Ile Lys Phe 425 430 435 Val Leu Ile Met Pro Cys Val Asp Asn Thr Leu Thr Arg Ile Arg 440 445 450 Gln Gly Trp Glu Arg Asn Ser Lys His 455 22 229 PRT Homo sapiens misc_feature Incyte ID No 1949083CD1 22 Met Leu Pro Val Ser Arg Thr Cys Leu Leu Glu Ser Ser Thr Arg 1 5 10 15 Leu Lys Pro His Glu Ala Gln Asn Tyr Arg Lys Lys Ala Leu Trp 20 25 30 Val Ser Trp Phe Ser Ile Ile Val Thr Leu Ala Leu Ala Val Ala 35 40 45 Ala Phe Thr Val Ser Val Met Arg Tyr Ser Ala Ser Ala Phe Gly 50 55 60 Phe Ala Phe Asp Ala Ile Leu Asp Val Leu Ser Ser Ala Ile Val 65 70 75 Leu Trp Arg Tyr Ser Asn Ala Ala Ala Val His Ser Ala His Arg 80 85 90 Glu Tyr Ile Ala Cys Val Ile Leu Gly Val Ile Phe Leu Leu Ser 95 100 105 Ser Ile Cys Ile Val Val Lys Ala Ile His Asp Leu Ser Thr Arg 110 115 120 Leu Leu Pro Glu Val Asp Asp Phe Leu Phe Ser Val Ser Ile Leu 125 130 135 Ser Gly Ile Leu Cys Ser Ile Leu Ala Val Leu Lys Phe Met Leu 140 145 150 Gly Lys Val Leu Thr Ser Arg Ala Leu Ile Thr Asp Gly Phe Asn 155 160 165 Ser Leu Val Gly Gly Val Met Gly Phe Ser Ile Leu Leu Ser Ala 170 175 180 Glu Val Phe Lys His Asp Ser Ala Val Trp Tyr Leu Asp Gly Ser 185 190 195 Ile Gly Val Leu Ile Gly Leu Thr Ile Phe Ala Tyr Gly Val Lys 200 205 210 Leu Leu Ile Asp Met Val Pro Lys Val Arg Gln Thr Arg His Tyr 215 220 225 Glu Met Phe Glu 23 311 PRT Homo sapiens misc_feature Incyte ID No 1996357CD1 23 Met Ala Val Asp Ile Gln Pro Ala Cys Leu Gly Leu Tyr Cys Gly 1 5 10 15 Lys Thr Leu Leu Phe Lys Asn Gly Ser Thr Glu Ile Tyr Gly Glu 20 25 30 Cys Gly Val Cys Pro Arg Gly Gln Arg Thr Asn Ala Gln Lys Tyr 35 40 45 Cys Gln Pro Cys Thr Glu Ser Pro Glu Leu Tyr Asp Trp Leu Tyr 50 55 60 Leu Gly Phe Met Ala Met Leu Pro Leu Val Leu His Trp Phe Phe 65 70 75 Ile Glu Trp Tyr Ser Gly Lys Lys Ser Ser Ser Ala Leu Phe Gln 80 85 90 His Ile Thr Ala Leu Phe Glu Cys Ser Met Ala Ala Ile Ile Thr 95 100 105 Leu Leu Val Ser Asp Pro Val Gly Val Leu Tyr Ile Arg Ser Cys 110 115 120 Arg Val Leu Met Leu Ser Asp Trp Tyr Thr Met Leu Tyr Asn Pro 125 130 135 Ser Pro Asp Tyr Val Thr Thr Val His Cys Thr His Glu Ala Val 140 145 150 Tyr Pro Leu Tyr Thr Ile Val Phe Ile Tyr Tyr Ala Phe Cys Leu 155 160 165 Val Leu Met Met Leu Leu Arg Pro Leu Leu Val Lys Lys Ile Ala 170 175 180 Cys Gly Leu Gly Lys Ser Asp Arg Phe Lys Ser Ile Tyr Ala Ala 185 190 195 Leu Tyr Phe Phe Pro Ile Leu Thr Val Leu Gln Ala Val Gly Gly 200 205 210 Gly Leu Leu Tyr Tyr Ala Phe Pro Tyr Ile Ile Leu Val Leu Ser 215 220 225 Leu Val Thr Leu Ala Val Tyr Met Ser Ala Ser Glu Ile Glu Asn 230 235 240 Cys Tyr Asp Leu Leu Val Arg Lys Lys Arg Leu Ile Val Leu Phe 245 250 255 Ser His Trp Leu Leu His Ala Tyr Gly Ile Ile Ser Ile Ser Arg 260 265 270 Val Asp Lys Leu Glu Gln Asp Leu Pro Leu Leu Ala Leu Val Pro 275 280 285 Thr Pro Ala Leu Phe Tyr Leu Phe Thr Ala Lys Phe Thr Glu Pro 290 295 300 Ser Arg Ile Leu Ser Glu Gly Ala Asn Gly His 305 310 24 92 PRT Homo sapiens misc_feature Incyte ID No 2061330CD1 24 Met Arg Phe Ile Phe Leu Lys Phe Trp Thr Tyr Thr Val Arg Ala 1 5 10 15 Ser Thr Asp Leu Thr Gln Thr Gly Asp Cys Ser Gln Cys Thr His 20 25 30 Gln Val Thr Glu Val Gly Gln Gln Ile Lys Thr Ile Phe Leu Phe 35 40 45 Tyr Ser Tyr Tyr Glu Cys Met Glu Thr Ile Lys Glu Thr Cys Leu 50 55 60 Tyr Asn Ala Thr Gln Tyr Lys Val Cys Ser Pro Arg Asn Asp Arg 65 70 75 Pro Asp Val Cys Tyr Asn Pro Ser Glu Pro Pro Ala Pro Pro Phe 80 85 90 Leu Lys 25 258 PRT Homo sapiens misc_feature Incyte ID No 2346947CD1 25 Met Ala Glu Ser Pro Gly Cys Cys Ser Val Trp Ala Arg Cys Leu 1 5 10 15 His Cys Leu Tyr Ser Cys His Trp Arg Lys Cys Pro Arg Glu Arg 20 25 30 Met Gln Thr Ser Lys Cys Asp Cys Ile Trp Phe Gly Leu Leu Phe 35 40 45 Leu Thr Phe Leu Leu Ser Leu Ser Trp Leu Tyr Ile Gly Leu Val 50 55 60 Leu Leu Asn Asp Leu His Asn Phe Asn Glu Phe Leu Phe Arg Arg 65 70 75 Trp Gly His Trp Met Asp Trp Ser Leu Ala Phe Leu Leu Val Ile 80 85 90 Ser Leu Leu Val Thr Tyr Ala Ser Leu Leu Leu Val Leu Ala Leu 95 100 105 Leu Leu Arg Leu Cys Arg Gln Pro Leu His Leu His Ser Leu His 110 115 120 Lys Val Leu Leu Leu Leu Ile Met Leu Leu Val Ala Ala Gly Leu 125 130 135 Val Gly Leu Asp Ile Gln Trp Gln Gln Glu Trp His Ser Leu Arg 140 145 150 Val Ser Leu Gln Ala Thr Ala Pro Phe Leu His Ile Gly Ala Ala 155 160 165 Ala Gly Ile Ala Leu Leu Ala Trp Pro Val Ala Asp Thr Phe Tyr 170 175 180 Arg Ile His Arg Arg Gly Pro Lys Ile Leu Leu Leu Leu Leu Phe 185 190 195 Phe Gly Val Val Leu Val Ile Tyr Leu Ala Pro Leu Cys Ile Ser 200 205 210 Ser Pro Cys Ile Met Glu Pro Arg Asp Leu Pro Pro Lys Pro Gly 215 220 225 Leu Val Gly His Arg Gly Ala Pro Met Leu Ala Pro Glu Asn Thr 230 235 240 Leu Met Ser Leu Arg Lys Thr Ala Glu Cys Gly Leu Leu Cys Leu 245 250 255 Arg Leu Met 26 226 PRT Homo sapiens misc_feature Incyte ID No 2795577CD1 26 Met Lys Met Val Ala Pro Trp Thr Arg Phe Tyr Ser Asn Ser Cys 1 5 10 15 Cys Leu Cys Cys His Val Arg Thr Gly Thr Ile Leu Leu Gly Val 20 25 30 Trp Tyr Leu Ile Ile Asn Ala Val Val Leu Leu Ile Leu Leu Ser 35 40 45 Ala Leu Ala Asp Pro Asp Gln Tyr Asn Phe Ser Ser Ser Glu Leu 50 55 60 Gly Gly Asp Phe Glu Phe Met Asp Asp Ala Asn Met Cys Ile Ala 65 70 75 Ile Ala Ile Ser Leu Leu Met Ile Leu Ile Cys Ala Met Ala Thr 80 85 90 Tyr Gly Ala Tyr Lys Gln Arg Ala Ala Trp Ile Ile Pro Phe Phe 95 100 105 Cys Tyr Gln Ile Phe Asp Phe Ala Leu Asn Met Leu Val Ala Ile 110 115 120 Thr Val Leu Ile Tyr Pro Asn Ser Ile Gln Glu Tyr Ile Arg Gln 125 130 135 Leu Pro Pro Asn Phe Pro Tyr Arg Asp Asp Val Met Ser Val Asn 140 145 150 Pro Thr Cys Leu Val Leu Ile Ile Leu Leu Phe Ile Ser Ile Ile 155 160 165 Leu Thr Phe Lys Gly Tyr Leu Ile Ser Cys Val Trp Asn Cys Tyr 170 175 180 Arg Tyr Ile Asn Gly Arg Asn Ser Ser Asp Val Leu Val Tyr Val 185 190 195 Thr Ser Asn Asp Thr Thr Val Leu Leu Pro Pro Tyr Asp Asp Ala 200 205 210 Thr Val Asn Gly Ala Ala Lys Glu Pro Pro Pro Pro Tyr Val Ser 215 220 225 Ala 27 136 PRT Homo sapiens misc_feature Incyte ID No 3255825CD1 27 Met Ile Ser Ile Thr Glu Trp Gln Lys Ile Gly Val Gly Ile Thr 1 5 10 15 Gly Phe Gly Ile Phe Phe Ile Leu Phe Gly Thr Leu Leu Tyr Phe 20 25 30 Asp Ser Val Leu Leu Ala Phe Gly Asn Leu Leu Phe Leu Thr Gly 35 40 45 Leu Ser Leu Ile Ile Gly Leu Arg Lys Thr Phe Trp Phe Phe Phe 50 55 60 Gln Arg His Lys Leu Lys Gly Thr Ser Phe Leu Leu Gly Gly Val 65 70 75 Val Ile Val Leu Leu Arg Trp Pro Leu Leu Gly Met Phe Leu Glu 80 85 90 Thr Tyr Gly Phe Phe Ser Leu Phe Lys Gly Phe Phe Pro Val Ala 95 100 105 Phe Gly Ser Trp Ala Met Ser Ala Thr Ser Pro Ser Trp Val Arg 110 115 120 Cys Ser Gly Asp Phe Lys Ala Leu Ala Arg Trp Ser Glu Lys Gln 125 130 135 Arg 28 458 PRT Homo sapiens misc_feature Incyte ID No 3393430CD1 28 Met Ala Trp Ala Ser Arg Leu Gly Leu Leu Leu Ala Leu Leu Leu 1 5 10 15 Pro Val Val Gly Ala Ser Thr Pro Gly Thr Val Val Arg Leu Asn 20 25 30 Lys Ala Ala Leu Ser Tyr Val Ser Glu Ile Gly Lys Ala Pro Leu 35 40 45 Gln Arg Ala Leu Gln Val Thr Val Pro His Phe Leu Asp Trp Ser 50 55 60 Gly Glu Ala Leu Gln Pro Thr Arg Ile Arg Ile Leu Asn Val His 65 70 75 Val Pro Arg Leu His Leu Lys Phe Ile Ala Gly Phe Gly Val Arg 80 85 90 Leu Leu Ala Ala Ala Asn Phe Thr Phe Lys Val Phe Arg Ala Pro 95 100 105 Glu Pro Leu Glu Leu Thr Leu Pro Val Glu Leu Leu Ala Asp Thr 110 115 120 Arg Val Thr Gln Ser Ser Ile Arg Thr Pro Val Val Ser Ile Ser 125 130 135 Ala Cys Ser Leu Phe Ser Gly His Ala Asn Glu Phe Asp Gly Ser 140 145 150 Asn Ser Thr Ser His Ala Leu Leu Val Leu Val Gln Lys His Ile 155 160 165 Lys Ala Val Leu Ser Asn Lys Leu Cys Leu Ser Ile Ser Asn Leu 170 175 180 Val Gln Gly Val Asn Val His Leu Gly Thr Leu Ile Gly Leu Asn 185 190 195 Pro Val Gly Pro Glu Ser Gln Ile Arg Tyr Ser Met Val Ser Val 200 205 210 Pro Thr Val Thr Ser Asp Tyr Ile Ser Leu Glu Val Asn Ala Val 215 220 225 Leu Phe Leu Leu Gly Lys Pro Ile Ile Leu Pro Thr Asp Ala Thr 230 235 240 Pro Phe Val Leu Pro Arg His Val Gly Thr Glu Gly Ser Met Ala 245 250 255 Thr Val Gly Leu Ser Gln Gln Leu Phe Asp Ser Ala Leu Leu Leu 260 265 270 Leu Gln Lys Ala Gly Ala Leu Asn Leu Asp Ile Thr Gly Gln Leu 275 280 285 Arg Ser Asp Asp Asn Leu Leu Asn Thr Ser Ala Leu Gly Arg Leu 290 295 300 Ile Pro Glu Val Ala Arg Gln Phe Pro Glu Pro Met Pro Val Val 305 310 315 Leu Lys Val Arg Leu Gly Ala Thr Pro Val Ala Met Leu His Thr 320 325 330 Asn Asn Ala Thr Leu Arg Leu Gln Pro Phe Val Glu Val Leu Ala 335 340 345 Thr Ala Ser Asn Ser Ala Phe Gln Ser Leu Phe Ser Leu Asp Val 350 355 360 Val Val Asn Leu Arg Leu Gln Leu Ser Val Ser Lys Val Lys Leu 365 370 375 Gln Gly Thr Thr Ser Val Leu Gly Asp Val Gln Leu Thr Val Ala 380 385 390 Ser Ser Asn Val Gly Phe Ile Asp Thr Asp Gln Val Arg Thr Leu 395 400 405 Met Gly Thr Val Phe Glu Lys Pro Leu Leu Asp His Leu Asn Ala 410 415 420 Leu Leu Ala Met Gly Ile Ala Leu Pro Gly Val Val Asn Leu His 425 430 435 Tyr Val Ala Pro Glu Ile Phe Val Tyr Glu Gly Tyr Val Val Ile 440 445 450 Ser Ser Gly Leu Phe Tyr Gln Ser 455 29 368 PRT Homo sapiens misc_feature Incyte ID No 3490990CD1 29 Met Phe Gly Gln Asn Leu Glu Val Gln Leu Ser Ser Ala Arg Thr 1 5 10 15 Glu Asn Thr Thr Val Val Trp Lys Ser Phe His Asp Ser Ile Thr 20 25 30 Leu Ile Val Leu Ser Ser Glu Val Gly Ile Ser Glu Leu Arg Leu 35 40 45 Glu Arg Leu Leu Gln Met Val Phe Gly Ala Met Val Leu Leu Val 50 55 60 Gly Leu Glu Glu Leu Thr Asn Ile Arg Asn Val Glu Arg Leu Lys 65 70 75 Lys Asp Leu Arg Ala Ser Tyr Cys Leu Ile Asp Ser Phe Leu Gly 80 85 90 Asp Ser Glu Leu Ile Gly Asp Leu Thr Gln Cys Val Asp Cys Val 95 100 105 Ile Pro Pro Glu Gly Ser Leu Leu Gln Glu Ala Leu Ser Gly Phe 110 115 120 Ala Glu Ala Ala Gly Thr Thr Phe Val Ser Leu Val Val Ser Gly 125 130 135 Arg Val Val Ala Ala Thr Glu Gly Trp Trp Arg Leu Gly Thr Pro 140 145 150 Glu Ala Val Leu Leu Pro Trp Leu Val Gly Ser Leu Pro Pro Gln 155 160 165 Thr Ala Arg Asp Tyr Pro Val Tyr Leu Pro His Gly Ser Pro Thr 170 175 180 Val Pro His Arg Leu Leu Thr Leu Thr Leu Leu Pro Ser Leu Glu 185 190 195 Leu Cys Leu Leu Cys Gly Pro Ser Pro Pro Leu Ser Gln Leu Tyr 200 205 210 Pro Gln Leu Leu Glu Arg Trp Trp Gln Pro Leu Leu Asp Pro Leu 215 220 225 Arg Ala Cys Leu Pro Leu Gly Pro Arg Ala Leu Pro Ser Gly Phe 230 235 240 Pro Leu His Thr Asp Ile Leu Gly Leu Leu Leu Leu His Leu Glu 245 250 255 Leu Lys Arg Cys Leu Phe Thr Val Glu Pro Leu Gly Asp Lys Glu 260 265 270 Pro Ser Pro Glu Gln Arg Arg Arg Leu Leu Arg Asn Phe Tyr Thr 275 280 285 Leu Val Thr Ser Thr His Phe Pro Pro Glu Pro Gly Pro Pro Glu 290 295 300 Lys Thr Glu Asp Glu Val Tyr Gln Ala Gln Leu Pro Arg Ala Cys 305 310 315 Tyr Leu Val Leu Gly Thr Glu Glu Pro Gly Thr Gly Val Arg Leu 320 325 330 Val Ala Leu Gln Leu Gly Leu Arg Arg Leu Leu Leu Leu Leu Ser 335 340 345 Pro Gln Ser Pro Thr His Gly Leu Arg Ser Leu Ala Thr His Thr 350 355 360 Leu His Ala Leu Thr Pro Leu Leu 365 30 91 PRT Homo sapiens misc_feature Incyte ID No 3635154CD1 30 Met Tyr Gly Lys Ile Ile Phe Val Leu Leu Leu Ser Glu Ile Val 1 5 10 15 Ser Ile Ser Ala Ser Ser Thr Thr Gly Val Ala Met His Thr Ser 20 25 30 Thr Ser Ser Ser Val Thr Lys Ser Tyr Ile Ser Ser Gln Thr Asn 35 40 45 Gly Glu Thr Gly Gln Leu Val His Arg Phe Thr Val Pro Ala Pro 50 55 60 Val Val Ile Ile Leu Ile Ile Leu Cys Val Met Ala Gly Ile Ile 65 70 75 Gly Thr Ile Leu Leu Phe Ser Tyr Ser Phe Arg Arg Leu Ile Lys 80 85 90 Gly 31 295 PRT Homo sapiens misc_feature Incyte ID No 4374347CD1 31 Met Gly Pro Pro Ser Ala Cys Pro His Arg Glu Cys Ile Pro Trp 1 5 10 15 Gln Gly Leu Leu Leu Thr Ala Ser Leu Leu Thr Phe Trp Asn Ala 20 25 30 Pro Thr Thr Ala Trp Leu Phe Ile Ala Ser Ala Pro Phe Glu Val 35 40 45 Ala Glu Gly Glu Asn Val His Leu Ser Val Val Tyr Leu Pro Glu 50 55 60 Asn Leu Tyr Ser Tyr Gly Trp Tyr Lys Gly Lys Thr Val Glu Pro 65 70 75 Asn Gln Leu Ile Ala Ala Tyr Val Ile Asp Thr His Val Arg Thr 80 85 90 Pro Gly Pro Ala Tyr Ser Gly Arg Glu Thr Ile Ser Pro Ser Gly 95 100 105 Asp Leu His Phe Gln Asn Val Thr Leu Glu Asp Thr Gly Tyr Tyr 110 115 120 Asn Leu Gln Val Thr Tyr Arg Asn Ser Gln Ile Glu Gln Ala Ser 125 130 135 His His Leu Arg Val Tyr Glu Ser Val Ala Gln Pro Ser Ile Gln 140 145 150 Ala Ser Ser Thr Thr Val Thr Glu Lys Gly Ser Val Val Leu Thr 155 160 165 Cys His Thr Asn Asn Thr Gly Thr Ser Phe Gln Trp Ile Phe Asn 170 175 180 Asn Gln Arg Leu Gln Val Thr Lys Arg Met Lys Leu Ser Trp Phe 185 190 195 Asn His Val Leu Thr Ile Asp Pro Ile Arg Gln Glu Asp Ala Gly 200 205 210 Glu Tyr Gln Cys Glu Val Ser Asn Pro Val Ser Ser Asn Arg Ser 215 220 225 Asp Pro Leu Lys Leu Thr Val Lys Tyr Asp Asn Thr Leu Gly Ile 230 235 240 Leu Ile Gly Val Leu Val Gly Ser Leu Leu Val Ala Ala Leu Val 245 250 255 Cys Phe Leu Leu Leu Arg Lys Thr Gly Arg Ala Ser Asp Gln Ser 260 265 270 Asp Phe Arg Glu Gln Gln Pro Pro Ala Ser Thr Pro Gly His Gly 275 280 285 Pro Ser Asp Ser Ser Asp Ser Ser Ile Ser 290 295 32 724 PRT Homo sapiens misc_feature Incyte ID No 4596747CD1 32 Met Phe Asp Thr Thr Pro His Ser Gly Arg Ser Thr Pro Ser Ser 1 5 10 15 Ser Pro Ser Leu Arg Lys Arg Leu Gln Leu Leu Pro Pro Ser Arg 20 25 30 Pro Pro Pro Glu Pro Glu Pro Gly Thr Met Val Glu Lys Gly Ser 35 40 45 Asp Ser Ser Ser Glu Lys Gly Gly Val Pro Gly Thr Pro Ser Thr 50 55 60 Gln Ser Leu Gly Ser Arg Asn Phe Ile Arg Asn Ser Lys Lys Met 65 70 75 Gln Ser Trp Tyr Ser Met Leu Ser Pro Thr Tyr Lys Gln Arg Asn 80 85 90 Glu Asp Phe Arg Lys Leu Phe Ser Lys Leu Pro Glu Ala Glu Arg 95 100 105 Leu Ile Val Asp Tyr Ser Cys Ala Leu Gln Arg Glu Ile Leu Leu 110 115 120 Gln Gly Arg Leu Tyr Leu Ser Glu Asn Trp Ile Cys Phe Tyr Ser 125 130 135 Asn Ile Phe Arg Trp Glu Thr Thr Ile Ser Ile Gln Leu Lys Glu 140 145 150 Val Thr Cys Leu Lys Lys Glu Lys Thr Ala Lys Leu Ile Pro Asn 155 160 165 Ala Ile Gln Ile Cys Thr Glu Ser Glu Lys His Phe Phe Thr Ser 170 175 180 Phe Gly Ala Arg Asp Arg Cys Phe Leu Leu Ile Phe Arg Leu Trp 185 190 195 Gln Asn Ala Leu Leu Glu Lys Thr Leu Ser Pro Arg Glu Leu Trp 200 205 210 His Leu Val His Gln Cys Tyr Gly Ser Glu Leu Gly Leu Thr Ser 215 220 225 Glu Asp Glu Asp Tyr Val Ser Pro Leu Gln Leu Asn Gly Leu Gly 230 235 240 Thr Pro Lys Glu Val Gly Asp Val Ile Ala Leu Ser Asp Ile Thr 245 250 255 Ser Ser Gly Ala Ala Asp Arg Ser Gln Glu Pro Ser Pro Val Gly 260 265 270 Ser Arg Arg Gly His Val Thr Pro Asn Leu Ser Arg Ala Ser Ser 275 280 285 Asp Ala Asp His Gly Ala Glu Glu Asp Lys Glu Glu Gln Val Asp 290 295 300 Ser Gln Pro Asp Ala Ser Ser Ser Gln Thr Val Thr Pro Val Ala 305 310 315 Glu Pro Pro Ser Thr Glu Pro Thr Gln Pro Asp Gly Pro Thr Thr 320 325 330 Leu Gly Pro Leu Asp Leu Leu Pro Ser Glu Glu Leu Leu Thr Asp 335 340 345 Thr Ser Asn Ser Ser Ser Ser Thr Gly Glu Glu Ala Asp Leu Ala 350 355 360 Ala Leu Leu Pro Asp Leu Ser Gly Arg Leu Leu Ile Asn Ser Val 365 370 375 Phe His Val Gly Ala Glu Arg Leu Gln Gln Met Leu Phe Ser Asp 380 385 390 Ser Pro Phe Leu Gln Gly Phe Leu Gln Gln Cys Lys Phe Thr Asp 395 400 405 Val Thr Leu Ser Pro Trp Ser Gly Asp Ser Lys Cys His Gln Arg 410 415 420 Arg Val Leu Thr Tyr Thr Ile Pro Ile Ser Asn Pro Leu Gly Pro 425 430 435 Lys Ser Ala Ser Val Val Glu Thr Gln Thr Leu Phe Arg Arg Gly 440 445 450 Pro Gln Ala Gly Gly Cys Val Val Asp Ser Glu Val Leu Thr Gln 455 460 465 Gly Ile Pro Tyr Gln Asp Tyr Phe Tyr Thr Ala His Arg Tyr Cys 470 475 480 Ile Leu Gly Leu Ala Arg Asn Lys Ala Arg Leu Arg Val Ser Ser 485 490 495 Glu Ile Arg Tyr Arg Lys Gln Pro Trp Ser Leu Val Lys Ser Leu 500 505 510 Ile Glu Lys Asn Ser Trp Ser Gly Ile Glu Asp Tyr Phe His His 515 520 525 Leu Glu Arg Glu Leu Ala Lys Ala Glu Lys Leu Ser Leu Glu Glu 530 535 540 Gly Gly Lys Asp Ala Arg Gly Leu Leu Ser Gly Leu Arg Arg Arg 545 550 555 Lys Arg Pro Leu Ser Trp Arg Ala His Gly Asp Gly Pro Gln His 560 565 570 Pro Asp Pro Asp Pro Cys Ala Arg Ala Gly Ile His Thr Ser Gly 575 580 585 Ser Leu Ser Ser Arg Phe Ser Glu Pro Ser Val Asp Gln Gly Pro 590 595 600 Gly Ala Gly Ile Pro Ser Ala Leu Val Leu Ile Ser Ile Val Ile 605 610 615 Cys Val Ser Leu Ile Ile Leu Ile Ala Leu Asn Val Leu Leu Phe 620 625 630 Tyr Arg Leu Trp Ser Leu Glu Arg Thr Ala His Thr Phe Glu Ser 635 640 645 Trp His Ser Leu Ala Leu Ala Lys Gly Lys Phe Pro Gln Thr Ala 650 655 660 Thr Glu Trp Ala Glu Ile Leu Ala Leu Gln Lys Gln Phe His Ser 665 670 675 Val Glu Val His Lys Trp Arg Gln Ile Leu Arg Ala Ser Val Glu 680 685 690 Leu Leu Asp Glu Met Lys Phe Ser Leu Glu Lys Leu His Gln Gly 695 700 705 Ile Thr Val Ser Asp Pro Pro Phe Asp Thr Gln Pro Arg Pro Asp 710 715 720 Asp Ser Phe Ser 33 331 PRT Homo sapiens misc_feature Incyte ID No 5052680CD1 33 Met Arg Pro Ala Leu Ala Val Gly Leu Val Phe Ala Gly Cys Cys 1 5 10 15 Ser Asn Val Ile Phe Leu Glu Leu Leu Ala Arg Lys His Pro Gly 20 25 30 Cys Gly Asn Ile Val Thr Phe Ala Gln Phe Leu Phe Ile Ala Val 35 40 45 Glu Gly Phe Leu Phe Glu Ala Asp Leu Gly Arg Lys Pro Pro Ala 50 55 60 Ile Pro Ile Arg Tyr Tyr Ala Ile Met Val Thr Met Phe Phe Thr 65 70 75 Val Ser Val Val Asn Asn Tyr Ala Leu Asn Leu Asn Ile Ala Met 80 85 90 Pro Leu His Met Ile Phe Arg Ser Gly Ser Leu Ile Ala Asn Met 95 100 105 Ile Leu Gly Ile Ile Ile Leu Lys Lys Arg Tyr Ser Ile Phe Lys 110 115 120 Tyr Thr Ser Ile Ala Leu Val Ser Val Gly Ile Phe Ile Cys Thr 125 130 135 Phe Met Ser Ala Lys Gln Val Thr Ser Gln Ser Ser Leu Ser Glu 140 145 150 Asn Asp Gly Phe Gln Ala Phe Val Trp Trp Leu Leu Gly Ile Gly 155 160 165 Ala Leu Thr Phe Ala Leu Leu Met Ser Ala Arg Met Gly Ile Phe 170 175 180 Gln Glu Thr Leu Tyr Lys Arg Phe Gly Lys His Ser Lys Glu Ala 185 190 195 Leu Phe Tyr Asn His Ala Leu Pro Leu Pro Gly Phe Val Phe Leu 200 205 210 Ala Ser Asp Ile Tyr Asp His Ala Val Leu Phe Asn Lys Ser Glu 215 220 225 Leu Tyr Glu Ile Pro Val Ile Gly Val Thr Leu Pro Ile Met Trp 230 235 240 Phe Tyr Leu Leu Met Asn Ile Ile Thr Gln Tyr Val Cys Ile Arg 245 250 255 Gly Val Phe Ile Leu Thr Thr Glu Cys Ala Ser Leu Thr Val Thr 260 265 270 Leu Val Val Thr Leu Arg Lys Phe Val Ser Leu Ile Phe Ser Ile 275 280 285 Leu Tyr Phe Gln Asn Pro Phe Thr Leu Trp His Trp Leu Gly Thr 290 295 300 Leu Phe Val Phe Ile Gly Thr Leu Met Tyr Thr Glu Val Trp Asn 305 310 315 Asn Leu Gly Thr Thr Lys Ser Glu Pro Gln Lys Asp Ser Lys Lys 320 325 330 Asn 34 398 PRT Homo sapiens misc_feature Incyte ID No 5373575CD1 34 Met Leu Gly Arg Ser Gly Tyr Arg Ala Leu Pro Leu Gly Asp Phe 1 5 10 15 Asp Arg Phe Gln Gln Ser Ser Phe Gly Phe Leu Gly Ser Gln Lys 20 25 30 Gly Cys Leu Ser Pro Glu Arg Gly Gly Val Gly Thr Gly Ala Asp 35 40 45 Val Pro Gln Ser Trp Pro Ser Cys Leu Cys His Gly Leu Ile Ser 50 55 60 Phe Leu Gly Phe Leu Leu Leu Leu Val Thr Phe Pro Ile Ser Gly 65 70 75 Trp Phe Ala Leu Lys Ile Val Pro Thr Tyr Glu Arg Met Ile Val 80 85 90 Phe Arg Leu Gly Arg Ile Arg Thr Pro Gln Gly Pro Gly Met Val 95 100 105 Leu Leu Leu Pro Phe Ile Asp Ser Phe Gln Arg Val Asp Leu Arg 110 115 120 Thr Arg Ala Phe Asn Val Pro Pro Cys Lys Leu Ala Ser Lys Asp 125 130 135 Gly Ala Val Leu Ser Val Gly Ala Asp Val Gln Phe Arg Ile Trp 140 145 150 Asp Pro Val Leu Ser Val Met Thr Val Lys Asp Leu Asn Thr Ala 155 160 165 Thr Arg Met Thr Ala Gln Asn Ala Met Thr Lys Ala Leu Leu Lys 170 175 180 Arg Pro Leu Arg Glu Ile Gln Met Glu Lys Leu Lys Ile Ser Asp 185 190 195 Gln Leu Leu Leu Glu Ile Asn Asp Val Thr Arg Ala Trp Gly Leu 200 205 210 Glu Val Asp Arg Val Glu Leu Ala Val Glu Ala Val Leu Gln Pro 215 220 225 Pro Gln Asp Ser Pro Ala Gly Pro Asn Leu Asp Ser Thr Leu Gln 230 235 240 Gln Leu Ala Leu His Phe Leu Gly Gly Ser Met Asn Ser Met Ala 245 250 255 Gly Gly Ala Pro Ser Pro Gly Pro Ala Asp Thr Val Glu Met Val 260 265 270 Ser Glu Val Glu Pro Pro Ala Pro Gln Val Gly Ala Arg Ser Ser 275 280 285 Pro Lys Gln Pro Leu Ala Glu Gly Leu Leu Thr Ala Leu Gln Pro 290 295 300 Phe Leu Ser Glu Ala Leu Val Ser Gln Val Gly Ala Cys Tyr Gln 305 310 315 Phe Asn Val Val Leu Pro Ser Gly Thr Gln Ser Ala Tyr Phe Leu 320 325 330 Asp Leu Thr Thr Gly Arg Gly Arg Val Gly His Gly Val Pro Asp 335 340 345 Gly Ile Pro Asp Val Val Val Glu Met Ala Glu Ala Asp Leu Arg 350 355 360 Ala Leu Leu Cys Arg Glu Leu Arg Pro Leu Gly Ala Tyr Met Ser 365 370 375 Gly Arg Leu Lys Val Lys Gly Asp Leu Ala Met Ala Met Lys Leu 380 385 390 Glu Ala Val Leu Arg Ala Leu Lys 395 35 220 PRT Homo sapiens misc_feature Incyte ID No 5524468CD1 35 Met Thr Trp Leu Val Leu Leu Gly Thr Leu Leu Cys Met Leu Arg 1 5 10 15 Val Gly Leu Gly Thr Pro Asp Ser Glu Gly Phe Pro Pro Arg Ala 20 25 30 Leu His Asn Cys Pro Tyr Lys Cys Ile Cys Ala Ala Asp Leu Leu 35 40 45 Ser Cys Thr Gly Leu Gly Leu Gln Asp Val Pro Ala Glu Leu Pro 50 55 60 Ala Ala Thr Ala Asp Leu Asp Leu Ser His Asn Ala Leu Gln Arg 65 70 75 Leu Arg Pro Gly Trp Leu Ala Pro Leu Phe Gln Leu Arg Ala Leu 80 85 90 His Leu Asp His Asn Glu Leu Asp Ala Leu Gly Arg Gly Val Phe 95 100 105 Val Asn Ala Ser Gly Leu Arg Leu Leu Asp Leu Ser Ser Asn Thr 110 115 120 Leu Arg Ala Leu Gly Arg His Asp Leu Asp Gly Leu Gly Ala Leu 125 130 135 Glu Lys Leu Leu Leu Phe Asn Asn Arg Leu Val His Leu Asp Glu 140 145 150 His Ala Phe His Gly Leu Arg Ala Leu Ser His Leu Tyr Leu Gly 155 160 165 Cys Asn Glu Leu Ala Ser Phe Ser Phe Asp His Leu His Gly Leu 170 175 180 Ser Ala Thr His Leu Leu Thr Leu Asp Leu Ser Ser Asn Arg Leu 185 190 195 Gly His Ile Ser Val Pro Glu Leu Ala Ala Leu Pro Ala Phe Leu 200 205 210 Lys Asn Gly Leu Tyr Leu His Asp Asn Thr 215 220 36 706 PRT Homo sapiens misc_feature Incyte ID No 5944279CD1 36 Met Glu Glu Asn Pro Thr Leu Glu Ser Glu Ala Trp Gly Ser Ser 1 5 10 15 Arg Gly Trp Leu Ala Pro Arg Glu Ala Arg Gly Gly Pro Ser Leu 20 25 30 Ser Ser Val Leu Asn Glu Leu Pro Ser Ala Ala Thr Leu Arg Tyr 35 40 45 Arg Asp Pro Gly Val Leu Pro Trp Gly Ala Leu Glu Glu Glu Glu 50 55 60 Glu Asp Gly Gly Arg Ser Arg Lys Ala Phe Thr Glu Val Thr Gln 65 70 75 Thr Glu Leu Gln Asp Pro His Pro Ser Arg Glu Leu Pro Trp Pro 80 85 90 Met Gln Ala Arg Arg Ala His Arg Gln Arg Asn Ala Ser Arg Asp 95 100 105 Gln Val Val Tyr Gly Ser Gly Thr Lys Thr Asp Arg Trp Ala Arg 110 115 120 Leu Leu Arg Arg Ser Lys Glu Lys Thr Lys Glu Gly Leu Arg Ser 125 130 135 Leu Gln Pro Trp Ala Trp Thr Leu Lys Arg Ile Gly Gly Gln Phe 140 145 150 Gly Ala Gly Thr Glu Ser Tyr Phe Ser Leu Leu Arg Phe Leu Leu 155 160 165 Leu Leu Asn Val Leu Ala Ser Val Leu Met Ala Cys Met Thr Leu 170 175 180 Leu Pro Thr Trp Leu Gly Gly Ala Pro Pro Gly Pro Pro Gly Pro 185 190 195 Asp Ile Ser Ser Pro Cys Gly Ser Tyr Asn Pro His Ser Gln Gly 200 205 210 Leu Val Thr Phe Ala Thr Gln Leu Phe Asn Leu Leu Ser Gly Glu 215 220 225 Gly Tyr Leu Glu Trp Ser Pro Leu Phe Tyr Gly Phe Tyr Pro Pro 230 235 240 Arg Pro Arg Leu Ala Val Thr Tyr Leu Cys Trp Ala Phe Ala Val 245 250 255 Gly Leu Ile Cys Leu Leu Leu Ile Leu His Arg Ser Val Ser Gly 260 265 270 Leu Lys Gln Thr Leu Leu Ala Glu Ser Glu Ala Leu Thr Ser Tyr 275 280 285 Ser His Arg Val Phe Ser Ala Trp Asp Phe Gly Leu Cys Gly Asp 290 295 300 Val His Val Arg Leu Arg Gln Arg Ile Ile Leu Tyr Glu Leu Lys 305 310 315 Val Glu Leu Glu Glu Thr Val Val Arg Arg Gln Ala Ala Val Arg 320 325 330 Thr Leu Gly Gln Gln Ala Arg Val Trp Leu Val Arg Val Leu Leu 335 340 345 Asn Leu Leu Val Val Ala Leu Leu Gly Ala Ala Phe Tyr Gly Val 350 355 360 Tyr Trp Ala Thr Gly Cys Thr Val Glu Leu Gln Glu Met Pro Leu 365 370 375 Val Gln Glu Leu Pro Leu Leu Lys Leu Gly Val Asn Tyr Leu Pro 380 385 390 Ser Ile Phe Ile Ala Gly Val Asn Phe Val Leu Pro Pro Val Phe 395 400 405 Lys Leu Ile Ala Pro Leu Glu Gly Tyr Thr Arg Ser Arg Gln Ile 410 415 420 Val Phe Ile Leu Leu Arg Thr Val Phe Leu Arg Leu Ala Ser Leu 425 430 435 Val Val Leu Leu Phe Ser Leu Trp Asn Gln Ile Thr Cys Gly Gly 440 445 450 Asp Ser Glu Ala Glu Asp Cys Lys Thr Cys Gly Tyr Asn Tyr Lys 455 460 465 Gln Leu Pro Cys Trp Glu Thr Val Leu Gly Gln Glu Met Tyr Lys 470 475 480 Leu Leu Leu Phe Asp Leu Leu Thr Val Leu Ala Val Ala Leu Leu 485 490 495 Ile Gln Phe Pro Arg Lys Leu Leu Cys Gly Leu Cys Pro Gly Ala 500 505 510 Leu Gly Arg Leu Ala Gly Thr Gln Glu Phe Gln Val Pro Asp Glu 515 520 525 Val Leu Gly Leu Ile Tyr Ala Gln Thr Val Val Trp Val Gly Ser 530 535 540 Phe Phe Cys Pro Leu Leu Pro Leu Leu Asn Thr Val Lys Phe Leu 545 550 555 Leu Leu Phe Tyr Leu Lys Lys Leu Thr Leu Phe Ser Thr Cys Ser 560 565 570 Pro Ala Ala Arg Thr Phe Arg Ala Ser Ala Ala Asn Phe Phe Phe 575 580 585 Pro Leu Val Leu Leu Leu Gly Leu Ala Ile Ser Ser Val Pro Leu 590 595 600 Leu Tyr Ser Ile Phe Leu Ile Pro Pro Ser Lys Leu Cys Gly Pro 605 610 615 Phe Arg Gly Gln Ser Ser Ile Trp Ala Gln Ile Pro Glu Ser Ile 620 625 630 Ser Ser Leu Pro Glu Thr Thr Gln Asn Phe Leu Phe Phe Leu Gly 635 640 645 Thr Gln Ala Phe Ala Val Pro Leu Leu Leu Ile Ser Ser Ile Leu 650 655 660 Met Ala Tyr Thr Val Ala Leu Ala Asn Ser Tyr Gly Arg Leu Ile 665 670 675 Ser Glu Leu Lys Arg Gln Arg Gln Thr Glu Ala Gln Asn Lys Val 680 685 690 Phe Leu Ala Arg Arg Ala Val Ala Leu Thr Ser Thr Lys Pro Ala 695 700 705 Leu 37 466 PRT Homo sapiens misc_feature Incyte ID No 6114480CD1 37 Met Ala Phe Val Leu Ile Leu Val Leu Ser Phe Tyr Glu Leu Val 1 5 10 15 Ser Gly Gln Trp Gln Val Thr Gly Pro Gly Lys Phe Val Gln Ala 20 25 30 Leu Val Gly Glu Asp Ala Val Phe Ser Cys Ser Leu Phe Pro Glu 35 40 45 Thr Ser Ala Glu Ala Met Glu Val Arg Phe Phe Arg Asn Gln Phe 50 55 60 His Ala Val Val His Leu Tyr Arg Asp Gly Glu Asp Trp Glu Ser 65 70 75 Lys Gln Met Pro Gln Tyr Arg Gly Arg Thr Glu Phe Val Lys Asp 80 85 90 Ser Ile Ala Gly Gly Arg Val Ser Leu Arg Leu Lys Asn Ile Thr 95 100 105 Pro Ser Asp Ile Gly Leu Tyr Gly Cys Trp Phe Ser Ser Gln Ile 110 115 120 Tyr Asp Glu Glu Ala Thr Trp Glu Leu Arg Val Ala Ala Leu Gly 125 130 135 Ser Leu Pro Leu Ile Ser Ile Val Gly Tyr Val Asp Gly Gly Ile 140 145 150 Gln Leu Leu Cys Leu Ser Ser Gly Trp Phe Pro Gln Pro Thr Ala 155 160 165 Lys Trp Lys Gly Pro Gln Gly Gln Asp Leu Ser Ser Asp Ser Arg 170 175 180 Ala Asn Ala Asp Gly Tyr Ser Leu Tyr Asp Val Glu Ile Ser Ile 185 190 195 Ile Val Gln Glu Asn Ala Gly Ser Ile Leu Cys Ser Ile His Leu 200 205 210 Ala Glu Gln Ser His Glu Val Glu Ser Lys Val Leu Ile Gly Glu 215 220 225 Thr Phe Phe Gln Pro Ser Pro Trp Arg Leu Ala Ser Ile Leu Leu 230 235 240 Gly Leu Leu Cys Gly Ala Leu Cys Gly Val Val Met Gly Met Ile 245 250 255 Ile Val Phe Phe Lys Ser Lys Gly Lys Ile Gln Ala Glu Leu Asp 260 265 270 Trp Arg Arg Lys His Gly Gln Ala Glu Leu Arg Asp Ala Arg Lys 275 280 285 His Ala Val Glu Val Thr Leu Asp Pro Glu Thr Ala His Pro Lys 290 295 300 Leu Cys Val Ser Asp Leu Lys Thr Val Thr His Arg Lys Ala Pro 305 310 315 Gln Glu Val Pro His Ser Glu Lys Arg Phe Thr Arg Lys Ser Val 320 325 330 Val Ala Ser Gln Gly Phe Gln Ala Gly Arg His Tyr Trp Glu Val 335 340 345 Asp Val Gly Gln Asn Val Gly Trp Tyr Val Gly Val Cys Arg Asp 350 355 360 Asp Val Asp Arg Gly Lys Asn Asn Val Thr Leu Ser Pro Asn Asn 365 370 375 Gly Tyr Trp Val Leu Arg Leu Thr Thr Glu His Leu Tyr Phe Thr 380 385 390 Phe Asn Pro His Phe Ile Ser Leu Pro Pro Ser Thr Pro Pro Thr 395 400 405 Arg Val Gly Val Phe Leu Asp Tyr Glu Gly Gly Thr Ile Ser Phe 410 415 420 Phe Asn Thr Asn Asp Gln Ser Leu Ile Tyr Thr Leu Leu Thr Cys 425 430 435 Gln Phe Glu Gly Leu Leu Arg Pro Tyr Ile Gln His Ala Met Tyr 440 445 450 Asp Glu Glu Lys Gly Thr Pro Ile Phe Ile Cys Pro Val Ser Trp 455 460 465 Gly 38 2801 DNA Homo sapiens misc_feature Incyte ID No 112301CB1 38 cgccttcccc gagcgagacc aaaacaggtg gaatccgggc tggagccgga gctccggcgg 60 cgcgggtggc ggcacgtccc tccagacagt accacaggca cctggagtac cggcatcggt 120 cgctgtggcc cccgagtgtc cgtcagagcc taggggagcc tgccctcccg cgcctcgtcg 180 gggcccggcc aggcaccttg gccgccggcg cacggacgcg ggcacgagca ctagatcacg 240 gctgctggac ctcggcacgt tgacaagatt tctctggggt accgcggagg attactttga 300 atttcggtgg tcgcctgtgg tctggcatat ttagaactta agtctattat ttcgggcacc 360 atgactttga ggcttttaga agactggtgc agggggatgg acatgaaccc tcggaaagcg 420 ctattgattg ccggcatctc ccagagctgc agtgtggcag aaatcgagga ggctctgcag 480 gctggtttag ctcccttggg ggagtacaga ctgcttggaa ggatgttcag gagggatgag 540 aacaggaaag tagccttagt agggcttact gcggagacta gtcacgccct ggtccctaag 600 gagataccgg gaaaaggggg tatctggaga gtgatcttta agccccctga cccagataat 660 acatttttaa gcagattaaa tgaattttta gcgggagagg gcatgacagt gggtgagttg 720 agcagagctc ttggacatga aaatggctcc ttagacccag agcagggcat gatcccggaa 780 atgtgggccc ctatgttggc acaggcatta gaggctcttc agcctgccct gcaatgcttg 840 aagtataaaa agctgagagt gttctcgggc agggagtctc cagaaccagg agaagaagaa 900 tttggacgct ggatgtttca tactactcag atgataaagg cgtggcaggt gccagatgta 960 gagaagagaa ggcgattgct agagagcctt cgaggcccag cacttgatgt tattcgtgtc 1020 ctcaagataa acaatccttt aattactgtc gatgaatgtc tgcaggctct tgaggaggta 1080 tttggggtta cagataatcc tagggagttg caggtcaaat atctaaccac ttaccagaag 1140 gatgaggaaa agttgtcggc ttatgtacta aggctggagc ctttgttaca gaagctggta 1200 cagagaggag caattgagag agatgctgtg aatcaggccc gcctagacca agtcattgct 1260 ggggcagtcc acaaaacaat tcgcagagag cttaatctgc cagaggatgg cccagcccct 1320 ggtttcttgc agttattggt actaataaag gattatgagg cagctgagga ggaggaggcc 1380 cttctccagg caatattgga aggtaatttc acctgagtct cagggaacca cgaagggata 1440 tggcaatgag tagagcatga aggtagaaca gtctatatac tcttgtgaca catacaatcc 1500 ctaccttgtg ctgccaagta actcattttt gtgcaattct cagtataagc cctttgtcgt 1560 ttctgtgcct atttaaagtc tcctaaaggt gtaattgact aggaaggatg tagttctaca 1620 ctgccattta cctatttaaa ttcatccttg tgaatatctt tgttgttgtt gttgagacag 1680 agtctcgctc tgtcacccag gctggagtgc agtgacgtga tcttggctca ctgcatcctc 1740 cgccttccag gtttaagcta ttctcctgcc tcagttgccc gagtagctgg gactacagga 1800 atgactcacc acacccagct aagttttgca ttatcagtag agacggggtt tctccatact 1860 ggtcaggctg gtctcgaact cctgacctca agtgatccac ctgccttggc ctcccaaagt 1920 gctgggatta caggcgtgag ccaccacacc cagcctcagt tcccttattt taataattgt 1980 cctatttcgt ggggttgcta taaagattac atgagacttt aatgggaaag tatttaggac 2040 agtgtatggg acaaagttag taccagacat gcataaggca tttgaaaacc tgggtgcttt 2100 ctctctcact cttaccattt atagacaggg gtcatataat tttttttgtt gagacggagt 2160 ctcgctctgt ggcccaggct ggagagcagt ggtgtgatct cagctcatgg gttcaagcga 2220 ttctcgtgcc tcagcctccc gagtagctgg gactataggc atgcgccacc aggcccagcc 2280 aatttttata tttttagtag agatggggtt tctccatgtt agccaggcta cccaggctgg 2340 tctcgatctc ctgacctcag gtgatccacc cacctgggcc tcccaaagtg ctgggattac 2400 aggcgtgagc cactgccccc tgccttctta cactttttct ttgagactgg gtcgcacagt 2460 cgcacagtga gactccatct cctatgaaaa aaaagattgg cctagcgtct ggctcaggcc 2520 tgtaatccca gcactttggg aggccaaggc gggcggatca caaggtcagg agatcgaggc 2580 cagcatggcc aacatggtga caccctgttt ctactaaaaa tacaaaaaaa attagccggg 2640 catggtggcg catgcctata gtgtcagcta ctctggagaa tcgcttgaac ccgggaggcg 2700 gaggttgcag tgagccgaga ttgcgtcact gcactacagc ctgggcaaca gagcgagact 2760 cccgtctcag aaaaaaaaag ttttggtgcc aaccggacga g 2801 39 2656 DNA Homo sapiens misc_feature Incyte ID No 997947CB1 39 ccactctcta gagctcccgg actcctagct ctgagaatgc ctgcggaatg atcgcccccc 60 aggccggctg ccgccgctgc cgctgctgct gttattgcta ctgctgctgc cgccgcctct 120 gcttccactc ggctctgact ggcaggcaga aagtgcaact gacgagggaa aggtctctgc 180 agtgagtgga gagcctacat aaaagagagt aaagaggggc aaaaacccag atcagaatgc 240 aggcgacgtc caaccttctc aacctcctgc tgctgtcttt gtttgccgga ttagatcctt 300 ccaagactca gattagtcct aaagaagggt ggcaggtgta cagctcagct caggatcctg 360 atgggcggtg catttgcaca gttgttgctc cagaacaaaa cctgtgttcc cgggatgcca 420 aaagcaggca acttcgccaa ctactggaaa aggttcagaa catgtcccag tctattgaag 480 tcttaaactt gagaactcag agagatttcc aatatgtttt aaaaatggaa acccaaatga 540 aagggctgaa ggcaaaattt cggcagattg aagatgatcg aaagacactt atgaccaagc 600 attttcagga gttgaaagag aaaatggacg agctcctgcc tttgatcccc gtgctggaac 660 agtacaaaac agatgctaag ttaatcaccc agttcaagga ggaaataagg aatctgtctg 720 ctgtcctcac tggtattcag gaggaaattg gtgcctatga ctacgaggaa ctacaccaaa 780 gagtgctgag cttggaaaca agacttcgtg actgcatgaa aaagctaaca tgtggcaaac 840 tgatgaaaat cacaggccca gttacagtca agacatctgg aacccgattt ggtgcttgga 900 tgacagaccc tttagcatct gagaaaaaca acagagtctg gtacatggac agttatacta 960 acaataaaat tgttcgtgaa tacaaatcaa ttgcagactt tgtcagtggg gctgaatcaa 1020 ggacatacaa ccttcctttc aagtgggcag gaactaacca tgttgtctac aatggctcac 1080 tctattttaa caagtatcag agtaatatca tcatcaaata cagctttgat atggggagag 1140 tgcttgccca acgaagcctg gagtatgctg gttttcataa tgtttacccc tacacatggg 1200 gtggattctc tgacatcgac ctaatggctg atgaaatcgg gctgtgggct gtgtatgcaa 1260 ctaaccagaa tgcaggcaat attgtcatca gccaacttaa ccaagatacc ttggaggtga 1320 tgaagagctg gagcactggc taccccaaga gaagtgcagg ggaatctttc atgatctgtg 1380 ggacactgta tgtcaccaac tcccacttaa ctggagccaa ggtgtattat tcctattcca 1440 ccaaaacctc cacatatgag tacacagaca ttcccttcca taaccaatac tttcacatat 1500 ccatgcttga ctacaatgca agagatcgag ctctctatgc ctggaacaat ggccaccagg 1560 tgctgttcaa tgtcaccctt ttccatatca tcaagacaga ggatgacaca taggcaaatg 1620 tgacatgttt tcattgattt aaacagtgtg atttgtgata aactctataa gaccccttcc 1680 gtttttttct tcactattat ttttcatcat ttctccaaag caaagcattt ttattgtaaa 1740 gttggtgttt caaaaacata gctgagcttg tctaacttac catgttggaa acacatctta 1800 acttctaaat ttacaaggcc tatcatgtcc ttgtcatgaa aagcactaaa aaaaaaaaga 1860 gtttaagtgg ctaaagtcat agttttgcaa gagattaatg atctgcctta tattagagtc 1920 agagactaat ggtggcttaa atgcacgaat gtcttttttt tttaaaactg tcatttttta 1980 ctgtcttttg ctccatatca ggaaatattt tggtaggaat taggagaaca aaaagcactt 2040 ttatcccatt tatttcttta aaaaatgtaa ggatttcatt tatattgaaa aataatatta 2100 atcattttgc tgttaacaca attctctgat gcggtgctgt acagtcattt ttaaatctct 2160 tgctaacatt ttattggcag tatgtatttc taccattgta accaccattg tgctattgta 2220 tctcttcact tctgtgaaag taatattttt tataaaatac actgaaattt aacctcagta 2280 attgagtcca ttttcaagtg tggtcaagaa taatcttctt ggcttacccc tttacataag 2340 cattataaac taaaatgaaa accaaaccag acacctgaca tagagtcttt attttacccc 2400 aagttttttg ggccactgac attgaatgca acaactgatt tcatacaact gagttactct 2460 gttcactcca ctgaatgcaa cccatatagt ttcttgcaca aggtgcatct ggattctaaa 2520 tattggattt gagttgactc tactcattta ttanacacta aagaaatttt gttcttcata 2580 gttaaangta ctagcattta attnanattt nacatacaac ttgcaataat gaaattcctt 2640 atgncnngac nctgaa 2656 40 968 DNA Homo sapiens misc_feature Incyte ID No 1521513CB1 40 tctacatcta tcggagctga acttcctaaa agacaaagtg tttatctttc aagattcatt 60 ctccctgaat cttaccaaca aaacactcct gaggagaaag aaagagaggg agggagagaa 120 aaagagagag agagaaacaa aaaaccaaag agagagaaaa aatgaattca tctaaatcat 180 ctgaaacaca atgcacagag agaggatgct tctcttccca aatgttctta tggactgttg 240 ctgggatccc catcctattt ctcagtgcct gtttcatcac cagatgtgtt gtgacatttc 300 gcatctttca aacctgtgat gagaaaaagt ttcagctacc tgagaatttc acagagctct 360 cctgctacaa ttatggatca ggttcagtca agaattgttg tccattgaac tgggaatatt 420 ttcaatccag ctgctacttc ttttctactg acaccatttc ctgggcgtta agtttaaaga 480 actgctcagc catgggggct cacctggtgg ttatcaactc acaggaggag caggaattcc 540 tttcctacaa gaaacctaaa atgagagagt tttttattgg actgtcagac caggttgtcg 600 agggtcagtg gcaatgggtg gacggcacac ctttgacaaa gtctctgagc ttctgggatg 660 taggggagcc caacaacata gctaccctgg aggactgtgc caccatgaga gactcttcaa 720 acccaaggca aaattggaat gatgtaacct gtttcctcaa ttattttcgg atttgtgaaa 780 tggtaggaat aaatcctttg aacaaaggaa aatctcttta agaacagaag gcacaactca 840 aatgtgtaaa gaaggaagag caagaacatg gccacaccca ccgccccaca cgagaaattt 900 gtgcgctgaa cttcaaagga cttcataagt atttgttact ctgatataaa taaaaataag 960 tagtttta 968 41 1837 DNA Homo sapiens misc_feature Incyte ID No 1863994CB1 41 ccccagcccc gctcagtccc gagcgcccgc agtcgtcgcg ccgccgcgcc aagcatgcag 60 taaaggctga aaatctgggt cacagctgag gaagacctca gacatggagt ccaggatgtg 120 gcctgcgctg ctgctgtccc acctcctccc tctctggcca ctgctgttgc tgcccctccc 180 accgcctgct cagggctctt catcctcccc tcgaacccca ccagccccag cccgcccccc 240 gtgtgccagg ggaggcccct cggccccacg tcatgtgtgc gtgtgggagc gagcacctcc 300 accaagccga tctcctcggg tcccaagatc acgtcggcaa gtcctgcctg gcactgcacc 360 cccagccacc ccatcaggct ttgaggaggg gccgccctca tcccaatacc cctgggctat 420 cgtgtggggt cccaccgtgt ctcgagagga tggaggggac cccaactctg ccaatcccgg 480 atttctggac tatggttttg cagcccctca tgggctcgca accccacacc ccaactcaga 540 ctccatgcga ggtgatggag atgggcttat ccttggagag gcacctgcca ccctgcggcc 600 attcctgttc gggggccgtg gggaaggtgt ggacccccag ctctatgtca caattaccat 660 ctccatcatc attgttctcg tggccactgg catcatcttc aagttctgct gggaccgcag 720 ccagaagcga cgcagaccct cagggcagca aggtgccctg aggcaggagg agagccagca 780 gccactgaca gacctgtccc cggctggagt cactgtgctg ggggccttcg gggactcacc 840 tacccccacc cctgaccatg aggagccccg agggggaccc cggcctggga tgccccaccc 900 caagggggct ccagccttcc agttgaaccg gtgagggcag gggcaatggg atgggagggc 960 aaagagggaa ggcaacttag gtcttcagag ctggggtggg ggtgccctct ggatgggtag 1020 tgaggaggca ggcgtggcct cccacagccc ctggccctcc caagggggct ggaccagctc 1080 ctctctggga ggcacccttc cttctcccag tctctcagga tctgtgtcct attctctgct 1140 gcccataact ccaactctgc cctctttggt tttttctcat gccaccttgt ctaagacaac 1200 tctgccctct taaccttgat tccccctctt tgtcttgaac ttccccttct attctggcct 1260 accccttggt tcctgactgt gccctttccc tcttcctctc aggattcccc tggtgaatct 1320 gtgatgcccc caatgttggg gtgcagccaa gcaggaggcc aaggggccgg cacagccccc 1380 atcccactga gggtggggca gctgtgggga gctggggcca caggggctcc tggctcctgc 1440 cccttgcaca ccacccggaa cactccccag ccccacgggc aatcctatct gctcgccctc 1500 ctgcaggtgg gggcctcaca tatctgtgac ttcgggtccc tgtccccacc cttgtgcact 1560 cacatgaaag ccttgcacac tcacctccac cttcacaggc catttgcaca cgctcctgca 1620 ccctctcccc gtccataccg ctccgctcag ctgactctca tgttctctcg tctcacattt 1680 gcactctctc cttcccacat tctgtgctca gctcactcag tggtcagcgt ttcctgcaca 1740 ctttacctct catgtgcgtt tcccggcctg atgttgtggt ggtgtgcggc gtgctcactc 1800 tctccctcat gaacacccac ccacctcgtt tcgcagc 1837 42 2124 DNA Homo sapiens misc_feature Incyte ID No 2071941CB1 42 gtgacgcggc tgcggaggtg acgcgggagg tcgcgcgccc cttccggcgc ggggagggcg 60 ctgaagatcg gggccgctcg gccgcaggcg cctccagcgc cgcgggatgt agcgcggggg 120 accgcggccc ccagcagagc ccgcctgccc ggcttgtcta ccatcagagg gagatctctg 180 ccccctgggg ctgagagacc ccaacctttc cccaagctga agctgcaggg tattgaggta 240 ccagccagat gtcttcccac aaaggatctg tggtggcaca ggggaatggg gctcctgcca 300 gtaacaggga agctgacacg gtggaactgg ctgaactggg acccctgcta gaagagaagg 360 gcaaacgggt aatcgccaac ccacccaaag ctgaagaaga gcaaacatgc ccagtgcccc 420 aggaagaaga ggaggaggtg cgggtactga cacttcccct gcaagcccac cacgccatgg 480 agaagatgga agagtttgtg tacaaggtct gggagggacg ttggagggtc atcccatatg 540 atgtgctccc tgactggcta aaggacaacg actatctgct acatggtcat agacctccca 600 tgccctcctt tcgggcttgc ttcaagagca tcttccgcat tcatacagaa actggcaaca 660 tctggaccca tctgcttggt ttcgtgctgt ttctcttttt gggaatcttg accatgctca 720 gaccaaatat gtacttcatg gcccctctac aggagaaggt ggtttttggg atgttctttt 780 tgggtgcagt gctctgcctc agcttctcct ggctctttca caccgtctat tgtcattcag 840 agaaagtctc tcggactttt tccaaactgg actattcagg gattgctctt ctaattatgg 900 ggagctttgt cccctggctc tattattcct tctactgctc cccacagcca cggctcatct 960 acctctccat cgtctgtgtc ctgggcattt ctgccatcat tgtggcgcag tgggaccggt 1020 ttgccactcc taagcaccgg cagacaagag caggcgtgtt cctgggactt ggcttgagtg 1080 gcgtcgtgcc caccatgcac tttactatcg ctgagggctt tgtcaaggcc accacagtgg 1140 gccagatggg ctggttcttc ctcatggctg tgatgtacat cactggagct ggcctttatg 1200 ctgctcgaat tcctgagcgc ttctttcctg gaaaatttga catatggttc cagtctcatc 1260 agattttcca tgtcctggtg gtggcagcag cctttgtcca cttctatgga gtctccaacc 1320 ttcaggaatt ccgttacggc ctagaaggcg gctgtactga tgacaccctt ctctgagcct 1380 tcccacctgc ggggtggagg aggaacttcc caagtgcttt taaaaataac ttctttgctg 1440 aagtgagagg aagagtctga gttgtctgtt tctagaagaa acctcttaga gaattcagta 1500 ccaaccaagc ttcagcccac tttcacaccc actgggcaat aaactttcca tttccattct 1560 cctagctggg gatggggcat ggtcaaactt agccatcccc tcctcagcaa ggcatctacc 1620 ggcccctcac agagacagta ctttgaaact catgttgaga ttttaccctc tcctccaacc 1680 attttgggaa aattatggac tgggactctt cagaaattct gtcttttctt ctggaagaaa 1740 atgtccctcc cttaccccca tccttaactt tgtatcctgg cttataacag gccatccatt 1800 tttgtagcac acttttcaaa aacaattata taccctggtc ccatctttct agggcctgga 1860 tctgcttata gagcaggaag aataaagcca ccaactttta cctagcccgg ctaatcatgg 1920 aagtgtgtcc aggcttcaag taacttgagt tttaattttt ttttttttct tggcagagta 1980 atgtaaaatt taaatgggga aagatattta atatttaata ctaagcttta aaaagaaacc 2040 tgctatcatt gctatgtatc ttgatgcaaa gactatgatg ttaataaaag aaagtacaga 2100 agagacttgg cattcaaaaa aaaa 2124 43 993 DNA Homo sapiens misc_feature Incyte ID No 2172512CB1 43 ccgcgcgctt actttgttta taacttgaaa aatcctctcc gtctcccttc cctgcctcct 60 ttcctttccc tttcctctgc cagtacaact agacccggcg tctggcgtcc ccggtgccca 120 gcattctgcg gggcaggcgg attaattgga attcttcaaa atgtcaggtg tggtacccac 180 agcccctgaa cagcctgcag gtgaaatgga aaatcaaaca aaaccaccag atccaaggcc 240 tgatgctcct cctgaataca gttctcattt tttaccagga ccccctggaa cagctgtccc 300 tccacctact ggctacccag gaggcttgcc tatgggatac tacagtccac agcaacccag 360 taccttccct ttgtaccagc cagttggtgg tatccatcct gtccggtatc agcctggcaa 420 atatcctatg ccaaatcagt ctgttccaat aacatggatg ccagggccaa ctcctatggc 480 aaactgccct cctggtctgg aatacttagt tcagttggac aacatacatg ttcttcagca 540 ttttgagcct ctggaaatga tgacatgttt tgaaactaat aatagatatg atattaaaaa 600 caactcagac cagatggttt acattgtaac cgaagacaca gatgacttta ccaggaatgc 660 ctatcggaca ctaaggccct tcgtcctccg ggtcactgat tgtatgggcc gagaaatcat 720 gacaatgcag agacccttca gatgcacctg ctgttgcttc tgttgcccct ctgccagaca 780 agagctggag gtgcagtgtc ctcctggtgt caccattggc tttgttgcgg aacattggaa 840 cctgtgcagg gcggtgtaca gcatccaaaa aaaaaaaaaa aaaattgcgg cgcaagctta 900 ttccctttag tgaggttaat ttttgggggc atgtgccgtg gcagtgcggt ggtgttggtg 960 gttgtgtggg ggtggggtgg gggttggtgg ggt 993 44 2214 DNA Homo sapiens misc_feature Incyte ID No 2483172CB1 44 ggctctcggc ccagcgcgcc tgccttcgcc gcccgccgtc gctcctcgcc cgctgcacga 60 cgacgcgacg cccctgctgc aggcggcgga cccgaccgga cccagaccca gacgcaagat 120 ggcgacggcc gcgtgactgc ctcagcgtcc ccgagctcgg ctccgagtgc acctacggac 180 tgactgtggg ggcagagaag ggcgagatca ggactctgtc tttgttaatc gtgactgcat 240 gaaggtcgcc tccctcgggc ctacttggtg ggagtgtctg gtattgttct aaggccagga 300 gcacggtgag ccacagtctg ttggtagaat ttggcgtctt gatagttgag aaaatggcga 360 tgacactgtt ggaagactgg tgccggggga tggatgtgaa ctcccagaga gctctgttag 420 tctggggcat cccagtgaac tgtgatgagg ctgaaatcga agagaccctc caggctgcga 480 tgccccaggt ctcctaccga atgcttggga gaatgttctg gagggaagaa aatgcgaaag 540 cagccttatt agagctcact ggcgctgtag attacgccgc gatccccagg gagatgccgg 600 gcaaaggagg ggtctggaaa gtgttattta agcccccaac ttctgatgct gaatttttag 660 aaagattgca cctcttccta gctagagagg ggtggaccgt gcaagatgtt gcccgtgtcc 720 ttgggtttca gaaccctact ccgaccccgg gcccagagat gccagcagag atgctaaact 780 atattttgga taatgttatt cagcctcttg ttgagtccat atggtacaag aggctgacac 840 ttttctcggg gagggacatc ccagggcctg gagaggaaac ctttgatccc tggctggagc 900 acactaatga ggtcctagag gagtggcagg tgtccgatgt agaaaagagg cggcggttga 960 tggagagtct tagaggcccc gccgctgatg ttattcgcat ccttaagtcc aacaaccccg 1020 cgataaccac tgccgaatgc ctgaaggcgc ttgagcaggt gtttgggagc gttgagagct 1080 ctagggatgc ccagatcaaa tttctgaaca cttatcagaa cccgggagaa aaattgtctg 1140 cttatgtcat tcgtctggag cctctgctac agaaggtggt agagaagggg gccattgata 1200 aagataatgt gaaccaggcc cgcctagagc aggtcattgc cggggccaac cacagcgggg 1260 ccatccgaag gcagctgtgg cttaccgggg ctggggaagg gccagcccca aacctctttc 1320 agttgctggt gcagatccgt gaggaggaag ccaaggagga ggaggaggag gctgaggcca 1380 cccttctgca gttaggcctg gaagggcact tctgagtgcc aggaaaggca gctttagtgc 1440 agacctagat cacagctact tttcttgtcc ctgtggggtc ttacagatgt gtctctgagt 1500 agtaaaggct tagccttgtt ctgttttgtt gttttttgga ggggaaggtt agtcaggcct 1560 gagtattcat gtaacattct aaaattgtgc cagcgagcac cgtgaacgac tgcaatgcaa 1620 gcgggtcttg ctggctaagg taaagggttg gttggacaca gcgcttagtg cacgctgtca 1680 tcatggacat cataatcagt tgtgaaaaac acgcgaacct atgacacttc ttattccaca 1740 ctgaatgtga aattgcatgt tcagatgttt actacgaggc ctggctcaca ggaagtgttc 1800 agtaaaagta tgcactgtta gattactgat aacgcggata gatttttgtt taccataaat 1860 tgttccagat ttatattaat ggaaggaaat gtgcatttat tagctattac tcaactttac 1920 aatgcaaaca tcttatttct catctttaaa catgtcgacc agtttaattg aaaagtattc 1980 tgagactgca aaatggggtg ttaaaaaata ctgcagttac ggagctgtgt aaaccagttt 2040 ctcattgcat aagatacaga tgtaaattgc atggagaggt tgatatgcac ctgtacagta 2100 attcactccc ccatttcaca tctttgtcag agaatagttc ttgttcatac tgagtgttct 2160 aaatttgaag ttatatatac aaattaaaat attttaaaaa ttcaaaaaaa aaaa 2214 45 897 DNA Homo sapiens misc_feature Incyte ID No 2656128CB1 45 gcaaaatgca tgacagtaac aatgtggaga aagacattac accatctgaa ttgcctgcaa 60 acccaggttg tctgcattca aaagagcatt ctattaaagc taccttaatt tggcgcttat 120 ttttcttaat catgtttctg acaatcatag tgtgtggaat ggttgctgct ttaagcgcaa 180 taagagctaa ctgccatcaa gagccatcag tatgtcttca agctgcatgc ccagaaagct 240 ggattggttt tcaaagaaag tgtttctatt tttctgatga caccaagaac tggacatcaa 300 gtcagaggtt ttgtgactca caagatgctg atcttgctca ggttgaaagc ttccaggaac 360 tgaatttcct gttgagatat aaaggcccat ctgatcactg gattgggctg agcagagaac 420 aaggccaacc atggaaatgg ataaatggta ctgaatggac aagacagtta gtcatgaaag 480 aagatggtgc caacttgtat gttgcaaagg tttcacaagt tcctcgaatg aatccaagac 540 ctgtcatggt ttcctatcct gggagcagga gagtgtgcct atttgaatga caaaggtgcc 600 agtagtgcca ggcactacac agagaggaag tggatttgtt ccaaatcaga tatacatgtc 660 tagatgttac agcaaagccc caactaatct ttagaagcat attggaactg ataactccat 720 tttaaaatga gcaaagaatt tatttcttat accaacaggt atatgaaaat atgctcaata 780 tcactaataa ctgggaaaat acaaatcaaa atcatagtaa aatattacct gttttcatgg 840 tgctaatatt acctgttctc ccactgctaa tgacataccc gagactgagt aatttaa 897 46 2167 DNA Homo sapiens misc_feature Incyte ID No 5855841CB1 46 gccggggccg gagttcgctg caagtcggcg gaaagtttgg ctgcgcgggt tcccccgaag 60 ttcagagtga agacatttcc acctggacac ctgaccatgt gcctgccctg agcagcgagg 120 cccaccaggc atctctgttg tgggcagcag ggccaggtcc tggtctgtgg accctcggca 180 gttggcaggc tccctctgca gtggggtctg ggcctcggcc ccaccatgtc gagcctcggc 240 ggtggctccc aggatgccgg cggcagtagc agcagcagca ccaatggcag cggtggcagt 300 ggcagcagtg gcccaaaggc aggagcagca gacaagagtg cagtggtggc tgccgccgca 360 ccagcctcag tggcagatga cacaccaccc cccgagcgtc ggaacaagag cggtatcatc 420 agtgagcccc tcaacaagag cctgcgccgc tcccgcccgc tctcccacta ctcttctttt 480 ggcagcagtg gtggtagtgg cggtggcagc atgatgggcg gagagtctgc tgacaaggcc 540 actgcggctg cagccgctgc ctccctgttg gccaatgggc atgacctggc ggcggccatg 600 gcggtggaca aaagcaaccc tacctcaaag cacaaaagtg gtgctgtggc cagcctgctg 660 agcaaggcag agcgggccac ggagctggca gccgagggac agctgacgct gcagcagttt 720 gcgcagtcca cagagatgct gaagcgcgtg gtgcaggagc atctcccgct gatgagcgag 780 gcgggtgctg gcctgcctga catggaggct gtggcaggtg ccgaagccct caatggccag 840 tccgacttcc cctacctggg cgctttcccc atcaacccag gcctcttcat tatgaccccg 900 gcaggtgtgt tcctggccga gagcgcgctg cacatggcgg gcctggctga gtaccccatg 960 cagggagagc tggcctctgc catcagctcc ggcaagaaga agcggaaacg ctgcggcatg 1020 tgcgcgccct gccggcggcg catcaactgc gagcagtgca gcagttgtag gaatcgaaag 1080 actggccatc agatttgcaa attcagaaaa tgtgaggaac tcaaaaagaa gccttccgct 1140 gctctggaga aggtgatgct tccgacggga gccgccttcc ggtggtttca gtgacggcgg 1200 cggaacccaa agctgccctc tccgtgcaat gtcactgctc gtgtggtctc cagcaaggga 1260 ttcgggcgaa gacaaacgga tgcacccgtc tttagaacca aaaatattct ctcacagatt 1320 tcattcctgt ttttatatat atattttttg ttgtcgtttt aacatctcca cgtccctagc 1380 ataaaaagaa aaagaaaaaa atttaaactg ctttttcgga agaacaacaa caaaaaagag 1440 gtaaagacga atctataaag taccgagact tcctgggcaa agaatggaca atcagtttcc 1500 ttcctgtgtc gatgtcgatg ttgtctgtgc aggagatgca gtttttgtgt agagaatgta 1560 aattttctgt aaccttttga aatctagtta ctaataagca ctactgtaat ttagcacagt 1620 ttaactccac cctcatttaa acttcctttg attctttccg accatgaaat agtgcatagt 1680 ttgcctggag aatccactca cgttcataaa gagaatgttg atggcgccgt gtagaagccg 1740 ctctgtatcc atccacgcgt gcagagctgc cagcagggag ctcacagaag gggagggagc 1800 accaggccag ctgagctgca cccacagtcc cgagactggg atcccccacc ccaacagtga 1860 ttttggaaaa aaaaatgaaa gttctgttcg tttatccatt gcgatctggg gagccccatc 1920 tcgatatttc caatcctggc tacttttctt agagaaaata agtccttttt ttctggcctt 1980 gctaatggca acagaagaaa gggcttcttt gcgtggtccc ctgctggtgg gggtgggtcc 2040 ccagggggcc ccctgcggcc tgggcccccc tgcccacggc cagcttcctg ctgatgaaca 2100 tgctgtttgt attgttttag gaaaccaggc tgttttgtga ataaaacgaa tgcatgtttg 2160 tgtcacg 2167 47 1235 DNA Homo sapiens misc_feature Incyte ID No 603462CB1 47 gtggagccgg cgagagagtg gcagcggggg ctgatggaag tgcagtgggg gctggagagg 60 gcaccctact gtatccagca tgctccaagg ccacagctct gtgttccagg ccttgctggg 120 gaccttcttc acctggggga tgacagcagc tggggcagct ctcgtgttcg tattctctag 180 tggacagagg cggatcttag atggaagtct tggctttgct gcaggggtca tgttggcagc 240 ttcctattgg tctcttctgg ccccagcagt tgagatggcc acgtcctctg ggggcttcgg 300 tgcctttgcc ttcttccctg tggctgttgg cttcaccctt ggagcggctt ttgtctactt 360 ggctgacctc ctgatgcctc acttgggtgc agcagaagac ccccagacgg ccctggcact 420 gaacttcggc tctacgttga tgaagaagaa gtctgatcct gagggtcccg cgctgctctt 480 ccctgagagt gaactttcca tccggataga caagagtgag aatggtgagg catatcagag 540 aaagaaggcg gcagccactg gccttccaga gggtcctgct gtccctgtgc cttctcgagg 600 gaatctggca cagcccggcg gcagcagctg gaggaggatc gcactgctca tcttggccat 660 cactatacac aacgttccag agggtctcgc tgttggagtt ggatttgggg ctatagaaaa 720 gacggcatct gctacctttg agagtgccag gaatttggcc attggaatcg ggatccagaa 780 tttccccgag ggcctggctg tcagccttcc cttgcgaggg gcaggcttct ccacctggag 840 agctttctgg tatgggcagc tgagcggcat ggtggagccc ctggccgggg tctttggtgc 900 ctttgccgtg gtgctggctg agcccatcct gccctacgct ctggcctttg ctgccggtgc 960 catggtctac gtggtcatgg acgacatcat ccccgaagcc cagatcagtg gtaatgggaa 1020 actggcatcc tgggcctcca tcctgggatt tgtagtgatg atgtcactgg acgttggcct 1080 gggctagggc tgagacgctt cggaccccgg gaaaggccat acgaagaaac agcagtggtt 1140 ggcttctatg ggacaacaag cttctttctt cacattaaaa cttttttcct tcctctcttc 1200 ttcatctcat tatcctgatt gactctaatt ataat 1235 48 2257 DNA Homo sapiens misc_feature Incyte ID No 747681CB1 48 ccgagccgag cggaccgaag gcgcgcccga gatgcaggtg agcaagagga tgctggcggg 60 gggcgtgagg agcatgccca gccccctcct ggcctgctgg cagcccatcc tcctgctggt 120 gctgggctca gtgctgtcag gctcggccac gggctgcccg ccccgctgcg agtgctccgc 180 ccaggaccgc gctgtgctgt gccaccgcaa gcgctttgtg gcagtccccg agggcatccc 240 caccgagacg cgcctgctgg acctaggcaa gaaccgcatc aaaacgctca accaggacga 300 gttcgccagc ttcccgcacc tggaggagct ggagctcaac gagaacatcg tgagcgccgt 360 ggagcccggc gccttcaaca acctcttcaa cctccggacg ctgggtctcc gcagcaaccg 420 cctgaagctc atcccgctag gcgtcttcac tggcctcagc aacctgacca agctggacat 480 cagcgagaac aagattgtta tcctgctgga ctacatgttt caggacctgt acaacctcaa 540 gtcactggag gttggcgaca atgacctcgt ctacatctct caccgcgcct tcagcggcct 600 caacagcctg gagcagctga cgctggagaa atgcaacctg acctccatcc ccaccgaggc 660 gctgtcccac ctgcacggcc tcatcgtcct gaggctccgg cacctcaaca tcaatgccat 720 ccgggactac tccttcaaga ggctctaccg actcaaggtc ttggagatct cccactggcc 780 ctacttggac accatgacac ccaactgcct ctacggcctc aacctgacgt ccctgtccat 840 cacacactgc aatctgaccg ctgtgcccta cctggccgtc cgccacctag tctatctccg 900 cttcctcaac ctctcctaca accccatcag caccattgag ggctccatgt tgcatgagct 960 gctccggctg caggagatcc agctggtggg cgggcagctg gccgtggtgg agccctatgc 1020 cttccgcggc ctcaactacc tgcgcgtgct caatgtctct ggcaaccagc tgaccacact 1080 ggaggaatca gtcttccact cggtgggcaa cctggagaca ctcatcctgg actccaaccc 1140 gctggcctgc gactgtcggc tcctgtgggt gttccggcgc cgctggcggc tcaacttcaa 1200 ccggcagcag cccacgtgcg ccacgcccga gtttgtccag ggcaaggagt tcaaggactt 1260 ccctgatgtg ctactgccca actacttcac ctgccgccgc gcccgcatcc gggaccgcaa 1320 ggcccagcag gtgtttgtgg acgagggcca cacggtgcag tttgtgtgcc gggccgatgg 1380 cgacccgccg cccgccatcc tctggctctc accccgaaag cacctggtct cagccaagag 1440 caatgggcgg ctcacagtct tccctgatgg cacgctggag gtgcgctacg cccaggtaca 1500 ggacaacggc acgtacctgt gcatcgcggc caacgcgggc ggcaacgact ccatgcccgc 1560 ccacctgcat gtgcgcagct actcgcccga ctggccccat cagcccaaca agaccttcgc 1620 tttcatctcc aaccagccgg gcgagggaga ggccaacagc acccgcgcca ctgtgccttt 1680 ccccttcgac atcaagaccc tcatcatcgc caccaccatg ggcttcatct ctttcctggg 1740 cgtcgtcctc ttctgcctgg tgctgctgtt tctctggagc cggggcaagg gcaacacaaa 1800 gcacaacatc gagatcgagt atgtgccccg aaagtcggac gcaggcatca gctccgccga 1860 cgcgccccgc aagttcaaca tgaagatgat atgaggccgg ggcggggggc agggaccccc 1920 gggcggccgg gcaggggaag gggcctggcc gccacctgct cactctccag tccttcccac 1980 ctcctcccta cccttctaca cacgttctct ttctccctcc cgcctccgtc ccctgctgcc 2040 ccccgccagc cctcaccacc tgccctcctt ctaccaggac ctcagaagcc cagacctggg 2100 gaccccacct acacaggggc attgacagac tggagttgaa agccgacgaa ccgacacgcg 2160 gcagagtcaa taattcaata aaaaagttac gaactttctc tgtaacttgg gtttcaataa 2220 ttatggattt ttatgaaaac ttgaaataaa aaaaaaa 2257 49 2359 DNA Homo sapiens misc_feature Incyte ID No 919469CB1 49 gtgggatttg aagatccact ccacttctgc tcatggcggg ccagggcctg cccctgcacg 60 tggccacact gctgactggg ctgctggaat gcctgggctt tgctggcgtc ctctttggct 120 ggccttcact agtgtttgtc ttcaagaatg aagattactt taaggatctg tgtggaccag 180 atgctgggcc gattggcaat gccacagggc aggctgactg caaagcccag gatgagaggt 240 tctcactcat cttcaccctg gggtccttca tgaacaactt catgacattc cccactggct 300 acatctttga ccggttcaag accaccgtgg cacgcctcat agccatattt ttctacacca 360 ccgccacact catcatagcc ttcacctctg caggctcagc cgtgctgctc ttcctggcca 420 tgccaatgct caccattggg ggaatcctgt ttctcatcac caacctgcag attgggaacc 480 tatttggcca acaccgttcg accatcatca ctctgtacaa tggagcattt gactcttcct 540 cggcagtctt ccttattatt aagcttcttt atgaaaaagg catcagcctc agggcctcct 600 tcatcttcat ctctgtctgc agtacctggc atgtagcacg cactttcctc ctgatgcccc 660 gggggcacat cccataccca ctgcccccca actacagcta tggcctgtgc cctgggaatg 720 gcaccacaaa ggaagagaag gaaacagctg agcatgaaaa cagggagcta cagtcaaagg 780 agttcctttc agcgaaggaa gagaccccag gggcagggca gaagcaggaa ctccgctcct 840 tctggagcta cgctttctct cggcgctttg cctggcacct ggtgtggctg tctgtgatac 900 agttgtggca ctacctcttc attggcactc tcaactcctt gctgaccaac atggccggtg 960 gggacatggc acgagtcagc acctacacaa atgcctttgc cttcactcag ttcggagtgc 1020 tgtgtgcccc ctggaatggc ctgctcatgg accggcttaa acagaagtac cagaaggaag 1080 caagaaagac aggttcctcc actttggcgg tggccctctg ctcgacggtg ccttcgctgg 1140 ccctgacatc cctgctgtgc ctgggcttcg ccctctgtgc ctcagtcccc atcctccctc 1200 tccagtacct caccttcatc ctgcaagtga tcagccgctc cttcctctat gggagcaacg 1260 cggccttcct cacccttgct ttcccttcag agcactttgg caagctcttt gggctggtga 1320 tggccttgtc ggctgtggtg tctctgctcc agttccccat cttcaccctc atcaaaggct 1380 cccttcagaa tgacccattt tacgtgaatg tgatgttcat gcttgccatt cttctgacat 1440 tcttccaccc ctttctggta tatcgggaat gccgtacttg gaaagaaagt ccctctgcaa 1500 ttgcatagtt cagaagccct cacttttcag ccccgaggat ggttttgttc atcttccacc 1560 acctttgagg acctcgtgtc ccaaaagact ttgcctatcc cagcaaaaca cacacacaca 1620 cacacacaca cacaaaataa agacacacaa ggacgtctgc gcagcaagaa aagaatctca 1680 gttgccaagc agattgatat cacacagact caaagcaaag gcatgtggaa cttctttatt 1740 tcaaaacaga agtgtctcct tgcacttagc cttggcagac ccttgactcc aggggagatg 1800 acctggggga ggaagtgtgt caactatttc tttaggcctg tttggctccg aagcctatat 1860 gtgcctggat cctctgccac gggttaaatt ttcaggtgaa gagtgaggtt gtcatggcct 1920 cagctatgct tcctggctct ccctcaagag tgcagccttg gctagagaac tcacagctct 1980 gggaaaaaga ggagcagaca gggttccctg ggcccagtct cagcccagcc actgatgctg 2040 gatgaccttg gcctgaccct ggtctggtct cagaatcact tttcccatct gtaaaattga 2100 gatgaatttt ggtgttgaaa gttcttcctg gagcagatgt cctagaaggt tttaggaata 2160 gtgacagagt caggccaccc caagggccat gggagccagc tgacctgctt gaccgaagga 2220 tttctgacag actatctttg gggatgtttt caagaaggga tataagttat ttactttggg 2280 catttaaaag aaaatttctc tcgggaataa ttttatagaa aaataaagct tctgtgtcta 2340 aggcaaaaaa aaaaaaaaa 2359 50 2052 DNA Homo sapiens misc_feature Incyte ID No 977658CB1 50 gggtttgaag ccgcgccgcg agggagcgag gtcgcagtga cagcggcggg cgatcggacc 60 caggctgccc cgccgtaccc gcctgcgtcc cgcgctcccg ccccagcatg acagccccgg 120 cgggtccgcg cggctcagag accgagcggc ttctgacccc caaccccggg tatgggaccc 180 aggcggggcc ttcaccggcc cctccgacac ccccagaaga ggaagacctt cgccgtcgtc 240 tcaaatactt tttcatgagt ccctgcgaca agtttcgagc caagggccgc aagccctgca 300 agctgatgct gcaagtggtc aagatcctgg tggtcacggt gcagctcatc ctgtttgggc 360 tcagtaatca gctggctgtg acattccggg aagagaacac catcgccttc cgacacctct 420 tcctgctggg ctactcggac ggagcggatg acaccttcgc agcctacacg cgggagcagc 480 tgtaccaggc catcttccat gctgtggacc agtacctggc gttgcctgac gtgtcactgg 540 gccggtatgc gtatgtccgt ggtgggggtg acccttggac caatggctca gggcttgctc 600 tctgccagcg gtactaccac cgaggccacg tggacccggc caacgacaca tttgacattg 660 atccgatggt ggttactgac tgcatccagg tggatccccc cgagcggccc cctccgcccc 720 ccagcgacga tctcaccctc ttggaaagca gctccagtta caagaacctc acgctcaaat 780 tccacaagct ggtcaatgtc accatccact tccggctgaa gaccattaac ctccagagcc 840 tcatcaataa tgagatcccg gactgctata ccttcagcgt cctgatcacg tttgacaaca 900 aagcacacag tgggcggatc cccatcagcc tggagaccca ggcccacatc caggagtgta 960 agcaccccag tgtcttccag cacggagaca acagcttccg gctcctgttt gacgtggtgg 1020 tcatcctcac ctgctccctg tccttcctcc tctgcgcccg ctcactcctt cgaggcttcc 1080 tgctgcagaa tgagtttgtg gggttcatgt ggcggcagcg gggacgggtc atcagcctgt 1140 gggagcggct ggaatttgtc aatggctggt acatcctgct cgtcaccagc gatgtgctca 1200 ccatctcggg caccatcatg aagatcggca tcgaggccaa gaacttggcg agctacgacg 1260 tctgcagcat cctcctgggc acctcgacgc tgctggtgtg ggtgggcgtg atccgctacc 1320 tgaccttctt ccacaactac aatatcctca tcgccacact gcgggtggcc ctgcccagcg 1380 tcatgcgctt ctgctgctgc gtggctgtca tctacctggg ctactgcttc tgtggctgga 1440 tcgtgctggg gccctatcat gtgaagttcc gctcactctc catggtgtct gagtgcctgt 1500 tctcgctcat caatggggac gacatgtttg tgacgttcgc cgccatgcag gcgcagcagg 1560 gccgcagcag cctggtgtgg ctcttctccc agctctacct ttactccttc atcagcctct 1620 tcatctacat ggtgctcagc ctcttcatcg cgctcatcac cggcgcctac gacaccatca 1680 agcatcccgg cggcgcaggc gcagaggaga gcgagctgca ggcctacatc gcacagtgcc 1740 aggacagccc cacctccggc aagttccgcc gcgggagcgg ctcggcctgc agccttctct 1800 gctgctgcgg aagggacccc tcggaggagc attcgctgct ggtgaattga ttcgacctga 1860 ctgccgttgg accgtaggcc ctggactgca gagacccccg cccccgaccc cgcttattta 1920 tttgtagggt ttgcttttaa ggatcggctc cctgtcgcgc ccgaggaggg cctggacctt 1980 tcgtgtcgga cccttggggg cggggagact gggtggggag ggtgttgaat aaaagggaaa 2040 ataaaaaaaa aa 2052 51 1939 DNA Homo sapiens misc_feature Incyte ID No 1004703CB1 51 cttgatggcg tcgggctgga gagccgcagt cccggctgca gcacctggga gaaggcagac 60 cgtgtgaggg ggcctgtggc ccagcgtgct gtggcctcgg ggagtgggaa gtggaggcag 120 gagccttcct tacacttcgc catgagtttc ctcatcgact ccagcatcat gattacctcc 180 cagatactat tttttggatt tgggtggctt ttcttcatgc gccaattgtt taaagactat 240 gagatacgtc agtatgttgt acaggtgatc ttctccgtga cgtttgcatt ttcttgcacc 300 atgtttgagc tcatcatctt tgaaatctta ggagtattga atagcagctc ccgttatttt 360 cactggaaaa tgaacctgtg tgtaattctg ctgatcctgg ttttcatggt gcctttttac 420 attggctatt ttattgtgag caatatccga ctactgcata aacaacgact gcttttttcc 480 tgtctcttat ggctgacctt tatgtatttc ttctggaaac taggagatct ctttcccatt 540 ctcagcccaa aacatgggat cttatccata gaacagctca tcagccgggt tggtgtgatt 600 ggagtgactc tcatggctct tctttctgga tttggtgctg tcaactgccc atacacttac 660 atgtcttact tcctcaggaa tgtgactgac acggatattc tagccctgga acggcgactg 720 ctgcaaacca tggatatgat cataagcaaa aagaaaagga tggcaatggc acggagaaca 780 atgttccaga agggggaagt gcataacaaa ccatcaggtt tctggggaat gataaaaagt 840 gttaccactt cagcatcagg aagtgaaaat cttactctta ttcaacagga agtggatgct 900 ttggaagaat taagcaggca gctttttctg gaaacagctg atctatatgc taccaaggag 960 agaatagaat actccaaaac cttcaagggg aaatatttta attttcttgg ttactttttc 1020 tctatttact gtgtttggaa aattttcatg gctaccatca atattgtttt tgatcgagtt 1080 gggaaaacgg atcctgtcac aagaggcatt gagatcactg tgaattatct gggaatccaa 1140 tttgatgtga agttttggtc ccaacacatt tccttcattc ttgttggaat aatcatcgtc 1200 acatccatca gaggattgct gatcactctt accaagttct tttatgccat ctctagcagt 1260 aagtcctcca atgtcattgt cctgctatta gcacagataa tgggcatgta ctttgtctcc 1320 tctgtgctgc tgatccgaat gagtatgcct ttagaatacc gcaccataat cactgaagtc 1380 cttggagaac tgcagttcaa cttctatcac cgttggtttg atgtgatctt cctggtcagc 1440 gctctctcta gcatactctt cctctatttg gctcacaaac aggcaccaga gaagcaaatg 1500 gcaccttgaa cttaagccta ctacagactg ttagaggcca gtggtttcaa aatttagata 1560 taagaggggg gaaaaatgga accagggcct gacattttat aaacaaacaa aatgctatgg 1620 tagcattttt caccttcata gcatactcct tccccgtcag gtgatactat gaccatgagt 1680 agcatcagcc agaacatgag agggagaact aactcaagac aatactcagc agagagcatc 1740 ccgtgtggat atgaggctgg tgtagaggcg gagaggagcc aagaaactaa aggtgaaaaa 1800 tacactggaa ctctggggca agacatgtct atggtagctg agccaaacac gtaggatttc 1860 cgttttaagg ttcacatgga aaaggttata gctttgcctt gagattgact cattaaaatc 1920 agagactgta aaaaaaaaa 1939 52 1138 DNA Homo sapiens misc_feature Incyte ID No 1334051CB1 52 caaactgcaa cttatatctg caatttattt tggtatagac aagaggtatg ccagtagcac 60 actggtggct tcagaagaaa ttctcaacac ctagctcgcc agagagtcta tgtatgggat 120 tgaacaatct gtaaactaaa ggatcctaat catgaaaata agtatgataa attataagtc 180 actattggca ctgttgttta tattagcctc ctggatcatt tttacagttt tccagaactc 240 cacaaaggtt tggtctgctc taaacttatc catctccctc cattactgga acaactccac 300 aaagtcctta ttccctaaaa caccactgat atcattaaag ccactaacag agactgaact 360 cagaataaag gaaatcatag agaaactaga tcagcagatc ccacccagac ctttcaccca 420 cgtgaacacc accaccagcg ccacacatag cacagccacc atcctcaacc ctcgagatac 480 gtactgcagg ggagaccagc tgcacatcct gctggaggtg agggaccact tgggacgcag 540 gaagcaatat ggcggggatt tcctgagggc caggatgtct tccccagcgc tgatggcagg 600 tgcttcagga aaggtgactg acttcaacaa cggcacctac ctggtcagct tcactctgtt 660 ctgggagggc caggtctctc tgtctctgct gctcatccac cccagtgaag gggtgtcagc 720 tctctggagt gcaaggaacc aaggctatga cagggtgatc ttcactggcc agtttgtcaa 780 tggcacttcc caagtccact ctgaatgtgg cctgatccta aacacaaatg ctgaattgtg 840 ccagtacctg gacaacagag accaagaagg cttctactgt gtgaggcctc aacacatgcc 900 ctgtgctgca ctcactcaca tgtattctaa gaacaagaaa gtttcttatc ttagcaaaca 960 agaaaagagc ctctttgaaa ggtaaaaata attacttctt gagactacct gtgcaaatat 1020 tgtgatttgg cctatatact gatccaaaga aaagtcttgt gagtgtatta attttgggtg 1080 tctttagtaa gagcctttgg ggaaaggatc tgtgaattca tttagagaca gtgcccat 1138 53 2117 DNA Homo sapiens misc_feature Incyte ID No 1336728CB1 53 tggccacagc aacacccact gagcacgctg ggagctgagt atggcgtccc tggtctcgct 60 ggagctgggg ctgcttctgg ctgtgctggt ggtgacggcg acggcgtccc cgcctgctgg 120 tctgctgagc ctgctcacct ctggccaggg cgctctggat caagaggctc tgggcggcct 180 gttaaatacg ctggcggacc gtgtgcactg caccaacggg ccgtgtggaa agtgcctgtc 240 tgtggaggac gccctgggcc tgggcgagcc tgaggggtca gggctgcccc cgggcccggt 300 cctggaggcc aggtacgtcg cccgcctcag tgccgccgcc gtcctgtacc tcagcaaccc 360 cgagggcacc tgtgaggaca ctcgggctgg cctctgggcc tctcatgcag accacctcct 420 ggccctgctc gagagcccca aggccctgac cccgggcctg agctggctgc tgcagaggat 480 gcaggcccgg gctgccggcc agacccccaa gacggcctgc gtagatatcc ctcagctgct 540 ggaggaggcg gtgggggcgg gggctccggg cagtgctggc ggcgtcctgg ctgccctgct 600 ggaccatgtc aggagcgggt cttgcttcca cgccttgccg agccctcagt acttcgtgga 660 ctttgtgttc cagcagcaca gcagcgaggt ccctatgacg ctggccgagc tgtcagcctt 720 gatgcagcgc ctgggggtgg gcagggaggc ccacagtgac cacagtcatc ggcacagggg 780 agccagcagc cgggaccctg tgcccctcat cagctccagc aacagctcca gtgtgtggga 840 cacggtatgc ctgagtgcca gggacgtgat ggctgcatat ggactgtcgg aacaggctgg 900 ggtgaccccg gaggcctggg cccaactgag ccctgccctg ctccaacagc agctgagtgg 960 agcctgcacc tcccagtcca ggccccccgt ccaggaccag ctcagccagt cagagaggta 1020 tctgtacggc tccctggcca cgctgctcat ctgcctctgc gcggtctttg gcctcctgct 1080 gctgacctgc actggctgca ggggggtcac ccactacatc ctgcagacct tcctgagcct 1140 ggcagtgggt gcactcactg gggacgctgt cctgcatctg acgcccaagg tgctggggct 1200 gcatacacac agcgaagagg gcctcagccc acagcccacc tggcgcctcc tggctatgct 1260 ggccgggctc tacgccttct tcctgtttga gaacctcttc aatctcctgc tgcccaggga 1320 cccggaggac ctggaggacg ggccctgcgg ccacagcagc catagccacg ggggccacag 1380 ccacggtgtg tccctgcagc tggcacccag cgagctccgg cagcccaagc ccccccacga 1440 gggctcccgc gcagacctgg tggcggagga gagcccggag ctgctgaacc ctgagcccag 1500 gagactgagc ccagagttga ggctactgcc ctatatgatc actctgggcg acgccgtgca 1560 caacttcgcc gacgggctgg ccgtgggcgc cgccttcgcg tcctcctgga agaccgggct 1620 ggccacctcg ctggccgtgt tctgccacga gttgccacac gagctggggg acttcgccgc 1680 cttgctgcac gcggggctgt ccgtgcgcca agcactgctg ctgaacctgg cctccgcgct 1740 cacggccttc gctggtctct acgtggcact cgcggttgga gtcagcgagg agagcgaggc 1800 ctggatcctg gcagtggcca ccggcctgtt cctctacgta gcactctgcg acatgctccc 1860 ggcgatgttg aaagtacggg acccgcggcc ctggctcctc ttcctgctgc acaacgtggg 1920 cctgctgggc ggctggaccg tcctgctgct gctgtccctg tacgaggatg acatcacctt 1980 ctgataccct gccctagtcc cccacctttg acttaagatc ccacacctca caaacctaca 2040 gcccagaaac cagaagcccc tatagaggcc ccagtcccaa ctccagtaaa gacactcttg 2100 tccttggaaa aaaaaaa 2117 54 1495 DNA Homo sapiens misc_feature Incyte ID No 1452856CB1 54 ctgaaatccc gcgaggatca accgagctcg ccgaaaggag ggaggaacgt atcccttctg 60 gaggctgtct cagggggcag agggaccgga ccggaagtga cgtgagcggg ttccggttgt 120 ctggagccca gcggcgggtg tgagagtccg taaggagcag cttccaggat cctgagatcc 180 ggagcagccg gggtcggagc ggctcctcaa gagttactga tctatgaaat ggcagagaat 240 ggaaaaaatt gtgaccagag acgtgtagca atgaacaagg aacatcataa tggaaatttc 300 acagacccct cttcagtgaa tgaaaagaag aggagggagc gggaagaaag gcagaatatt 360 gtcctgtgga gacagccgct cattaccttg cagtattttt ctctggaaat ccttgtaatc 420 ttgaaggaat ggacctcaaa attatggcat cgtcaaagca ttgtggtgtc ttttttactg 480 ctgcttgctg tgcttatagc tacgtattat gttgaaggag tgcatcaaca gtatgtgcaa 540 cgtatagaga aacagtttct tttgtatgcc tactggatag gcttaggaat tttgtcttct 600 gttgggcttg gaacagggct gcacaccttt ctgctttatc tgggtccaca tatagcctca 660 gttacattag ctgcttatga atgcaattca gttaattttc ccgaaccacc ctatcctgat 720 cagattattt gtccagatga agagggcact gaaggaacca tttctttgtg gagtatcatc 780 tcaaaagtta ggattgaagc ctgcatgtgg ggtatcggta cagcaatcgg agagctgcct 840 ccatatttca tggccagagc agctcgcctc tcaggtgctg aaccagatga tgaagagtat 900 caggaatttg aagagatgct ggaacatgca gagtctgcac aagactttgc ctcccgggcc 960 aaactggcag ttcaaaaact agtacagaaa gttggatttt ttggaatttt ggcctgtgct 1020 tcaattccaa atcctttatt tgatctggct ggaataacgt gtggacactt tctggtacct 1080 ttttggacct tctttggtgc aaccctaatt ggaaaagcaa taataaaaat gcatatccag 1140 aaaatttttg ttataataac attcagcaag cacatagtgg agcaaatggt ggctttcatt 1200 ggtgctgtcc ccggcatagg tccatctctg cagaagccat ttcaggagta cctggaggct 1260 caacggcaga agcttcacca caaaagcgaa atgggcacac cacagggaga aaactggttg 1320 tcctggatgt ttgaaaagtt ggtcgttgtc atggtgtgtt acttcatcct atctatcatt 1380 aactccatgg cacaaagtta tgccaaacga atccagcagc ggttgaactc agaggagaaa 1440 actaaataag tagagaaagt tttaaactgc agaaattgga gtggatgggt tctgc 1495 55 1747 DNA Homo sapiens misc_feature Incyte ID No 1562471CB1 55 accagcagaa ggctgggagt ctgtagtttg ttcctgctgc caggctccac tgaggggaac 60 ggggacctgt ctgaagagaa gatgcccctg ctgacactct acctgctcct cttctggctc 120 tcaggctact ccattgccac tcaaatcacc ggtccaacaa cagtgaatgg cttggagcgg 180 ggctccttga ccgtgcagtg tgtttacaga tcaggctggg agacctactt gaagtggtgg 240 tgtcgaggag ctatttggcg tgactgcaag atccttgtta aaaccagtgg gtcagagcag 300 gaggtgaaga gggaccgggt gtccatcaag gacaatcaga aaaaccgcac gttcactgtg 360 accatggagg atctcatgaa aactgatgct gacacttact ggtgtggaat tgagaaaact 420 ggaaatgacc ttggggtcac agttcaagtg accattgacc cagcaccagt cacccaagaa 480 gaaactagca gctccccaac tctgaccggc caccacttgg acaacaggca caagctcctg 540 aagctcagtg tcctcctgcc cctcatcttc accatattgc tgctgctttt ggtggccgcc 600 tcactcttgg cttggaggat gatgaagtac cagcagaaag cagccgggat gtccccagag 660 caggtactgc agcccctgga gggcgacctc tgctatgcag acctgaccct gcagctggcc 720 ggaacctccc cgcgaaaggc taccacgaag ctttcctctg cccaggttga ccaggtggaa 780 gtggaatatg tcaccatggc ttccttgccg aaggaggaca tttcctatgc atctctgacc 840 ttgggtgctg aggatcagga accgacctac tgcaacatgg gccacctcag tagccacctc 900 cccggcaggg gccctgagga gcccacggaa tacagcacca tcagcaggcc ttagcctgca 960 ctccaggctc cttcttggac cccaggctgt gagcacactc ctgcctcatc gaccgtctgc 1020 cccctgctcc cctcatcagg accaacccgg ggactggtgc ctctgcctga tcagccagca 1080 ttgcccctag ctctgggttg ggcttggggc caagtctcag ggggcttcta ggagttgggg 1140 ttttctaaac gtcccctcct ctcctacata gttgaggagg gggctaggga tatgctctgg 1200 ggctttcatg ggaatgatga agatgataat gagaaaaatg ttatcattat tatcatgaag 1260 taccattatc ataatacaat gaacctttat ttattgccta ccacatgtta tgggctgaat 1320 aatggccccc aaagatatct gtgtcctaat cctcagaact tgtgactgtt accttctgtg 1380 gcagaaaggg acagtgcaga tgtatgtaag ttaaggactt tgagatagag aggttattct 1440 tgctgattca ggtgggccca aaatatcacc acaagggtcc tcataagaaa gaggccagaa 1500 ggtcaaagag gtagagacaa agtgatgatg gaagtggacg tgggtgtgac gtgagcaggg 1560 gccatgaatg ccgcagcctt cagatgccag aaagggaaag gaatggattc ccctgcctgg 1620 agcctccaaa agaaaccagc cctgcccacg ccttgacttg agcccattga aactgatctt 1680 gagctcctgg cctccagaat tgcaggagaa taaatttgtg ttgtttttaa tgaaaaaaaa 1740 aaaaaaa 1747 56 1473 DNA Homo sapiens misc_feature Incyte ID No 1618158CB1 56 acagcgggac agcccggcag ccttgggctt ccagcgctgg cttcatcgcc acctccctgc 60 cttctcccac ttccgcattc ttaggtgacg gatggtggca ccatcaagca aaagatcttc 120 accttcgacg ccatgttctc caccaactac tcacacatgg agaactaccg caagcgagag 180 gacctggtgt accagtccac tgtgaggctg cccgaggtcc ggatctcaga caatggtccc 240 tatgagtgcc atgtgggcat ctacgaccgc gccaccaggg agaaggtggt cctggcatca 300 ggcaacatct tcctcaacgt catggctcct cccacctcca ttgaagtggt ggctgctgac 360 acaccagccc ccttcagccg ctaccaagcc cagaacttca cgctggtctg catcgtgtct 420 ggaggaaaac cagcacccat ggtttatttc aaacgagatg gggaaccaat cgacgcagtg 480 cccctatcag agccaccagc tgcgagctcc ggccccctac aggacagcag gcccttccgc 540 agccttctgc accgtgacct ggatgacacc aagatgcaga agtcactgtc cctcctggac 600 gccgagaacc ggggtgggcg accctacacg gagcgcccct cccgtggcct gaccccagat 660 cccaacatcc tcctccagcc aaccacagag aacataccag agacggtcgt gagccgtgag 720 tttccccgct gggtccacag cgccgagccc acctacttcc tgcgccacag ccgcaccccg 780 agcagtgacg gcactgtgga agtacgtgcc ctgctcacct ggaccctcaa cccacagatc 840 gacaacgagg ccctcttcag ctgcgaggtc aagcacccag ctctgtcgat gcccatgcag 900 gcagaggtca cgctggttgc ccccaaagga cccaaaattg tgatgacgcc cagcagagcc 960 cgggtagggg acacagtgag gattctggtc catgggtttc agaacgaagt cttcccggag 1020 cccatgttca cgtggacgcg ggttgggagc cgcctcctgg acggcagcgc tgagttcgac 1080 gggaaggagc tggtgctgga gcgggttccc gccgagctca atggctccat gtatcgctgc 1140 accgcccaga acccactggg ctccaccgac acgcacaccc ggctcatcgt gtttgaaaac 1200 ccaaatatcc caagaggaac ggaggactct aatggttcca ttggccccac tggtgcccgg 1260 ctcaccttgg tgctcgccct gacagtgatt ctggagctga cgtgaaggca cccgccccgg 1320 ccactccatc aggcactgac atctccacga ccggttttca tttcttttct aaactatttc 1380 cagtcttgtt cttagtctct ttccatctgt gtcttggctt cttcagtcgg tttaattaaa 1440 acaaacagaa caattttccc caaaaaaaaa aaa 1473 57 1591 DNA Homo sapiens misc_feature Incyte ID No 1656935CB1 57 attaaacgac tcactatagg gaatttggcc ctcgaggcaa gaattcggca cgagggcttc 60 tataggagag ctttagaatg aagtcattta gaggagcagg cgaatcctaa ccgcatctct 120 ctctttagct ggactgaacc caaacatgaa tgtcaacagc atggacatga ccggtggctt 180 gtcggtgaag gacccatccc agtcccagtc acgcctcccc cagtggacgc accccaactc 240 catggataac ttgcccagtg ccgcttcccc cctggagcag aaccctagca agcatggtgc 300 tatccctgga ggtctaagca ttgggcctcc aggtaagtcc tccattgatg actcctatgg 360 ccggtacgat ttaatccaga acagtgagtc accagccagt cctcccgtag ctgttcccca 420 tagctggtca cgtgccaaat ctgacagtga taaaatctca aatggctcta gcatcaactg 480 gcccccagaa ttccatccgg gagttccatg gaaaggactg cagaatattg accctgagaa 540 tgaccctgac gtcactcctg gcagtgtccc cactgggcct accatcaaca ccaccatcca 600 ggatgtcaac cgctacctcc tcaagagtgg agggtcctcc ccgccatcat ctcagaatgc 660 cacgctgcct tcttcgagtg cctggccact cagtgcctcc ggctacagta gctctttcag 720 cagcattgca tccgcaccta gtgttgcagg taaactgtca gacatcaaat cgacgtggtc 780 ctctggccct acctcccaca cgcaagcctc tctgtctcat gaactatgga aggtgcccag 840 aaacagtact gcacccacga ggccacctcc agggttaacc aatcccaagc cctcctccac 900 ctggggtgcc agccccctcg gctggaccag ctcctactcc tcgggttctg cctggagcac 960 cgacacctca ggaagaacca gcagctggct cgttcttcga aacctcactc cccagattga 1020 tggttctaaa ctgcggacat tgtgtttgca acatgggcct cttatcacat tccacctgaa 1080 tctgactcaa ggcaatgctg tggtccggta cagctccaag gaggagggct tgccaaaggc 1140 ccaggaagtc ctctgcacaa ttgtgcgtcc ttgggagaca cttagccatt ccttgggccc 1200 gagtttccgc ttggttggaa cgaaggaagt tggaattcgg gtttccttta agccgccaga 1260 gggcccaggc cgcattggcc agagcacaat tttccaaggt ctggcacaat tccacgacca 1320 gaggggcgtt tccaagctca caggacgtgg cgggattcac aggccacgcg ggaggggcaa 1380 ggcttctcac caacttgcac atatgagaca ttgtgaatta acattttaag agcgttgcga 1440 ctaattggga caatcatcgg acaaggaccc tgagttcaat tttgtaaagt gccctgttat 1500 aaatgtttgc cgtgtagaat aaaggtttct ttccactata tcccattgta tcgggatata 1560 tcacatcgta acagtgttat tttgggaaga a 1591 58 1858 DNA Homo sapiens misc_feature Incyte ID No 1859305CB1 58 gcaggcgcgg cgaaacttcc ctctacccgc ccggcccgcg gcgcgcaccg ttggcgctgg 60 acgcttcctc cttggaagcg cctctccctc aggtctcaag aactgttttg agatgcagga 120 attcatctaa ttttcactgc cgggcgaggt gtgagagccc tagcatctga aagtggtcga 180 cttgcgagtt gttatggaga aaacttgtat agatgcactt cctcttacta tgaattcttc 240 agaaaagcaa gagactgtat gtatttttgg aactggtgat tttggaagat cactgggatt 300 gaaaatgctc cagtgtggtt attctgttgt ttttggaagt cgaaaccccc agaagaccac 360 cctactgccc agtggtgcag aagtcttgag ctattcagaa gcagccaaga agtctgacat 420 cataatcata gcaatccaca gagagcatta tgattttctc acagaattaa ctgaggttct 480 caatggaaaa atattggtag acatcagcaa caacctcaaa atcaatcaat atccagaatc 540 taatgcagag taccttgctc atttggtgcc aggagcccac gtggtaaaag catttaacac 600 catctcagcc tgggctctcc agtcaggagc actggatgca agtcggcagg tgtttgtgtg 660 tggaaatgac agcaaagcca agcaaagagt gatggatatt gttcgtaatc ttggacttac 720 tccaatggat caaggatcac tcatggcagc caaagaaatt gaaaagtacc ccctgcagct 780 atttccaatg tggaggttcc ccttctattt gtctgctgtg ctgtgtgtct tcttgttttt 840 ctattgtgtt ataagagacg taatctaccc ttatgtttat gaaaagaaag ataatacatt 900 tcgtatggct atttccattc caaatcgtat ctttccaata acagcactta cactgcttgc 960 tttggtttac ctccctggtg ttattgctgc cattctacaa ctgtaccgag gcacaaaata 1020 ccgtcgattc ccagactggc ttgaccactg gatgctttgc cgaaagcagc ttggcttggt 1080 agctctggga tttgccttcc ttcatgtcct ctacacactt gtgattccta ttcgatatta 1140 tgtacgatgg agattgggaa acttaaccgt tacccaggca atactcaaga aggagaatcc 1200 atttagcacc tcctcagcct ggctcagtga ttcatatgtg gctttgggaa tacttgggtt 1260 ttttctgttt gtactcttgg gaatcacttc tttgccatct gttagcaatg cagtcaactg 1320 gagagagttc cgatttgtcc agtccaaact gggttatttg accctgatct tgtgtacagc 1380 ccacaccctg gtgtacggtg ggaagagatt cctcagccct tcaaatctca gatggtatct 1440 tcctgcagcc tacgtgttag ggcttatcat tccttgcact gtgctggtga tcaagtttgt 1500 cctaatcatg ccatgtgtag acaacaccct tacaaggatc cgccagggct gggaaaggaa 1560 ctcaaaacac tagaaaaagc attgaatgga aaatcaatat ttgaaacaaa gttcaattta 1620 gctggatttc tgaactatgg ttttgaatgt ttaaagaaga atgatgggta cagttaggaa 1680 agtttttttc ttacaccgtg actgagggaa acattgcttg tctttgagaa attgactgac 1740 atactggaag agaacaccat tttatctcag gttagtgaag aatcagtgca ggtccctgac 1800 tcttattttc ccagaggcca tggagctgag attgagacta gccttgtggt tttcacac 1858 59 1454 DNA Homo sapiens misc_feature Incyte ID No 1949083CB1 59 caccctggtg tcttcccctg tggccctgca aggcatatca tgcttcctgt ctctaggacc 60 tgcttactag aaagcagcac ccgcctgaaa cctcacgaag cccagaacta caggaagaag 120 gcattgtggg tgtcctggtt ctccatcatt gtcaccctgg ccctcgcggt ggctgccttt 180 actgtctccg ttatgaggta cagcgcctct gcttttgggt ttgcatttga tgccatcctg 240 gacgtcctgt catcggcgat tgtcctgtgg cgttacagca acgcggccgc tgtgcactct 300 gcccataggg agtacatagc ctgtgtcatc ttgggggtga tattccttct gtcatccata 360 tgtatagtgg tcaaagccat ccatgacctc tcaactaggc tgctcccaga agtggacgat 420 ttcctgttca gtgtctccat tttaagtggg attctttgca gcatcctggc cgtgttgaag 480 ttcatgctgg ggaaggttct gaccagtaga gcactcataa cagatgggtt taactccctc 540 gtgggtggcg tgatgggctt ctccattctt ctgagcgcgg aagtgttcaa gcatgactcg 600 gcggtctggt acctggacgg cagcataggc gttctgatcg gcctcaccat atttgcctat 660 ggggtcaaac tcctcatcga catggtgccg aaggtgaggc agacacgtca ctacgagatg 720 tttgagtgaa gggggccagc atccgcatga gaccatcgag atgaggagtt cccacatagg 780 caaagggtgc caatatttaa ctgaacatct ggtttctttt tggaagtttt ctttcacatg 840 gtttgtcatt acaagacaag gtctgcccag ccaggtggat ctaccttgcc cccatcacct 900 gccgccccca tcaaacatgt tgggacaatg cccataggaa tggacctcct tccccgtctc 960 cagctgggac tggcgttttt tagtctctgg agtatgatgg ttctcatggg taggatgaga 1020 tctttggcag aaaggtcttc ggtggtgctc tgagcctgcg ctgcatagga ctgagcagac 1080 ccacctcctc cagcttgggt ggccctgcca ctcctggttc caagtctctc ctttcctggc 1140 aggtcttaag ggaagattgt acccctcacc ctttacatac ccagaatcat cagtatgtca 1200 cttcctaatt tctatcagtg tatctcatta tttcatactg ttttactaat cctaagtcta 1260 aacagatttg ctcaaaagga gaccattcta ttttttaaag tacttagtga tacacgtata 1320 agctttgcat ggacgaatta aataagcaca ttgacctttt cttgtacatt cagaacctga 1380 acatccatgt gaaaactggg tccatttttg agagatgtga aactacagtt tatatgtaat 1440 aaataaatat aata 1454 60 2310 DNA Homo sapiens misc_feature Incyte ID No 1996357CB1 60 ggcccggatg ttcggtgcag ctgccagatc cgctgatcta gtgcttctcg aaaaaaacct 60 tcaggcggcc catggctgtc gatattcaac cagcatgcct tggactttat tgtgggaaga 120 ccctattatt taaaaatggc tcaactgaaa tatatggaga atgtggggta tgcccaagag 180 gacagagaac gaatgcacag aaatattgtc agccttgcac agaatctcct gaactttatg 240 attggctcta tcttggattt atggcaatgc ttcctctggt tttacattgg ttcttcattg 300 aatggtactc ggggaaaaag agttccagcg cacttttcca acacatcact gcattatttg 360 aatgcagcat ggcagctatt atcaccttac ttgtgagtga tccagttggt gttctttata 420 ttcgttcatg tcgagtattg atgctttctg actggtacac gatgctttac aacccaagtc 480 cagattacgt taccacagta cactgtactc atgaagccgt ctacccacta tataccattg 540 tatttatcta ttacgcattc tgcttggtat taatgatgct gctccgacct cttctggtga 600 agaagattgc atgtgggtta gggaaatctg atcgatttaa aagtatttat gctgcacttt 660 acttcttccc aattttaacc gtgcttcagg cagttggtgg aggcctttta tattacgcct 720 tcccatacat tatattagtg ttatctttgg ttactctggc tgtgtacatg tctgcttctg 780 aaatagagaa ctgctatgat cttctggtca gaaagaaaag acttattgtt ctcttcagcc 840 actggttact tcatgcctat ggaataatct ccatttccag agtggataaa cttgagcaag 900 atttgcccct tttggctttg gtacctacac cagccctttt ttacttgttc actgcaaaat 960 ttaccgaacc ttcaaggata ctctcagaag gagccaatgg acactgagtg tagacatgtg 1020 aaatgccaaa aacctgagaa gtgctcctaa taaaaaagta aatcaatctt aacagtgtat 1080 gagaactatt ctatcatata tgggaacaag attgtcagta tatcttaatg tttgggtttg 1140 tctttgtttt gtttatggtt agacttacag acttggaaaa tgcaaaactc tgtaatactc 1200 tgttacacag ggtaatatta tctgctacac tggaaggccg ctaggaagcc cttgcttctc 1260 tcaacagttc agctgttctt tagggcaaaa tcatgtttct gtgtacctag caatgtgttc 1320 ccattttatt aagaaaagct ttaacacgtg taatctgcag tccttaacag tggcgtaatt 1380 gtacgtacct gttgtgtttc agtttgtttt tcacctataa tgaattgtaa aaacaaacat 1440 acttgtgggg tctgatagca aacatagaaa tgatgtatat tgttttttgt tatctattta 1500 ttttcatcaa tacagtattt tgatgtattg caaaaataga taataattta tataacaggt 1560 tttctgttta tagattggtt caagatttgt ttggattatt gttcctgtaa agaaaacaat 1620 aataaaaagc ttacctacat aaaatttcaa tgttttgaca cttaattgtt gtttggcaca 1680 atagtatgga agtaattcaa actggtaaat agtttcctct catatctcgg gtatatatac 1740 ataccatatt ttattgatcc agagatactt atttcacttt gtgacatctc tgaattagga 1800 tgcatcttac aactgatggc ttattaggtt taatgaaata cagaagatac acagtataaa 1860 aagggttttc ctgtggttgg tttgtggttt gtgataggtg ttctgtgatg tttatgcttt 1920 gaaggcctta agactcatgg ttgcaaccat ggaagcaaaa tgaaattttt agctcttaac 1980 ctaacaacct gaccatgttt atccattttt attgtttaga agtttattta ctgatacttg 2040 gtggaggttg tgtgaattag ttaaatttta aatgtttaag acttctatta acagctgcaa 2100 aatatgaaag taagtgcact cacttttcct gtagtagtct gtcttttgaa ttcacagcag 2160 ttgtatcctt gagttacttt gttaatgtat ttttctcagt acatttaacc actgggaaat 2220 gaacccttgt acgaatgtgt ttcttcttct ctgtaggaat aaaaaataaa tataaaaatt 2280 ttatttgtat tgcacacaaa aaaaaaaaaa 2310 61 744 DNA Homo sapiens misc_feature Incyte ID No 2061330CB1 61 agtggtgtgt tacctgccga cagcataaag cgaggcaagg tccagccgtt ccgcccggca 60 tacaagctta tggagcagcc ccctttgaag atctccaggt ggacttcaca gagatgtcaa 120 agtgtagagg tgatcgagtg tggatcaaga actggaacgt agcctctttg tgtccactgt 180 ggaaaggacc ccagactgtc gttctgagca ctcccaccgc tgtgaaggta gaaggaatcc 240 cagcctggat ccaccacagc catgtaaaac ctgcagcgcc tgaaacctgg gaggcaagac 300 caagcccaga caacccctgc agagtgaccc tgaagaagac gacaagccct gctccagtca 360 cacccggaag ctgactggtc cacgcacggc cgaagcctga ggaagctcat catgagattc 420 atttttctta aattttggac ttatacagta agggcttcaa ctgatcttac tcaaactggg 480 gactgttccc agtgtactca tcaggtcacc gaagtaggac agcaaattaa aacaatcttt 540 ctgttctata gttattatga atgtatggaa acaataaaag aaacttgttt gtataatgcc 600 actcagtaca aggtatgtag cccgagaaat gaccgacctg atgtgtgtta taacccatct 660 gagccccctg caccaccgtt tttgaaataa gaataagaac tggccttttc ctaggtgata 720 caagtaaaat aataactaga acag 744 62 1109 DNA Homo sapiens misc_feature Incyte ID No 2346947CB1 62 gaagcagtgc agagaggaga gcggagcgcn agtgccgctg agcaaaggcc ttcaccatgg 60 ccgagtcccc cggctgctgc tccgtctggg cccgctgcct ccactgcctg tatagctgcc 120 actggaggaa atgccccaga gagaggatgc aaaccagcaa gtgcgactgt atctggtttg 180 gcctgctctt cctcaccttc ctcctttccc tgagctggct gtacatcggg ctcgtccttc 240 tcaatgacct gcacaacttc aatgaattcc tcttccgccg ctggggacac tggatggact 300 ggtccctggc attcctgctg gtcatctctc tactggtcac atatgcatcc ttgctattgg 360 tcctggccct gctcctgcgg ctttgtagac agcccctgca tctgcacagc ctccacaagg 420 tgctgctgct cctcattatg ctgcttgtgg cggctggcct tgtgggactg gacatccaat 480 ggcagcagga gtggcatagc ttgcgtgtgt cactgcaggc cacagcccca ttccttcata 540 ttggagcagc cgctggaatt gccctcctgg cctggcctgt ggctgatacc ttctaccgta 600 tccaccgaag aggtcccaag attctgctac tgctcctatt ttttggagtt gtcctggtca 660 tctacttggc ccccctatgc atctcctcac cctgcatcat ggaacccaga gacttaccac 720 ccaagcctgg gctggtggga caccgagggg cccccatgct ggctcccgag aacaccctga 780 tgtccttgcg gaagacagct gaatgcggac tactgtgttt gagactgatg tgatggtcag 840 ctccgatggg gtccccttcc tcatgcatga tgagcacctc agcaggacca cgaatgtagc 900 ctctgtattc ccaacccgaa tcacagccca cagcagtgac ttctcctgga ctgaactgaa 960 gagactcaat gctggatcct ggttcctaga gaggcgaccc ttctgggggg ccaaaccgct 1020 ggcaggccct gatcagaaag aggctgagag tcagtcggta ccagcattag aagagctatt 1080 ggaggaagct gcagccctca accctttca 1109 63 2511 DNA Homo sapiens misc_feature Incyte ID No 2795577CB1 63 gcagccgtcg ccttcggagc gaagggtacc gacccggcag aagctcggag ctctcggggt 60 atcgaggagg caggcccgcg ggcgcacggg cgagcgggcc gggagccgga gcggcggagg 120 agccggcagc agcggcgcgg cgggctccag gcgaggcggt cgacgctcct gaaaacttgc 180 gcgcgcgctc gcggcactgc gcccggagcg atgaagatgg tcgcgccctg gacgcggttc 240 tactccaaca gctgctgctt gtgctgccat gtccgcaccg gcaccatcct gctcggcgtc 300 tggtatctga tcatcaatgc tgtggtactg ttgattttat tgagtgccct ggctgatccg 360 gatcagtata acttttcaag ttctgaactg ggaggtgact ttgagttcat ggatgatgcc 420 aacatgtgca ttgccattgc gatttctctt ctcatgatcc tgatatgtgc tatggctact 480 tacggagcgt acaagcaacg cgcagcctgg atcatcccat tcttctgtta ccagatcttt 540 gactttgccc tgaacatgtt ggttgcaatc actgtgctta tttatccaaa ctccattcag 600 gaatacatac ggcaactgcc tcctaatttt ccctacagag atgatgtcat gtcagtgaat 660 cctacctgtt tggtccttat tattcttctg tttattagca ttatcttgac ttttaagggt 720 tacttgatta gctgtgtttg gaactgctac cgatacatca atggtaggaa ctcctctgat 780 gtcctggttt atgttaccag caatgacact acggtgctgc tacccccgta tgatgatgcc 840 actgtgaatg gtgctgccaa ggagccaccg ccaccttacg tgtctgccta agccttcaag 900 tgggcggagc tgagggcagc agcttgactt tgcagacatc tgagcaatag ttctgttatt 960 tcacttttgc catgagcctc tctgagcttg tttgttgctg aaatgctact ttttaaaatt 1020 tagatgttag attgaaaact gtagttttca acatatgctt tgctggaaca ctgtgataga 1080 ttaactgtag aattcttcct gtacgattgg ggatataatg ggcttcacta accttcccta 1140 ggcattgaaa cttcccccaa atctgatgga cctagaagtc tgcttttgta cctgctgggc 1200 cccaaagttg ggcatttttc tctctgttcc ctctcttttg aaaatgtaaa ataaaaccaa 1260 aaatagacaa ctttttcttc agccattcca gcatagagaa caaaacctta tggaaacagg 1320 aatgtcaatt gtgtaatcat tgttctaatt aggtaaatag aagtccttat gtatgtgtta 1380 caagaatttc ccccacaaca tcctttatga ctgaagttca atgacagttt gtgtttggtg 1440 gtaaaggatt ttctccatgg cctgaattaa gaccattaga aagcaccagg ccgtgggagc 1500 agtgaccatc tgctgactgt tcttgtggat cttgtgtcca gggacatggg gtgacatgcc 1560 tcgtatgtgt tagagggtgg aatggatgtg tttggcgctg catgggatct ggtgcccctc 1620 ttctcctgga ttcacatccc cacccagggc ccgcttttac taagtgttct gccctagatt 1680 ggttcaagga ggtcatccaa ctgactttat caagtggaat tgggatatat ttgatatact 1740 tctgcctaac aacatggaaa agggttttct tttccctgca agctacatcc tactgctttg 1800 aacttccaag tatgtctagt caccttttaa aatgtaaaca ttttcagaaa aatgaggatt 1860 gccttccttg tatgcgcttt ttaccttgac tacctgaatt gcaagggatt tttatatatt 1920 catatgttac aaagtcagca actctcctgt tggttcatta ttgaatgtgc tgtaaattaa 1980 gtcgtttgca attaaaacaa ggtttgccca caaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2040 aaaaaaaaaa aaaaaaaaca caatacgaaa caacaagaac agcaagaatc aaaaagctta 2100 aaatcctcga gtgcacaatg aagaaaacag gggggcgccc ctctaggggt cccagtttcg 2160 gtcggggtga ttggggggac tgagcccttc ctatagggac cccctaattc tgatttcagg 2220 ggcggggcgg tttttaaaaa gcgcggttaa cgggggaaac acccctgggg gttatccccc 2280 ctcttttaag cggcgtgttg gtgggaaaga caccgccctt ttttgcgccc aagtgggggc 2340 atatatctcc ccggtgaggg cgccctctac ccgatatctg gcctttcccc agaagttttg 2400 cccgcgccct ctactttggg gactttgggt gccgccacct ttattaaggg ggcgtttata 2460 ccagcggcgg gggtttgtgg gcgtcctcgc gcgggaggcc cgctccaccc t 2511 64 788 DNA Homo sapiens misc_feature Incyte ID No 3255825CB1 64 cccacgcgtc cgcagctgcg tcctctgggc cacgctccac ttgcccgctt ccacccggaa 60 agccccccag gctgagtgcg gcatgatctc catcaccgaa tggcagaaga ttggtgtggg 120 gatcaccggt ttcggcatct tcttcatcct ctttggaaca ctcctgtact ttgattccgt 180 gctcctggcc tttggaaacc tgctgttcct gacgggcctg tccctcatca ttggcctgag 240 gaagaccttt tggttcttct tccaacggca caaactcaag ggaaccagct tcctcctggg 300 gggtgtggtt atcgtgctcc tacgctggcc cctcctcggc atgttcctgg aaacctacgg 360 attcttcagc ctctttaagg gctttttccc tgtcgccttc ggttcctggg caatgtctgc 420 aacatcccct tcctgggtgc gctgttccgg agacttcaag gcactagctc gatggtctga 480 aaaacagaga tgagctcctt gaacttggat cattggttga gggggctaga gggagaatgg 540 gaaccacccc ctcagtcccc tgcactgact cactccccga catatccgga cctccccaag 600 tccagaagga aggaatggag ctgagcaact gacgtcaaat ccccaagtcg actcaagagg 660 ctgccaggaa gcagagatgc agaccccaag gagactgggc tggggctggt atcacaccct 720 cactctatat ttatgggagg aaaagtgaag attaaattcc caagttgtgc gtgtgtctaa 780 aaaaaaaa 788 65 1831 DNA Homo sapiens misc_feature Incyte ID No 3393430CB1 65 gccttataaa gtagcctctg catctgcctg cctcgggcag aggagggcta ccctggggct 60 gagagttcac ctgtctcagg aaccacctga gcccacagat cctgtgggca gcggccaggg 120 cagccatggc ttgggcaagt aggctgggcc tgctgctggc actgctgctg cccgtggtcg 180 gtgcctccac gccaggcacc gtggtccgac tcaacaaggc agcattgagc tacgtgtctg 240 aaattgggaa agcccctctc cagcgggccc tgcaggtcac tgtccctcat ttcctggact 300 ggagtggaga ggcgcttcag cccaccagga tccggattct gaatgtccat gtgccccgcc 360 tccacctgaa attcattgct ggtttcggag tgcgcctgct ggcagcagct aattttactt 420 tcaaggtctt tcgcgcccca gagcccctgg agctgacgct gcctgtggaa ctgctggctg 480 acacccgcgt gacccagagc tccatcagga cccctgtggt cagcatctct gcctgctctt 540 tattctcggg ccacgccaac gagtttgatg gcagtaacag cacctcccac gcgctgctgg 600 tcctggtgca gaagcacatt aaagctgtct tgagtaacaa gctgtgcctg agcatctcca 660 acctggtgca gggtgtcaat gtccacctgg gcaccttaat tggcctcaac cccgtgggtc 720 ctgagtccca gatccgctat tccatggtca gtgtgcccac tgtcaccagt gactacattt 780 ccctggaagt caatgctgtt ctcttcctgc tgggcaagcc catcatcctg cccacggatg 840 ccaccccttt tgtgttgcca aggcatgtgg gtaccgaggg ctccatggcc accgtgggcc 900 tctcccagca gctgtttgac tctgcgctcc tgctgctgca gaaggccggt gccctcaacc 960 tggacatcac agggcagctg aggtcggatg acaacctgct gaacacctct gctctgggcc 1020 ggctcatccc ggaggtggcc cgccagtttc ccgagcccat gcctgtggtg ctcaaggtgc 1080 ggctgggtgc cacacctgtg gccatgctcc acacaaacaa cgccaccctg cggctgcagc 1140 ccttcgtgga ggtcctggcc acagcctcca actcggcttt ccagtccctc ttctccctgg 1200 atgtggtagt gaacttgaga ctccagctct ctgtgtccaa ggtgaagctt caggggacca 1260 cgtctgtgct gggggatgtc cagctcacgg tggcctcctc caacgtgggc ttcattgata 1320 cagatcaggt gcgcacactg atgggcaccg tttttgagaa gcccctgctg gaccatctca 1380 atgctctctt ggccatggga attgccctcc ctggtgtggt caacctccac tatgtcgccc 1440 ctgagatctt tgtctatgag ggctacgtgg tgatatccag tggactcttc taccagagct 1500 gaggcaagac cactgggagg cctgagagtg ggccagctcg ctgctcaggc gaatttctca 1560 tttcaagcca ctggggaaac tgaggcaaaa ccatacttag tcatcaccaa caagctggac 1620 tgcttagctg ggctgtttta tcttccctga gtgcctgggt ctccctccct cacttctgcc 1680 ctttcccttc ctcctcctct tctcctccct cttccctcat ctcccccctc cttcctctgc 1740 cccaccccag gggggagcag actgctcctc caggctgtat agacctgccc tcttgcatta 1800 aacaacttct cttgagctgc aaaaaaaaaa a 1831 66 1499 DNA Homo sapiens misc_feature Incyte ID No 3490990CB1 66 tgtttgagtt gggtgaagaa ggcgggaagt taatcctctt ccaatcagct ccccatctcg 60 ccctctggcg gctccggacc acaggccgag ttactctgat taccgccatg ctccaagacc 120 cgcactgaca gtccccacct cccgttctct gtcatcggtt ccctcaatgg agtccacatg 180 tttgggcaga atctggaggt gcagctgagc tctgcgagga ccgagaacac gactgtggtg 240 tggaaaagct tccatgacag catcaccctc attgttctgt catctgaggt gggcatctct 300 gagctgaggc tggagagact actccaaatg gtgtttggag ccatggtcct tcttgtggga 360 cttgaagaac tgaccaatat ccgcaacgtg gagagactga agaaggactt gagggccagt 420 tattgcctca tcgacagctt cctgggggac tcggagctca tcggggacct gacccagtgt 480 gtggactgcg tgattcctcc agaggggtcc ctcttgcagg aagccctctc cgggttcgct 540 gaggccgcgg gcacgacctt cgtcagtctg gtggtgtccg gccgggtggt ggcagcaaca 600 gagggttggt ggcggctggg gacgcccgag gccgtgctgc tcccctggct ggtggggtcc 660 ctgccgccgc agaccgctcg cgactacccg gtgtacctac cgcacgggag ccccacggtc 720 ccacaccggc tcctgaccct gactctgctg ccgagcctgg agctgtgtct actctgcggg 780 ccgagcccac ccctcagcca gttgtatcca cagcttctgg agcgctggtg gcagccactg 840 ctggacccgt tgcgggcctg tctgccgttg ggaccccggg cgctgcccag tggcttcccc 900 cttcacacag acatcctcgg gctgctgctc ctccacctgg aactgaagcg ctgcctcttc 960 accgtggagc ccttggggga taaagagcct tcaccagaac agcgccggcg cctcctccga 1020 aacttctata ccctggtcac ctccacgcac ttcccaccag agccagggcc accagagaag 1080 acagaagatg aggtctacca ggcccagctg cccagagctt gctacctggt gttggggact 1140 gaggaaccag gcacaggagt gcgtctggtg gccttgcagc tggggcttcg gcggctgctg 1200 ctgctgctgt ctccccagag tcccacccat gggctgcgaa gcctggccac ccacactctg 1260 catgccctca ccccacttct ttgactacct agcagtgggt gatggacaca gacatggggc 1320 tgttagcgtc tctctgttta ttcgctcaca ataatacaca gcccctggat ggggaggggg 1380 taggaggggc tacaacaggg tggggtggga ggggaggaga catccacttc cctggcccct 1440 ctcccctctg tgcttggggg ggaaagggag ggagggggac tccccctaac cccccagaa 1499 67 365 DNA Homo sapiens misc_feature Incyte ID No 3635154CB1 67 gtttttttgc actaacttca ggagccagct cgtgatctca ggatgtatgg aaaaataatc 60 tttgtattac tattgtcaga aattgtgagc atatcagcat caagtaccac tggtgtggca 120 atgcacactt caacctcttc ttcagtcaca aagagttaca tctcatcaca gacaaatgga 180 gaaacgggac aacttgtcca tcgtttcact gtaccagctc ctgtagtgat aatactcatt 240 attttgtgtg tgatggctgg tattattgga acgatcctct tattttctta cagttttcgc 300 cgactgataa agggctgagg gtgtagcctg catgctgccg atcttgctct gaaccggccg 360 cattg 365 68 1102 DNA Homo sapiens misc_feature Incyte ID No 4374347CB1 68 gaggacagag caggcagcag agaccatggg gcccccctca gcttgtcccc acagagaatg 60 catcccctgg caggggctct tgctcacagc ctcactttta actttctgga acgcacccac 120 cactgcctgg ctctttattg catcagcgcc ctttgaagtt gctgaagggg agaatgttca 180 tctctctgtg gtttatctgc ccgagaatct ttacagctat ggctggtaca aagggaaaac 240 ggtggagccc aaccagctaa tcgcagcata tgtaatagac actcacgtta ggactccagg 300 gcctgcatac agcggtcgag agacaatatc acccagtgga gatctgcatt tccagaacgt 360 caccctagag gacacgggat actacaacct acaagtcaca tacagaaatt ctcagattga 420 acaggcatct caccatctcc gtgtatacga gtcagtggct cagccctcca tccaagccag 480 cagcaccaca gtcacagaga agggctccgt ggtcctgacc tgccacacaa ataacactgg 540 aacctctttc cagtggattt tcaacaacca gcgtctgcag gtcacgaaga ggatgaagct 600 gtcctggttt aaccatgtgc tcaccataga ccccatcagg caggaggacg ctggggagta 660 tcagtgtgag gtctccaacc cagtcagctc caacaggagc gaccccctca agctgactgt 720 aaaatatgac aacactctag gcatcctgat cggggtcctg gttgggagtc ttctggtggc 780 tgcacttgtg tgtttcctgc tcctccgaaa aactggcagg gccagcgatc agagtgactt 840 cagggagcag cagcccccag cctccacccc cggccatgga ccctctgaca gctctgacag 900 ctccatctcc taggaattgc tacactctga cacaaacatt tactgctgga tcgaccacaa 960 agcagatgtg gcttcttagg ttcctctggg agctgctcct gtgggttgat ggagcgtccc 1020 tgaagccccc agccctgggg atggggaagg acatggagcc tgagccagag aaccagctct 1080 gagtcctgag gagacacagg cc 1102 69 2546 DNA Homo sapiens misc_feature Incyte ID No 4596747CB1 69 cccggggcgc gcccaccgcg ccgcatccat gttcgacacc acaccccact ctggccggag 60 cacgccaagc agctccccat cgctccggaa acggctgcag ctcctgcccc caagccggcc 120 cccacctgag ccagaaccag gcaccatggt ggagaaggga tcagatagct cctcagagaa 180 gggtggggtg cctgggaccc ccagcaccca gagcctaggc agccggaact tcatccgcaa 240 cagcaagaag atgcagagct ggtacagtat gctgagcccc acttataagc agcgtaatga 300 ggacttccgg aaactgttca gcaaactccc cgaagcagaa cgcctcattg tggattactc 360 ctgcgccctg cagcgtgaga tcctgctcca gggccgcctc tacctctctg agaactggat 420 ctgcttctac agcaacatct tccgctggga gaccacgatc tccatccagc tgaaggaagt 480 gacatgtctg aagaaggaaa agacggccaa gctgatcccc aacgccatcc agatctgcac 540 ggagagcgag aagcatttct tcacttcctt tggggcccgt gaccgctgct tcctcctcat 600 cttccgcctc tggcagaatg cactgcttga aaagacgctg agtccccgcg agctctggca 660 cctggtgcat cagtgctacg gctcagagct gggcctcacc agtgaggatg aggactatgt 720 ctcccccttg cagctgaacg gtctggggac ccccaaggaa gtgggagatg tgatcgccct 780 gagcgacatc acctcctcgg gggcagctga ccgcagccag gagccaagcc cagtgggttc 840 gcgccgtggc catgtcacgc ccaacctttc ccgagccagc agcgacgcag accatggggc 900 agaggaggac aaggaggagc aggtagacag ccagccagac gcctcctcca gccagacagt 960 gaccccggtg gctgaacccc cgagcacaga gcccacccag cctgacgggc ccaccaccct 1020 gggccccttg gatctgctgc ccagtgagga gctattgaca gacacaagta actcctcttc 1080 atccactggg gaggaagcgg acttggctgc cctgcttccc gacctctccg gccgcctcct 1140 catcaactct gtcttccatg tgggcgctga gcggctccag cagatgctct tctcggactc 1200 gcccttcctc cagggcttcc tacagcagtg caagttcaca gacgtgacgc tgagcccctg 1260 gagtggggac agcaagtgcc accagcgccg ggtgctgacg tacaccatcc ccatcagcaa 1320 cccactgggc cccaagagcg cctccgtggt ggagacacag acgctgttcc ggcgcggccc 1380 ccaggccggc gggtgtgtgg tggactccga ggtgctgacg cagggcatcc cctaccagga 1440 ctacttctac actgcccacc gctactgcat cctgggtctg gcccggaaca aggcgcggct 1500 ccgagtgtct tctgagatcc gctaccgaaa gcagccgtgg agcctggtga agtcgctcat 1560 tgagaagaac tcgtggagcg gcattgaaga ctatttccac catctggagc gagagctcgc 1620 caaggctgag aagctgtctc tggaggaagg cgggaaggat gcccggggct tgctatccgg 1680 cctgcggcgg cggaagcggc ccctgagctg gcgggctcac ggggacgggc cccagcaccc 1740 agatcctgac ccctgtgccc gggccggcat tcacacctcg ggctccctca gctcccgctt 1800 ctccgaacca tctgtggacc agggccccgg ggcaggcatc cccagtgccc tggttctcat 1860 cagcattgtg atctgtgtga gccttatcat cctcatcgcc ctcaacgtcc tgctcttcta 1920 ccgcctctgg tccctggaaa ggacagccca cacctttgag tcctggcaca gcctggccct 1980 ggccaagggc aagttccccc agacggccac agagtgggcc gagatcctgg cgctgcagaa 2040 gcaattccac agcgtggagg tgcacaagtg gaggcagatc ctgcgggcct ccgtggagct 2100 cctggatgag atgaagttct cgctggagaa gctgcaccaa ggcatcacag tctcagaccc 2160 tccctttgac acccagcccc ggcccgatga cagcttttcc tgaggacccc ggccacgcag 2220 ctgttccccc acatggacag atggacacac agagcctcgg cggccactgc tggcacggtg 2280 tgagcgccag gcatctccca cccgcccctc ccgacggccc aaccaggggc tgtgcagacg 2340 tggggaccac ggaaccgaga tgcactttag accagggagc tggcccggcc tctggcaggc 2400 cccccactaa cttattttgc ccggctgagg ttgtgggggg cgcctcctgg ggtgcacgat 2460 tccctcagct ctgggtttaa tgtattatat ttatttgggg ccgacagtgc cccaataaag 2520 ggtcagaagt gaaaaataaa aaaaaa 2546 70 1845 DNA Homo sapiens misc_feature Incyte ID No 5052680CB1 70 ctctggcgga ctgcctggcg gaagcgggaa cgtcgcatcc tgaggtaaag gtgcacggca 60 tcctgggaca tgtagtctgg ccggggctcg gacgccccct cggatgaatg ggaccgaagc 120 tgactgcgaa ctacagcttc ttggcagcgt cggtgttggc cgcgggagaa ggggagaccg 180 cggcggcccc cagtgagagc ggctttccag gacggtgcga tgtgctgcgc agcgaagagg 240 caggaggccg gcttcctggg gtagcggtac aggcgggcgc ttactctgtg cgcttgcttc 300 cccaaccctg caccggccat gcgcccggcc ttggcggtgg gcctggtgtt cgcaggctgc 360 tgcagtaacg tgatcttcct agagctcctg gcccggaagc atccaggatg tgggaacatt 420 gtgacatttg cacaattttt atttattgct gtggaaggct tcctctttga agctgatttg 480 ggaaggaagc caccagctat cccaataagg tactatgcca taatggtgac catgttcttc 540 accgtgagcg tggtgaacaa ctatgccctg aatctcaaca ttgccatgcc cctgcatatg 600 atatttagat ccggttctct aattgccaac atgattctag gaattatcat tttgaagaaa 660 agatacagta tattcaaata tacctccatt gccctggtgt ctgtggggat atttatttgc 720 acttttatgt cagcaaagca ggtgacttcc cagtccagct tgagtgagaa tgatggattc 780 caggcatttg tgtggtggtt actaggtatt ggggcattga cttttgctct tctgatgtca 840 gcaaggatgg ggatattcca agagactctc tacaaacgat ttgggaaaca ctccaaggag 900 gctttgtttt ataatcacgc ccttccactt ccgggtttcg tcttcttggc ttctgatatt 960 tatgaccatg cagttctatt caataagtct gagttatatg aaattcccgt catcggagtg 1020 accctgccca tcatgtggtt ctacctcctc atgaacatca tcactcagta cgtgtgcatc 1080 cggggtgtgt ttatcctcac cacggaatgc gcctccctca ccgtcacgct cgtcgtgacc 1140 ctacgcaaat ttgtgagcct catcttttcc atcttgtact tccagaaccc cttcaccctg 1200 tggcactggc tgggcacctt gtttgtcttc attgggacct taatgtacac agaggtgtgg 1260 aacaacctag ggaccacaaa aagtgagcct cagaaggaca gcaagaagaa ctgaggcctg 1320 tctggagtac gtagaccagt gtcgtcgtga gggtgggacc ctgtgaaggt ctgaccaccg 1380 tttcgctttt gttaatgccg agctacccgc agtgctgagc cagccgtgca aaaggaaatc 1440 ttcaggaggg gacttctcac gttgctcaga ctgacacatg tagactaaat agaaacccct 1500 cagccctaaa atagaaaaaa gaacaggtct agactattga acaggcgatt catttatttc 1560 tgttttgttt accgacatat tcagtattat tcttgttttc tgaattctga gtctcctgaa 1620 caaaaggctt actatccatg gtcttggaaa agattgtccc ttctcttgct gttgtaatgc 1680 atctctgcta cagcagtcat tgtcatcctg tgaccttatc ccttttgtct cccatcacct 1740 tttccttctt cagcagcacc tcacagtcag tcagacgctg caggcaccac tatcaccagg 1800 agtggccaag taaaccgaga caccagtaac agcagggtgg acttc 1845 71 1940 DNA Homo sapiens misc_feature Incyte ID No 5373575CB1 71 gtctcctgtc aaaagccatg ctcggcaggt ctgggtaccg ggcgctgccc ctgggtgatt 60 ttgaccgctt ccagcagtcg agcttcggct ttctgggctc gcagaagggc tgcttgtccc 120 cggagcgggg cggcgtgggg acaggggccg atgtacccca gagctggccc tcctgcctct 180 gtcatggcct catcagtttc ctggggttct tgctgctgtt ggtcaccttc cccatttctg 240 gctggtttgc cctgaagatt gtgcccacct acgagcggat gattgtgttc cgcctgggcc 300 ggatccgcac cccccaggga cctggcatgg ttctgctctt gcccttcatt gactcctttc 360 agagggtgga tctgaggaca cgagccttca acgtccctcc ctgcaagctg gcctctaagg 420 acggggctgt gctgtccgtg ggagccgatg tccagtttcg catctgggac ccggtgctgt 480 cggtgatgac tgtgaaagac ctgaacacag ccacacgcat gacagcccag aacgccatga 540 ccaaggccct gctcaagagg ccgctgcggg agatccagat ggagaagctc aagatcagcg 600 accagcttct gctggagatc aacgatgtga ccagggcctg ggggctggag gtagaccgcg 660 tggagctggc agtggaggcc gtgctccagc cgccccagga cagcccagct gggcccaacc 720 tggacagcac cctccagcag ctggccctgc acttcctggg aggaagcatg aactcaatgg 780 caggaggtgc cccgtccccg gggccagcag acaccgtgga gatggtgagt gaagttgagc 840 cacctgcccc tcaagttggt gccaggtcca gtccgaagca gcctctggcg gaggggctac 900 tgactgctct acagcccttc ctgtctgagg ccctggtcag ccaagtcggg gcctgctacc 960 agttcaatgt cgtcctgccc agcggcaccc aaagcgccta cttcctggac ctcactacag 1020 gacgaggaag agtgggacac ggggtgcctg atggcatccc tgatgtggtg gtggagatgg 1080 ccgaggcaga cctgcgggcc ctgctatgca gagagctgcg gcccctgggg gcctacatga 1140 gtggacggct gaaggtgaag ggcgacctgg ctatggccat gaagctggag gctgtcctca 1200 gggccttgaa gtagcagcct tggctgactt tccagagccc agtcccaagc ctggcaccaa 1260 gcccgagggg cctcttggag gaggaggtgt tcatctgcac cacagagagt tgaggcccta 1320 acaaatttca ggcccagcca agagcccatg aatggaggct gcaggaggct gagtccggct 1380 gccatgcacg tctcccctac agtggttctc tggacaaggc tttgtccatc ccggtcccca 1440 gctgagtgcc cagcgctgag ctgggtgcac ggtgtgattc caggaggaga gccaggcctg 1500 ccctgccctg ctggcttcct gactggagag acaggaccca cagaaacagc ctgacagcag 1560 ctggtttggt ccttgtgtga gggaccaagc atgtggccca ggctctaagc tctgcgggga 1620 ttggagaggg atggggaggg aagggaaggc agctccaaga agaggtccct gtggcgaagt 1680 tacctgggga tcctggctgg cccaccttcc tggctgcagt ccaggcccgt gctggcggga 1740 ttgggcatgg gaaggagcag ggcctgctgc ttccctggcg ctgctcccaa agatttctga 1800 ctcatctgcc agctctgtcc tgcatgcctg gcgagctggg gcccagggca gcatgaagga 1860 gagccctgcg ttctgtgctt cttaccagag gtttgcaagc ctcagacaaa taaatgtggt 1920 gtttacaatg taaaaaaaaa 1940 72 880 DNA Homo sapiens misc_feature Incyte ID No 5524468CB1 72 gcgaagccga agggagcgcg gctaagagtg ccgcaccgcc tcacaacctg ggaaccggag 60 agtaggggcc gtcggctggc aagaacccgc cgtgcctcct cggcaagggc catccggtgc 120 cacccatgtc gcactagagc agaagagggt gagtcctgga actgcaacct gcacagagct 180 gctctgtact gtccctggtg gtcgccgcca tgacctggtt ggtgctgctg gggacactgc 240 tctgcatgct gcgcgttggg ttaggcaccc cggactccga gggtttcccg ccccgtgcgc 300 tccacaactg cccctacaaa tgtatctgcg ctgccgacct gctaagctgc actggcctag 360 ggctgcagga cgtgccagcc gagttacctg ccgctactgc ggacctcgac ctgagccaca 420 acgcgctcca gcgcctgcgc cccggctggt tggcgcccct cttccagctg cgcgccctgc 480 acctagacca caacgaacta gatgcgctgg gtcgcggcgt cttcgtcaac gccagcggcc 540 tgaggctgct cgatctatca tctaacacgt tgcgggcgct tggccgccac gacctcgacg 600 ggctgggggc gctggagaag ctgcttctgt tcaataaccg cttggtgcac ttggacgagc 660 atgccttcca cggcctgcgc gcgctcagcc atctctacct gggctgcaac gaactcgcct 720 cgttctcctt cgaccacctg cacggtctga gcgccaccca cctgcttact ctggacctct 780 cctccaaccg gctgggacac atctccgtac ctgagctggc cgcgctgccg gccttcctca 840 agaacggcct ctacctgcac gacaacacat aaaaaaaaaa 880 73 2403 DNA Homo sapiens misc_feature Incyte ID No 5944279CB1 73 agccacctgc tggccaggta cccctccctt acctggggca gtgtctgcct ggtggccact 60 agagacagcc cagcctgggc catggaagaa aacccgacct tggaatcaga agcctggggc 120 tcctctaggg ggtggctggc cccccgggag gccagaggag gcccatcgct gtcttctgtg 180 ctgaacgagc tgcccagtgc tgccaccctt cggtaccgag accctggggt gctgccttgg 240 ggggcgctgg aggaggagga ggaggatgga ggaaggagca gaaaggcctt cacagaagtc 300 acccagacag agctgcagga ccctcaccct tcccgggaac tgccctggcc catgcaggcc 360 agacgggcac acaggcaaag aaatgccagc agggaccagg tggtctatgg ctctggaact 420 aagacggacc gatgggcgcg gctacttcgg aggtccaagg agaaaacaaa ggaaggcttg 480 cgaagcctgc agccctgggc gtggacactg aagaggatcg ggggccagtt tggcgccggc 540 acggagtcct acttctccct gctgcgcttc ctgctccttc ttaacgtgct ggcctctgtg 600 ctcatggcct gcatgacgct gctgcccacc tggttgggag gcgctccccc aggccctccc 660 ggccccgaca tctcctcgcc ctgcggctcc tataaccccc actcccaggg cctggtcacc 720 tttgccaccc agctcttcaa cttgctctcg ggtgagggtt acctggaatg gtcccctctc 780 ttctatggct tctacccgcc ccgcccacgc ctggcggtca cctacctgtg ctgggccttt 840 gccgttggcc tcatctgcct cctgctcatc ctgcatcgct cggtgtctgg gctgaagcag 900 acactgctgg cggagtccga ggctctgacc agctacagcc accgggtgtt ctcggcctgg 960 gacttcggtc tctgcgggga cgtccacgtg cggctgcgcc agcgcatcat cttgtacgaa 1020 ttaaaggtgg agctggagga gacagtggtg cggcgccagg ctgcggtgcg gacgctgggc 1080 cagcaagcca gggtttggtt ggtgcgggtg ctgctcaacc tgctggtggt cgcgctcctg 1140 ggggcagcct tctatggcgt ctactgggct acggggtgca ccgtggagct gcaggagatg 1200 ccccttgtcc aggagttgcc actgctgaag cttggggtga attaccttcc gtccatcttc 1260 atcgctgggg tcaattttgt gctgccgccc gtgttcaagc tcattgctcc actggagggc 1320 tacactcgga gtcgccagat cgtttttatc ctgctcagga ccgtgtttct tcgcctcgcc 1380 tccctggtgg tcctgctctt ctctctctgg aatcagatca cttgtggggg cgactccgag 1440 gctgaggact gcaaaacctg tggctacaat tacaaacaac ttccgtgctg ggagactgtc 1500 ctgggccagg aaatgtacaa acttctgctc tttgatctgc tgactgtctt ggcagtcgcg 1560 ctgctcatcc agtttcctag aaagctcctc tgtggcctct gtcctggggc gctgggtcgt 1620 ctggcgggga cccaggagtt ccaggtgccc gacgaggtgc tggggctcat ctacgcgcag 1680 acggtggtct gggtggggag ttttttctgc cctttactgc ccctgcttaa cacggtcaag 1740 ttcctgctgc ttttctacct gaagaagctt accctcttct ccacctgctc cccggctgcc 1800 cgcaccttcc gggcctccgc ggcgaatttc tttttcccct tggtccttct cctgggtctg 1860 gccatctcca gcgttcccct gctttacagc atcttcctga tcccgccttc taagctttgt 1920 ggtccattcc gggggcagtc gtccatctgg gcccagatcc ctgagtctat ttccagcctc 1980 cctgagacca cccagaattt cctcttcttc ctggggaccc aggcttttgc tgtgcccctt 2040 ctgctgatct ccagcatcct gatggcgtac actgtggctc tggctaactc ctacggacgc 2100 ctcatctctg agctcaaacg tcagagacag acggaggcgc agaataaagt cttcctggca 2160 cggcgcgctg tggcgctgac ctccaccaaa ccggctcttt gacccccgca gcccacgtcc 2220 cgctttcaga ccccaggccc attgtaagcc taggtcacaa catctgtaaa ctaggagaac 2280 tggagaagac tccacgccct tccagctttg gtatctggag atttccaggg cccctcgccg 2340 ccacgtccct gactctcggg tgatcttcct tgtatcaata aatacagccg aggttggtga 2400 gcc 2403 74 2850 DNA Homo sapiens misc_feature Incyte ID No 6114480CB1 74 cggctcgagc ggctcgagtg aagagcctct ccacggctcc tgcgcctgag acagctggcc 60 tgacctccaa atcatccatc cacccctgct gtcatctgtt ttcatagtgt gagatcaacc 120 cacaggaata tccatggctt ttgtgctcat tttggttctc agtttctacg agctggtgtc 180 aggacagtgg caagtcactg gaccgggcaa gtttgtccag gccttggtgg gggaggacgc 240 cgtgttctcc tgctccctct ttcctgagac cagtgcagag gctatggaag tgcggttctt 300 caggaatcag ttccatgctg tggtccacct ctacagagat ggggaagact gggaatctaa 360 gcagatgcca cagtatcgag ggagaactga gtttgtgaag gactccattg caggggggcg 420 tgtctctcta aggctaaaaa acatcactcc ctcggacatc ggcctgtatg ggtgctggtt 480 cagttcccag atttacgatg aggaggccac ctgggagctg cgggtggcag cactgggctc 540 acttcctctc atttccatcg tgggatatgt tgacggaggt atccagttac tctgcctgtc 600 ctcaggctgg ttcccccagc ccacagccaa gtggaaaggt ccacaaggac aggatttgtc 660 ttcagactcc agagcaaatg cagatgggta cagcctgtat gatgtggaga tctccattat 720 agtccaggaa aatgctggga gcatattgtg ttccatccac cttgctgagc agagtcatga 780 ggtggaatcc aaggtattga taggagagac gtttttccag ccctcacctt ggcgcctggc 840 ttctatttta ctcgggttac tctgtggtgc cctgtgtggt gttgtcatgg ggatgataat 900 tgttttcttc aaatccaaag ggaaaatcca ggcggaactg gactggagaa gaaagcacgg 960 acaggcagaa ttgagagacg cccggaaaca cgcagtggag gtgactctgg atccagagac 1020 ggctcacccg aagctctgcg tttctgatct gaaaactgta acccatagaa aagctcccca 1080 ggaggtgcct cactctgaga agagatttac aaggaagagt gtggtggctt ctcagggttt 1140 ccaagcaggg agacattact gggaggtgga cgtgggacaa aatgtagggt ggtatgtggg 1200 agtgtgtcgg gatgacgtag acagggggaa gaacaatgtg actttgtctc ccaacaatgg 1260 gtattgggtc ctcagactga caacagaaca tttgtatttc acattcaatc cccattttat 1320 cagcctcccc cccagcaccc ctcctacacg agtaggggtc ttcctggact atgagggtgg 1380 gaccatctcc ttcttcaata caaatgacca gtcccttatt tataccctgc tgacatgtca 1440 gtttgaaggc ttgttgagac cctatatcca gcatgcgatg tatgacgagg aaaaggggac 1500 tcccatattc atatgtccag tgtcctgggg atgagacaga gaagaccctg cttaaagggc 1560 cccacaccac agacccagac acagccaagg gagagtgctc ccgacaggtg gccccagctt 1620 cctctccgga gcctgcgcac agagagtcac gccccccact ctcctttagg gagctgaggt 1680 tcttctgccc tgagccctgc agcagcggca gtcacagctt ccagatgagg ggggattggc 1740 ctgaccctgt gggagtcaga agccatggct gccctgaagt ggggacggaa tagactcaca 1800 ttaggtttag tttgtgaaaa ctccatccag ctaagcgatc ttgaacaagt cacaacctcc 1860 caggctcctc atttgctagt cacggacagt gattcctgcc tcacaggtga agattaaaga 1920 gacaacgaat gtgaatcatg cttgcaggtt tgagggcaca gtgtttgcta atgatgtgtt 1980 tttatattat acattttccc accataaact ctgtttgctt attccacatt aatttacttt 2040 tctctatacc aaatcaccca tggaatagtt attgaacacc tgctttgtga ggctcaaaga 2100 ataaagagga ggtaggattt ttcactgatt ctataagccc agcattacct gataccaaaa 2160 ccaggcaaag aaaacagaag aagaggaagg aaaactacag gtccatatcc ctcattaaca 2220 cagacacaaa aattctaaat aaaattttaa caaattaaac taaacaatat atttaaagat 2280 gatatataac tactcagtgt ggtttgtccc acaaatgcag agttggttta atatttaaat 2340 atcaaccagt gtaattcagc acattaatag agtaggaaag aaaccatagg aaggagagac 2400 gaaggaaaga gaaaaggggg cgccccaact agtgagctgg caccccgggg attttccggc 2460 gcggactctc aggggggtag cgggtatcga agcagctttg aagacggaga ctcggggggg 2520 gccgggacca aattccccaa gaggggcggt tatcggcgcg cgctggcctc ggtgttaaac 2580 gccggagtgg gaacccaggg gtaccaagtt agggcttgag ccgaccgtat gttgggcttc 2640 cagctagaga ctgcaaggaa agaagaagga ggctagaggc caggatagtg gagagagaac 2700 agacgcgaga acaaggggaa atgaggacgc gaggggagag atgaggagag atagagatgt 2760 gacgagcagc gaggagagcc gggaccggag aggcaacgga gaagtgacga acgaagaaag 2820 acaagggagc gaaggaacgc agaagtggaa 2850 

What is claimed is:
 1. An isolated polypeptide selected from the group consisting of: a) a polypeptide comprising the amino acid sequence of SEQ ID NO:26, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:26, c) a biologically active fragment of a polypeptide having the amino acid sequence of SEQ ID NO:26, and d) an immunogenic fragment of a polypeptide having the amino acid sequence of SEQ ID NO:26.
 2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1-37.
 3. An isolated polynucleotide encoding a polypeptide of claim
 1. 4. An isolated polynucleotide encoding a polypeptide of claim
 2. 5. An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID NO:38-74.
 6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim
 3. 7. A cell transformed with a recombinant polynucleotide of claim
 6. 8. A transgenic organism comprising a recombinant polynucleotide of claim
 6. 9. A method of producing a polypeptide of claim 1, the method comprising: a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and b) recovering the polypeptide so expressed.
 10. A method of claim 9, wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:1-37.
 11. An isolated antibody which specifically binds to a polypeptide selected from the group consisting of: a) a polypeptide comprising the amino acid sequence of SEQ ID NO:26, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:26, c) a biologically active fragment of a polypeptide having the amino acid sequence of SEQ ID NO:26, and d) an immunogenic fragment of a polypeptide having the amino acid sequence of SEQ ID NO:26.
 12. An isolated polynucleotide selected from the group consisting of: a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:63, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to the polynucleotide sequence of SEQ ID NO:63, c) a polynucleotide complementary to a polynucleotide of a), d) a polynucleotide complementary to a polynucleotide of b), and e) an RNA equivalent of a)-d).
 13. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim
 12. 14. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising: a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
 15. A method of claim 14, wherein the probe comprises at least 60 contiguous nucleotides.
 16. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising: a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
 17. A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.
 18. A composition of claim 17, wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:1-37.
 19. A method for treating a disease or condition associated with decreased expression of functional MEMAP, comprising administering to a patient in need of such treatment the composition of claim
 17. 20. A method of screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising: a) exposing a sample comprising a polypeptide of claim 1 to a compound, and b) detecting agonist activity in the sample.
 21. A composition comprising an agonist compound identified by a method of claim 20 and a pharmaceutically acceptable excipient.
 22. A method for treating a disease or condition associated with decreased expression of functional MEMAP, comprising administering to a patient in need of such treatment a composition of claim
 21. 23. A method of screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising: a) exposing a sample comprising a polypeptide of claim 1 to a compound, and b) detecting antagonist activity in the sample.
 24. A composition comprising an antagonist compound identified by a method of claim 23 and a pharmaceutically acceptable excipient.
 25. A method for treating a disease or condition associated with overexpression of functional MEMAP, comprising administering to a patient in need of such treatment a composition of claim
 24. 26. A method of screening for a compound that specifically binds to the polypeptide of claim 1, the method comprising: a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim
 1. 27. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, the method comprising: a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1, b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim
 1. 28. A method of screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising: a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.
 29. A method of assessing toxicity of a test compound, the method comprising: a) treating a biological sample containing nucleic acids with the test compound, b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 12 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 12 or fragment thereof, c) quantifying the amount of hybridization complex, and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.
 30. A diagnostic test for a condition or disease associated with the expression of MEMAP in a biological sample, the method comprising: a) combining the biological sample with an antibody of claim 11, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex, and b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.
 31. The antibody of claim 11, wherein the antibody is: a) a chimeric antibody, b) a single chain antibody, c) a Fab fragment, d) a F(ab′)₂ fragment, or e) a humanized antibody.
 32. A composition comprising an antibody of claim 11 and an acceptable excipient.
 33. A method of diagnosing a condition or disease associated with the expression of MEMAP in a subject, comprising administering to said subject an effective amount of the composition of claim
 32. 34. A composition of claim 32, wherein the antibody is labeled.
 35. A method of diagnosing a condition or disease associated with the expression of MEMAP in a subject, comprising administering to said subject an effective amount of the composition of claim
 34. 36. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 11, the method comprising: a) immunizing an animal with a polypeptide having the amino acid sequence of SEQ ID NO:26, or an immunogenic fragment thereof, under conditions to elicit an antibody response, b) isolating antibodies from said animal, and c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having the amino acid sequence of SEQ ID NO:26.
 37. A polyclonal antibody produced by a method of claim
 36. 38. A composition comprising the polyclonal antibody of claim 37 and a suitable carrier.
 39. A method of making a monoclonal antibody with the specificity of the antibody of claim 11, the method comprising: a) immunizing an animal with a polypeptide having the amino acid sequence of SEQ ID NO:26, or an immunogenic fragment thereof, under conditions to elicit an antibody response, b) isolating antibody producing cells from the animal, c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells, d) culturing the hybridoma cells, and e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having the amino acid sequence of SEQ ID NO:26.
 40. A monoclonal antibody produced by a method of claim
 39. 41. A composition comprising the monoclonal antibody of claim 40 and a suitable carrier.
 42. The antibody of claim 11, wherein the antibody is produced by screening a Fab expression library.
 43. The antibody of claim 11, wherein the antibody is produced by screening a recombinant immunoglobulin library.
 44. A method of detecting a polypeptide having the amino acid sequence of SEQ ID NO:26 in a sample, the method comprising: a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having the amino acid sequence of SEQ ID NO:26 in the sample.
 45. A method of purifying a polypeptide having the amino acid sequence of SEQ ID NO:26 from a sample, the method comprising: a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and b) separating the antibody from the sample and obtaining the purified polypeptide having the amino acid sequence of SEQ ID NO:26.
 46. A microarray wherein at least one element of the microarray is a polynucleotide of claim
 13. 47. A method of generating a transcript image of a sample which contains polynucleotides, the method comprising: a) labeling the polynucleotides of the sample, b) contacting the elements of the microarray of claim 46 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and c) quantifying the expression of the polynucleotides in the sample.
 48. An array comprising different nucleotide molecules affixed in distinct physical locations on a solid substrate, wherein at least one of said nucleotide molecules comprises a first oligonucleotide or polynucleotide sequence specifically hybridizable with at least 30 contiguous nucleotides of a target polynucleotide, and wherein said target polynucleotide is a polynucleotide of claim
 12. 49. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 30 contiguous nucleotides of said target polynucleotide.
 50. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 60 contiguous nucleotides of said target polynucleotide.
 51. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to said target polynucleotide.
 52. An array of claim 48, which is a microarray.
 53. An array of claim 48, further comprising said target polynucleotide hybridized to a nucleotide molecule comprising said first oligonucleotide or polynucleotide sequence.
 54. An array of claim 48, wherein a linker joins at least one of said nucleotide molecules to said solid substrate.
 55. An array of claim 48, wherein each distinct physical location on the substrate contains multiple nucleotide molecules, and the multiple nucleotide molecules at any single distinct physical location have the same sequence, and each distinct physical location on the substrate contains nucleotide molecules having a sequence which differs from the sequence of nucleotide molecules at another distinct physical location on the substrate.
 56. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.
 57. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:2.
 58. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:3.
 59. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:4.
 60. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:5.
 61. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:6.
 62. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:7.
 63. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:8.
 64. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:9.
 65. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:10.
 66. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:11.
 67. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:12.
 68. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:13.
 69. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:14.
 70. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:15.
 71. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:16.
 72. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:17.
 73. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:18.
 74. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:19.
 75. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:20.
 76. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:21.
 77. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:22.
 78. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:23.
 79. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:24.
 80. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:25.
 81. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:26.
 82. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:27.
 83. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:28.
 84. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:29.
 85. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:30.
 86. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:31.
 87. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:32.
 88. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:33.
 89. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:34.
 90. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:35.
 91. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:36.
 92. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:37.
 93. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:38.
 94. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:39.
 95. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:40.
 96. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:41.
 97. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:42.
 98. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:43.
 99. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:44.
 100. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:45.
 101. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:46.
 102. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:47.
 103. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:48.
 104. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:49.
 105. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:50.
 106. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:51.
 107. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:52.
 108. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:53.
 109. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:54.
 110. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:55.
 111. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:56.
 112. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:57.
 113. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:58.
 114. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:59.
 115. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:60.
 116. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:61.
 117. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:62.
 118. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:63.
 119. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:64.
 120. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:65.
 121. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:66.
 122. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:67.
 123. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:68.
 124. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:69.
 125. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:70.
 126. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:71.
 127. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:72.
 128. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:73.
 129. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:74. 